JULY 20119

Natio

Ca

KingdomSaudi

onal HealSaudi C

ancer InSa

m of SaudHealth Clth InformCancer R

ncidencudi Ara2016

di ArabiaCouncil mation C

Registry

ce Repabia

a

Center

ort

1

2 2

Heal

Heal

Mr.

General

M

Direct

Natio

Director, O

Oncology, H

Kin

Ms. Wa

th Data Anal

Saudi C

Mr. Zeya

th Data Anal

Saudi C

. Mohamm

Manager As

anagement,

Informati

Dr. Hind

tor of Nationa

onal Health I

Saudi Hea

Dr. Hani A

Oncology Cen

Hematology a

ng Fahad Sp

afa Al-Zah

lyst and Qua

Cancer Regis

ad Al-Sha

lyst and Qua

Cancer Regis

med Al-She

sistant of He

National He

on Center

Al-Mutlaq

al Health Re

nformation C

alth Council

Al-Hashm

nter, Consult

and Stem Ce

pecialist Hosp

Rev

Pre

rani

ality Specialis

stry

hrani

ality Specialis

stry

ehri

ealth Data

ealth

q

gistries

Center

i

tant Medical

ell Transplan

pital

viewed

epared

st

st

H

Con

nt

Exec

He

d by

by

Mr. A

Health Data A

Sau

Ms.

Data Manag

trol and Prev

Sau

Dr

cutive directo

And Preven

Hospit

Dr. S

ad, Section o

Center

Hospit

Ms. M

Acting Mana

National H

Sa

Ahmed Al

Analyst and Q

udi Cancer R

Amal Al-M

ger of Golf Ce

vention (KFS

udi Cancer R

r. Ali Al-Za

or, Gulf Cente

ntion , King F

tal & Resear

houki Baz

of Medical O

r, King Faisa

tal & Resear

Malak Al-J

ager, Saudi C

Health Inform

audi Health C

-Rawaji

Quality Spec

Registry

Madouj

enter for Can

SH&RC) - Ad

Registry

ahrani

er for Cance

Faisal Specia

rch Center

zarbashi

Oncology, On

l Specialist

rch Center

Jamaan

Cancer Regi

mation Cente

Council

cialist

ncer

dviser for

r Control

alist

ncology

stry

er

3

Cancer Registry Annual Reports

Cancer Registry Dashboard

4 4

Introduct

This is

published by

publications

years: 1994

reports until 2

This repo

that can be

measuremen

cancer.

The strucoutlined aPart I- Ma

This part

the backgrou

Registry used

present the

tumor topogr

at the time of

programs we

Part II- Ov

Part II pr

Saudi Arabia

December 20

are used to p

age groups.

common can

addition, incid

number of c

(ASR), Crud

Rates (per 1

primary canc

demonstrate

by gender in

Saudi Arabia

Part III- CCommon

In this pa

cancers repo

are outlined.

and proporti

ASR, and th

gender are a

most commo

with the ASR

developing c

tion

the twentieth

y the Saudi

included the

- 1996,1997 -

2015.

rt provides st

used for be

nt on early de

cture of thas followsaterials an

of the report

und and met

d in collecting

basics of c

raphy, morpho

f diagnosis. A

e have used to

verview o

resents the o

a diagnosed b

016. Figures

present cance

Morphology

ncers are als

dence tables

cases, Age-St

e Incidence R

100,000 popu

cer site. Sepa

distribution o

n each of the

a.

Cancer Incn Sites 201

art, the incide

orted among t

For each ca

ons of all ne

e correspond

also presente

on cancers a

R reported fro

ountries.

h cancer inc

Cancer Reg

Incidence R

-1998,1999-20

tatistics on ca

etter planning

etection and m

his report cs: nd Method

t contains info

thods of the

g and analyzin

oding and c

ology and ext

lso we describ

o analyze the d

f Cancer I

overall cance

between 01 J

s, tables, line

er distribution

distributions

so presented

are used to p

tandardized I

Rate (CIR), a

ulation) by ge

arate bar char

of the most co

13 administra

cidence fo16

ence of the

he saudi male

ancer site, the

ewly diagnos

ing cancer ra

ed. In addition

among Saudis

om selected d

cidence repo

istry. Previou

Reports for th

000, and year

ancer incidenc

g and effectiv

management o

can be

ds

ormation abou

Saudi Cance

ng the data. W

classification o

tent of diseas

be the softwar

data.

Incidence

er incidence

anuary and 3

and bar chart

by gender an

for the mos

d in tables. I

resent the tota

ncidence Rat

and Cumulativ

ender for eac

rts are used t

ommon cancer

ative regions o

r Most

most commo

es and female

e total numbe

sed cases, th

anking for eac

n, ASR for th

s is compare

developed an

ort

us

he

rly

ce

ve

of

ut

er

We

of

se

re

in

31

ts

nd

st

In

al

te

ve

ch

to

rs

of

on

es

er

he

ch

he

ed

nd

PS

t

c

s

p

a

P

a

t

P

S

Part IV-CaSaudis

This part pr

he Non-Saud

cancer. The a

separately du

population in w

and 44 years e

Part V-Inc

This part c

all newly diag

he Non-Saudi

Distributio

age group

Distributio

Saudis by

Cancer In

among Sa

Cancer In

among No

Age-stand

frequencie

gender an

Part VI- Ar

It is enc

Statistics in S

ancer Incid

resents numb

dis including t

analysis of the

ue to the n

which large pr

especially amo

idence Ta

contains the fo

nosed cancer

is diagnosed i

n of cancer

and gender

n of cance

age group a

ncidence (pe

audis by age

ncidence (pe

on-Saudis by

ardized inci

es among S

d administra

rabic Sum

losed an Ara

audi Arabia fo

dence amo

ers of cancer

he most com

e Non-Saudis

nature of th

roportion aged

ong males.

ables

ollowing detai

r types for the

n 2016.

cases amon

.

er cases a

and gender.

er 100,000

group and g

er 100,000

y age group a

dence rate

Saudis by c

ative regions.

mmary

abic summar

or the Year 20

ong Non-

cases among

mon types of

is performed

he expatriate

d between 25

iled tables for

e Saudis and

ng Saudis by

mong Non-

populations)

ender.

populations)

and gender.

and relative

cancer site,

.

ry of Cancer

16.

5

g

f

d

e

5

r

d

y

-

)

)

e

,

r

6 6

Table of c

Introduction

PART I

MATERIALS A

Background on S

Saudi Cancer Re

Definitions of Sta

PART II

OVERVIEW O

Cancer Incidence

Cancer Distributi

Cancer Incidence

Childhood Cance

Distribution of Ca

International Com

PART III

CANCERS INC

Cancer Incidence

Female Breast C

Colorectal Cance

Thyroid Cancer (

Non- Hodgkin's L

Leukaemia (C91

Hodgkin's Lymph

Corpus Uteri Can

Lung Cancer (C3

Liver Cancer (C2

Prostate Cancer

PART IV

CANCER AMO

Cancer Incidence

PART V

INCIDENCE TA

Table 5.1.1

Table 5.1.2

Table 5.1.3

Table 5.1.4

Table 5.2.1

ontents

AND MOTHEDS

Saudi Arabia

egistry

atistical Terms

F CANCER INC

e in Saudi Arabia,

ion Among Saudi

e Among Adults (>

er Reported to Sa

ancer Cases in 13

mparison of Age-S

CIDENCE FOR

e for Most Commo

Cancer (C50)

er (C18-C20)

(C73)

Lymphoma (C82-C

-C95)

homa (C81)

ncer (C54)

33-C34

22)

(C61)

ONG NON-SAU

e Among Non-Sau

ABLES

Number of Cas

Number of Cas

Age-Spesific InPrimary Site an

Age-Spesific InPrimary Site an

Number of CasSaudi Males ( p

S

CIDENCE, 2016

, 2016

Nationals, 2016

> 14 Years), 2016

udi Cancer Regis

3 Administrative R

Standardized Incid

MOST COMMO

on Sites, 2016

C85; C96)

UDI 2016

udi Population. 20

ses Among Saudi

ses Among Saudi

cidence Rate (AIRnd Age groups, 20

cidence Rate (AIRnd Age groups, 20

ses, Relative Frequper 100,000) by P

6

6

try (≤ 14 Years), 2

Regions of Saudi A

dence Rates

ON SITES 2016

016

Males by Primary

Females by Prima

R), Age Standardi016.

R), Age Standardi016

uency, Crude Incirimary Site, Age G

2016

Arabia, 2016

6

y Site And Age Gro

ary Site And Age G

sed Incidence Ra

sed Incidence Ra

dence Rate (CIR)Groups and Regio

oups, 2016

Groups, 2016

ate (ASR) Among S

ate (ASR) Among S

) Age-Standardiseons 2016

Saudi Males (per

Saudi Females (p

ed Incidence Rate

r 100,000) by

per 100,000) by

(ASR) Among

5

9

9

12

15

18

21

22

26

31

33

34

36

38

40

42

44

46

48

50

52

56

60

61

62

63

64

Table 5.2.2

Table 5.2.3-

Table 5.2.4-

Table 5.3.1

Table 5.3.2

Table 5.3.3

Table5.3.4

Table 5.4.1

Table 5.4.2

Table 5.4.3

Table 5.4.4

Number Of CasSaudi Males ( p

Number Of CasSaudi Males ( p

Number Of CasSaudi Males ( p

Number Of CasSaudi Females

Number Of CasSaudi Females

Number of CasSaudi Females

Number Of CasSaudi Females

Number of Cas

Number of Cas

Age-Spesific Inby Primary Site

Age-Spesific Inby Primary Site

Acknowledgme

Arabic Summar

ses, Relative Freqper 100,000) by P

ses, Relative Freqper 100,000) by P

ses, Relative Freqper 100,000) by P

ses, Relative Freq( per 100,000) by

ses, Relative Freq( per 100,000) by

ses, Relative Freq( per 100,000) by

ses, Relative Freq( per 100,000) by

ses Among Non-S

ses Among Non-S

cidence Rate (AIRe and Age groups,

cidence Rate (AIRe and Age groups,

ent

ry

quency, Crude Incrimary Site, Age G

quency, Crude Incrimary Site, Age.

quency, Crude Incrimary Site, Age G

quency, Crude Incy Primary Site, Ag

quency, Crude Incy Primary Site, Ag

quency, Crude Incy Primary Site, Ag

quency, Crude Incy Primary Site, Ag

audi Males by Pri

audi Females by P

R), Age Standardi 2016

R), Age Standardi 2016

cidence Rate (CIRGroups and Regio

cidence Rate (CIR

cidence Rate (CIRGroups and Regio

cidence Rate (CIRe Groups and Re

cidence Rate (CIRe Groups and Re

cidence Rate (CIRe Groups and Re

cidence Rate (CIRe

mary Site And Ag

Primary Site And

sed Incidence Ra

sed Incidence Ra

) Age-Standardiseons 2016

) Age-Standardise

) Age-Standardiseons 2016.

) Age-Standardisegions 2016

) Age-Standardisegions 2016

R) Age-Standardizegions 2016

) Age-Standardise

e Groups, 2016

Age Groups, 2016

ate (ASR) Among

ate (ASR) Among

ed Incidence Rate

ed Incidence Rate

ed Incidence Rate

ed Incidence Rate

ed Incidence Rate

ed Incidence Rate

ed Incidence Rate

6

Non-Saudi Males

Non-Saudi Femal

e (ASR) Among

e (ASR) Among

e (ASR) Among

e (ASR) Among

e (ASR) Among

e (ASR) Among

e (ASR) Among

(per 100,000)

es (per 100,000)

65

66

67

68

69

70

71

72

73

74

75

76

79

7

8 8

MATE

PAERIALS

ARTS AND

T I D METH

HODS

Backgrou

Saudi A

fifths of the

Arabian Gulf

approximatel

divided into 1

Figure 1.Saudi Ara

The estim

31,787,580.

20,081,582 o

9,850,218 (4

The Non-

8,028,355 (6

females. Fig

Saudi popul

respectively.

Figure 1.2Saudis (%2016.

und on Sa

Arabia is a va

Arabian Pe

f in the east to

ly 2,149,700*

13 administrat

1 : Adminabia.

mated populatio

Saudi natio

of these 10,2

9%) were fem

-Saudi popul

69%) were ma

ures 1.2 and

ation pyramid

2 : Popula%) by gend

audi Arabi

ast country ex

eninsula. It st

o the Red Se

square kilome

ive regions Fi

istrative r

on for Saudi A

onals were

31,364 (51%

males.

ation was11,

ales and 3,67

1.3 show the

ds by gende

ation pyrader and ag

a

xtending over

tretches from

a in the west

eters in area a

igure 1.1.

regions of

Arabia in 2016

estimated to

) were males

705,998 of t

77,643 (31%)

e Saudi and

er and age g

mids of ge group,

four-

m the

. It is

and is

f

6 was

o be

s and

these

were

Non-

group

FigSau201

Sau

T

base

the

Fais

In 2

the

for H

Org

T

data

regio

facil

regis

T

revie

prov

addi

natio

gure 1.3 : Pudis (%) b16.

udi cance

The Saudi Ca

ed registry es

Ministry of H

sal Specialist H

014; SCR wa

department o

Health Informa

ganization

The SCR cons

a collection fr

onal offices to

ities in the K

stry is support

The committee

ews cancer

vides help in

ition to ensu

onal and intern

Populationby gender

r registry.

ancer Registr

stablished in 1

Health (MOH)

Hospital and r

as moved to S

of National Re

ation.

nal structu

sists of the m

rom all over

o ensure full

Kingdom as s

ted by registry

e provides sc

statistics rep

disseminatin

uring data co

national guide

n pyramidand age g

.

ry (SCR) is

1992 under th

) in the prem

research Cen

Saudi Health C

egistries in Na

ure.

main office wh

the country

coverage of

shown in Fig

y committee.

cientific guida

ports, data re

ng reliable in

onfidentiality

elines.

ds of Non-group,

a population-

he authority of

mises of King

ter in Riyadh.

Council under

ational Center

hich oversees

through five

all healthcare

gure 1.4. The

ance to SCR,

equests, and

nformation; In

according to

9

-

f

g

.

r

r

s

e

e

e

,

d

n

o

153463 75+ 161494

108210 70-74 110862

148312 156808

243697 227960

336326 308905

431579 407708

541114 45- 49 511696

643959 40- 44 619628

760653 35- 39 741778

867516 30- 34 851823

963289 25- 29 941694

1037331 20- 24 949321

896157 15- 19 864870

948277 10-14 921048

1063173 5-9 1025746

1088308 0-4 1048877

10231364 9850218

10.6

10.4

9.3

8.8

10.1

9.4

8.5

7.4

6.3

5.3

4.2

3.3

2.4

1.4

1.1

1.5

024681012

Males

10.6

10.4

9.4

8.8

9.6

9.6

8.6

7.5

6.3

5.2

4.1

3.1

2.3

1.6

1.1

1.6

0 2 4 6 8 10 12

Females

27442 75+ 10874

32802 70- 74 18347

71669 28410

206541 46059

385823 64380

644397

65- 69

60 - 64

55 - 59

50 - 54 98491

946332 45- 49 261977

1286648 40- 44 487949

1362508 35- 39 535049

927661 30- 34 416233

708776 25- 29 418649

278503 20- 24 206601

235852 15- 19 219171

287737 10-14 271257

349437 5-9 332676

276227 0-4 261520

8028355 3677643

3.4

4.4

3.6

2.9

3.5

8.8

11.6

17.0

16.0

11.8

8.0

4.8

2.6

0.9

0.4

0.3

0 5 10 15 20

7.1

9.0

7.4

6.0

5.6

11.4

11.3

14.5

13.3

7.1

2.7

1.8

1.3

0.8

0.5

0.3

0 2 4 6 8 10 12 14 16

Males Females

65-69 60-64 55-59 50-54

10 10

Regional

Each of t

director who

Staffing cons

SCR Main O

accuracy an

Quality cont

morphology,

patient), and

prepares ann

community,

organizations

Offices

the SCR offic

o is responsib

sists of senio

Office supervi

d quality of d

trol processe

staging inform

consolidation

nual reports fo

government

s and the publ

ces operates

ble for the d

or and junior

ises regional

data collected

es include ve

mation, case l

n of data. The

or disseminat

t departmen

lic.

under a reg

aily managem

r tumor regist

offices to en

d from all reg

erification of

inkage (tumor

e Main Office

tion to the me

nts, internat

gional

ment.

trars.

nsure

gions.

site,

r and

also

edical

tional

Sa

(D

(Je

Ma

(M

audi CanceO

Centra

(Riyadh, Q

Easter

ammam, Ahs

Weste

eddah, Makka

Southe

(Asir, Baha,

adinah & N

Madinah, Tab

er RegistrOffice

al Regio

Qassim & Ha

rn Regio

sa & Hafar A

rn Regio

ah, Taif & Qu

ern Regio

, Jazan & Naj

Northern R

uk, Jouf & N

ry Main

n ail)

on

Al Batin)

on unfudah)

on

jran)

Region

orthern

Data ma

A royal

mandatory

opportunity

SCR strives

government

laboratories

Cancer

medical r

histopatholo

registrars.

identification

demograph

number, na

date, prima

basis of dia

and histolog

identified a

Classificatio

(ICD-O-3),

Organizatio

changes we

behaviors a

Summary S

consistency

Manual 200

The case

were classi

While there

nagement

decree has

modifiable

for compreh

s for full acc

tal and priv

s throughout

data are

records ba

ogical diagno

Abstracted

ns (name,

ic informa

ationality), a

ry site, histo

agnosis). Th

gy (morpholo

nd coded ac

on of Diseas

published

on (WHO), 20

ere made in

as well as

Stage 2000

y in stage co

00 is availabl

es diagnosed

fied accordi

e have not

t

s categorize

disease. Th

hensive data

cess to canc

vate hospita

the Kingdom

abstracted

ased on

osis by SCR

data inc

ID Number

tion (addre

nd tumor de

logy, behavi

he primary s

ogy) of the m

ccording to

ses for Onco

by the

000. Starting

coding of c

staging acco

to increase

oding SEER

e on the web

d on or after 0

ng to the up

been any

ed cancer a

his ensures

a collection.

cer data from

als, clinics

m.

from patie

clinical an

R trained ca

cludes pers

r, gender, a

ess, teleph

etails (diagn

or, grade, st

site (topogra

malignancies

the Internati

ology 3rd Ed

World He

from year 2

cancer types

ording to S

e accuracy

Summary S

b.

01 January 2

pdated ICD-

changes in

as a

the

The

m all

and

ents’

nd/or

ancer

sonal

age),

hone

nosis

tage,

aphy)

s are

ional

dition

ealth

2001,

and

EER

and

Stage

2008

-O-3.

the

prim

rega

lym

that

cou

that

now

lym

hem

in e

with

cha

the

note

for a

S

hem

soft

Inte

(IAR

for

effo

info

and

mal

ana

wer

mary site co

arding histo

phoma are

t were prev

nted as mali

t were previo

w considered

phoma and

matopoietic d

ither the repo

h the SEER

nges reflect

pathology a

ed that ICD-

analysis purp

Since the W

matopoietic

ware, Can

ernational A

RC), Lyon, F

analysis and

ort is made to

rmation, to e

consolidate

ignancy is

alysis. Data

re generated

odes, there

ology (cell

particularly

viously cons

gnant. Also s

ously coded a

d benign. Co

d leukemia

diseases will

ort's ability o

R staging

t advances

nd behavior

-O-3 codes a

poses.

WHO has no

disease b

nReg 4.33

Agency for

France) cann

d they have

o accurately

ensure that a

ed, as app

counted on

entry and

by CanReg

are significa

types). Leu

affected. S

idered benig

small numbe

as borderline

unts of ovar

a as well

change due

or definition.

guidelines,

in the unde

of cancers.

are converte

ot yet conve

ehavior ch

(develope

Research

not include t

e been exclu

code patien

all data revie

propriate, so

nly once fo

incidence ta

software.

ant changes

ukemia and

Some cases

gn are now

er of cancers

e tumors are

rian cancers,

as some

e to changes

However, as

the ICD-O

rstanding of

It should be

ed to ICD-10

rted ICD-10

anges, our

d by the

on Cancer

these cases

uded. Every

nt and tumor

ewed, linked,

o that each

or statistical

ables output

11

s

d

s

w

s

e

,

e

s

s

O

f

e

0

0

r

e

r

s

y

r

,

h

l

t

12 12

Notificati

This rep

between Ja

cases ident

reported in

anticipated

will decreas

improved d

reporting la

publishing t

years wh

completene

DefinitionSpecific I

The num

specific per

gender gro

population o

Age-Stan

The Ag

measure of

had a stan

necessary w

differ with

frequently u

Standard P

incidence i

Incidence R

populations

on

port covers

anuary and

ified after thi

n subsequen

that the num

se as case a

during past

p between y

the incidence

ile mainta

ess of data.

ns of StatiIncidence

mber of canc

riod in a pop

up, divided

of that age a

ndardized

ge-standardiz

f a rate that

ndard age s

when compa

respect to

used standa

Population (s

is known a

Rate. The rat

s.

data that w

December

is date (late r

nt incidence

mber of late

ascertainmen

years. Our

year of diagn

e report to a

ining high

istical Ter Rate (AIR

er cases oc

ulation of a s

by the num

nd gender g

Rate (ASR

zed rate i

a population

structure. St

aring several

age struct

ard populatio

see below).

as the Worl

te is express

were diagno

2016. Incid

reporting) wi

e reports. I

e-reported ca

nt processes

aim is red

nosis and yea

a maximum

quality

rms Age-R)

ccurring durin

specific age

mber of midy

roup.

R)

is a summ

n would have

andardizatio

populations

ture. The m

on is the W

The calcula

ld Standard

sed per 100

osed

dent

ll be

It is

ases

has

duce

ar of

of 2

and

ng a

and

year

mary

e if it

on is

that

most

World

ated

ized

.000

Wo

*DolCont

Cru

T

tota

the

num

indi

100

age

dem

the

crud

alte

acro

diffe

ord

com

betw

stan

orld Stand

Age Cla

0 - 4 5 - 9 10 -14 15 -19 20 - 2425 - 2930 - 3435 - 3940 - 4445 - 4950 - 5455 - 5960 - 6466 - 6970 - 74 75 +

Total

l R. Payne P.Wtinents Vol.I. Int

ude Incide

The crude in

al number of

total popu

mber of ca

viduals. All

0.000 popula

e and the cru

mographic st

population

de rate ove

ered. It is not

oss geograp

erent popula

er to assess

mpare incide

ween regis

ndardize the

dard Popu

ass

4 9 4 9 4 9 4 9 4 9 4

Waterhouse J. Caternational Unio

ence Rate

cidence rate

f cases regis

lation. It de

ases occurr

rates are t

ation. Cance

ude rate is st

tructure of th

structure c

er that per

t appropriate

phical areas

ation age s

s time trend

ence across

stries it is

rates with re

lation

Popula

12.0010.00 9.000 9.000 8.000 8.000 6.000 6.000 6.000 6.000 5.000 4.000 4.000 3.000 2.000 2.000

100.0

ancer Incidenceon against Canc

(CIR)

e for a cance

stered as a p

enotes the

ring in eac

thus, expres

r rates vary

trongly influe

he populatio

changes ove

riod may b

e to compare

of cancer re

structures. T

s in registra

geographic

s necessar

espect to age

ation

00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0

000

e in Five cer. 1966

er site is the

proportion of

approximate

ch 100.000

ssed as per

greatly with

enced by the

on. Hence, if

er time the

be artificially

e crude rates

egistries with

Therefore, in

ation data or

cal areas or

ry to first

e.

e

f

e

0

r

h

e

f

e

y

s

h

n

r

r

t

Cumulati

Cumulati

risk of indiv

specified pe

number of

who would

cancer befo

had the rat

the age sta

between po

this report t

used. The c

cancer age

five-year ag

ICD - 10

The Wo

Classificatio

ICD - O -

The Wo

Classificatio

has been

neoplasms

includes a

four-digit nu

for behavio

aggressiven

Incidence

An incide

a new even

as the num

population

the populati

ve inciden

ve incidence

viduals deve

eriod. For ca

new born ch

be expect

ore the age

tes of cance

andardized

opulations of

the age rang

cumulative r

e-specific rate

ge intervals.

rld Health

on of Disease

3

orld Health

on of Diseas

the stan

for over 25

four charact

umeric code

or and a

ness (grade)

e rate

ence rate is

nt occurs in a

ber of new c

over a defin

ion at risk of

nce rate

e rate is th

eloping the d

ancer, it is e

hildren (out o

ed to deve

of 65 (or 70

ers currently

rate, it perm

f different ag

ges 0-64 and

rate is the su

es; which ar

Organization

es, tenth edit

Organization

es for Onco

dard codin

5 years. The

ter code for

for cell type

one-digit c

.

defined as t

a population

cases of dise

ned time pe

developing t

he probability

disease durin

xpressed as

of 100, or 10

lop a partic

0, or 75) if

y observed.

mits compar

ge structures

d 0-74 years

ummation of

re computed

n’s Internati

tion.

n’s Internati

logy, 3rd Ed

ng system

e coding sys

r primary sit

e, one-digit c

code for tu

he rate at w

n. It is calcula

ease arising

eriod, divided

that disease

y or

ng a

s the

000)

cular

they

Like

rison

s. In

s are

f the

d for

onal

onal

ition

for

stem

te, a

code

umor

which

ated

in a

d by

.

Me

T

num

Me

T

arra

Me

M

orig

lym

Ra

It

min

Ra

T

spe

of t

the

pop

Ra

It

qua

den

Re

T

can

of a

Su

S

bro

dise

ean

The simple m

mbers.

edian

The midpoin

anged in orde

etastasis

Metastasis is

ginal site to

ph nodes, sk

nge

t is the diffe

nimum values

nk

This measu

ecific cancer

the number

most and

pulation acco

tio

t is the relati

antity is a

nominator.

elative freq

This statistic

ncer cases re

all cancer. It i

mmary St

Staging is t

ad categori

ease.

mathematical

nt of the ra

er of value.

s the distant s

other organ

keletal and o

erence betw

s in a set of o

re reflects

site relative

of registrati

least frequ

ording to thei

ion between

numerator

quency

is defined a

egistered rela

is expressed

tage

he grouping

ies based

l average of

ange numbe

spread of ca

s of the bod

or visceral org

ween the ma

observations

the import

e to other sit

ons. Rankin

uent cancer

r frequency.

two quantiti

and the se

as the numbe

ative to the t

d as a percen

g of cancer

on the ext

two or more

ers that are

ncer from its

dy, including

gans.

aximum and

s.

tance of a

tes, in terms

ng illustrates

sites in a

ies. The first

econd is a

er of specific

total number

ntage.

cases into

tent of the

13

e

e

s

g

d

a

s

s

a

t

a

c

r

o

e

14 14

OVERVIE

PAEW OF

ARTCANC

2016

T II CER INCIDENNCE

Cancer in

Between

the total nu

reported to

17,602. Ove

than men;

9,558 (54.3%

reported am

Saudi, and 2

Total of 16

13,161 (78.

(21.9%) wer

Total of 7

analysis: 2

nationalities

to ICD-10 c

not include

Table 2.1.

Table 2.1Saudi Ca

Analyz

Male Femal

5803 7358

Table 2.2

Region Riyadh Makkah Eastern Asir Madinah Qassim Jazan Tabuk Hail Jouf Najran Baha Northern Unknown International

Total

**unknown nat

ncidence i

January 01

mber of new

the Saudi C

erall cancer

it affected

%) females.

mong Saudi n

206 of unkno

6,859 cases

.1%) were S

re Non-Saud

743 cases

206 cases

s, and 537 c

codes. The

in situ case

: Distribuancer Regi

Saudiszed

le Total M

8 13161 1

2 : Distribu

l

tionalities, in situ

in Saudi A

and Decem

wly diagnose

Cancer Regi

was more

8,044 (45.7

Total of 13,5

nationals, 3,8

own nationali

were analy

Saudi nation

di.

were exclu

of them w

ases failed t

software (C

es in the stat

ution of anistry by na

s Non Analyze

Male Female

184 217

ution of ca

Male 1604 1352 1094 498 293 225 149 154 79 92 87 82 67 26 1

5803

u and ICD-10 co

Arabia, 201

mber 31, 20

ed cancer ca

stry (SCR) w

among wom

7%) males

562 cases w

834 among n

ity.

yzed, of wh

nals and 3,

uded from

were unkno

to be conver

CanReg-4) d

tistical analy

nalyzed anationality

Unked

Total Male

401 111

ancer case

% 27.6 23.3 18.9 8.6 5.0 3.9 2.6 2.7 1.4 1.6 1.5 1.4 1.2 0.4 0.0

100.0

onversion failure

16.

016,

ases

was

men

and

were

non-

hich

698

the

own

rted

oes

ysis,

Am

(55

100

can

100

The

74.

Eas

ma

/10

wh

am

40.

,Ta

nd non-anand gende

known Natio

e Female

95

es among

ASR 96.4 73.2

104.3 68.7 54.7 56.5 33.7 67.1 33.7 71.4 53.9 49.3 69 NA NA 74.7

e are excluded

mong Saudis 5,803 (44.1%5.9%) were fe

0 to 126. Th

ncers were

0,000 in fema

e overall age-s

7/100,000 in m

stern region

ales and fe

00,000 for

ereas, Jazan

mong males

.6/100,000 fo

able 2.2 and F

alyzed caer, 2016.

onality

Total Male

206 1872

Saudi nat

Female 2093 1673 1445 520 328 330 206 200 151 124 122 80 58 25 3

7358 1

from analysis

emales with a

e crude incid

56.6/100,000

ales.

standardized

males and 91.

reported th

emales (104

males and

n region rep

and femal

or males an

Figure 2.1.

ncer case

NoAnalyzed

e Female T

2 1826 3

tionals by

% A28.4 1322.7 8719.6 137.1 664.5 604.5 802.8 402.7 782.1 641.7 951.7 71.1 370.8 530.3 N0.0 N

100.0 91

) were males

a male to fem

dence rates

0 in males

incidence rate

.3/100,000 in f

he highest A

4.3/100,000

females re

ported the lo

les (33.7/10

d females re

es reported

on –Saudis Non

Total Male

3698 74

y regions,

ASR Al30.1 3697.7 302

31.3 2536.2 1010.6 6210.8 5550.6 3558.1 3544.6 2305.5 2161.7 2097.5 1623.8 125

NA 51NA 4 1.3 1316

s and 7,358

male ratio of

(CIR) of all

and 74.5 /

e (ASR) was

females.

ASR among

and 131.3

espectively),

owest ASR

00,000 and

espectively)

d to

n Analyzed

Female Total

62 136

2016.

l % 97 28.1 25 23.0 39 19.3

8 7.7 1 4.7 5 4.2 5 2.7 4 2.7 0 1.7 6 1.6 9 1.6 2 1.2 5 0.9 0.4

0.0 61 100.0

15

l

16 16

Bah

Jaza

Norther

Madina

Ha

As

Najra

Tabu

Qassim

Makka

Jou

Riyad

Easter

Figure 2.2016.

*ASR per 100,

The age-

diagnosis w

Figure 2.2.

Figure 2.2

1

10

100

1000

0

AIR

(Per

100

,000

)

0

ha

an

rn

ah

ail

sir

an

uk

m

ah

uf

dh

rn

1 : Age St

000 population.

-specific incid

was 57 years

2 : Age-Sp

0 -5 -1

20

tandardize

.

dence rate (

with a range

pecific Inc

10 -15 -2

37.5

40.6

49

33.7

33.7

40

ed Rate (A

(AIR) increas

e of (0 -116)

cidence Ra

20 -25 -

53.8

60.6

64.6

66.2

9.3

69

54.7

68

53.9

67.

56.5

60

Male Fem

ASR)* of al

sed with adv

) for males, a

ate (AIR) f

-30 -35 -

Age Gro

Male F

2

71.7

78.1

80.8

87

9

8.7

1

73.2

71.4

80

male

ll cancer s

vancing age

and 51 years

for all can

-40 -45

ups

Female

.7

95.5

96.4

104.3

100

sites amon

in both gend

s with a rang

cer amon

-50 -55

3

120

ng Saudi n

ders. The me

ge of (0-116)

g Saudis,

-60 -65

130.1

131.3

140

nationals,

edian age at

for females,

2016.

-70 75+

t

,

1

1

2

2

3

3

Confirma

hematologic

reports (2.0

laboratory te

of cases, Ta

Table 2.3

Basis of

Histology

Cytology /

Histology

Medical Im

DCO (Dea

Unknown

Surgical

Laborator

Autopsy

Total

Cancer D

In female

2,451 (33.3

(60-74) yea

Figure 2.3groups, 2

0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

0-14

6.6

ation of ma

cal and cyto

0%), and de

ests for tumo

able 2.3.

3 : Basis o

f Diagnosis

of primary

/ Haematolo

of metastas

maging

ath Certificat

ry test (Tumo

Distributio

es the highe

%) cancer ca

rs, with a tot

3 : Distrib2016.

4 1

8

3.8

alignancy w

ological repo

eath certificat

or markers w

f diagnos

s

gical

es

te Only)

or Markers)

n among S

st number o

ases. Where

tal of 1,649 (2

bution of c

15-29

.6 8.6

was based

rts (4.9%), t

te only (1.2%

were the sou

is of canc

Saudi Nat

of cancer cas

eas, in males

28.5%) canc

cancer cas

30-44

13.6

22.1

Male Fema

mainly on

then histolog

%). Other s

rce is about

cer cases,

tionals,201

ses reported

s the highest

cer cases.

ses among

45-59

25.5

33.3

le

histopatholo

gy of metast

ources such

0.1%, and u

2016.

No

11521

645

548

259

154

26

5

2

1

13161

16.

d for the age

number of c

g Saudi na

60-74

28.5

22.5

ogy reports

tases (4.2%

h as surgica

unknown sou

e group (45-5

cases was re

ationals b

75+

17.3

5

9

(87.5%), f

), then med

l and clinica

urce was pres

%

87.5

4.9

4.2

2.0

1.2

0.2

0.0

0.0

0.0

100.0

59) years, w

eported for th

y gender

9.8

followed by

ical imaging

al notes and

sent in 0.2%

0

with a total of

he age group

and age

17

y

g

d

%

f

p

18 18

Figure 2.4by gende

4 : Distriber and age

butions of e groups, 2

most freq2016.

quent type

es of cancer among Saudi nattionals

16.7

2.2

3.8

4.4

5.4

5.6

7.4

10.5

11.7

14.1

18.1

5 10 15 20 25 30

Other SitesNasopharynxColorectal

ThyroidBrain, CNSBoneTestisLeukaemiaNHLHodgkin lymphoma

15.1

1.6

2.7

2.7

3.0

5.7

5.9

6.0

12.2

18.6

26.4

051015202530

Other Sites Colorectal

Connective,Soft tissue Bone

Brain, CNS

LeukaemiaNHL

Ovary

Breast Hodgkin lymphoma

Thyroid

Male (497)Female (629 )

15-29 Years

Connective,Soft tissue

6.53.6

4.34.7

5.46.56.5

7.69.1

13.432.2

10203040

Other Sites Eye

Thyroid Adrenal gland

Connective,Soft tissueNHL

Kidney Bone

Hodgkin lymphoma Brain, CNS

Leukaemia

Female (276 )

0-14 Years

7.62.12.4

3.13.7

5.07.1

11.013.4

15.529.1

0 10 30 40

Other SitesKidneyTestisConnective,Soft tissueAdrenal glandEyeBoneNHLHodgkin lymphomaBrain, CNSLeukaemia

20

Male (381)

27.0

3.3

4.3

4.8

5.4

5.9

6.6

7.6

8.4

11.2

15.4

10 20 30 40 50

Other SitesStomachKidneyBrain, CNSNasopharynxTestisLeukaemiaHodgkin lymphomaThyroidNHLColorectal

14.2

1.7

1.7

2.3

2.6

2.7

3.3

3.3

6.5

20.6

41.1

01020304050

Other Sites Cervix Uteri Brain, CNS

Ovary Corpus Uteri

Hodgkin lymphoma

LeukaemiaNHL

Colorectal

ThyroidBreast

Female (1622 ) Male (785 )

30-44 Years

34.3

3.7

4.0

4.0

4.2

4.5

4.7

4.9

6.0

6.9

22.9

0 10 20 30 40 50

Other SitesBrain, CNSProstateNasopharynxBladderKidneyThyroidLiverLungNHLColorectal

Male (1474)

18.8

1.8

1.8

2.0

2.3

2.6

3.8

6.8

10.1

11.3

38.7

1020304050

Other Sites Kidney

Cervix Uteri Lung

Leukaemia Ovary

NHL

Corpus Uteri Thyroid

ColorectalBreast

45-59 Years

Female (2451 )

23.8

2.7

2.8

3.2

3.4

3.7

3.7

7.1

11.9

12.8

25.0

010203040

Other SitesPancreas

LungOvary

Gallbladder etc.Thyroid

LiverNHL

Corpus UteriColorectal

Breast

Female (1658 )

28.1

2.3

3.8

4.4

4.7

4.9

6.5

6.8

7.7

12.1

18.7

10 30 40

Other SitesLeukaemiaKidneyStomachPancreasBladderNHLLiverLungProstateColorectal

20

Male (1649 )

60-74 Years

Table 2.4

Sites Breast Colorectal

Thyroid

NHL

Leukaemia

Hodgkin’s

Corpus Ut

Lung

Liver

Prostate

Table 2.5

Male

Colorectal

NHL

Prostate

Leukaemia

Lung

Liver

Hodgkin’s

Bladder

Thyroid

Brain, CNS

4 : Most co

a

lymphoma

eri

: Most co

a

lymphoma

S

ommon ca

ommon ca

ancers am

N2216

10

8

6

4

4

4

4

4

ncers amo

No

955

469

405

334

298

290

265

299

222

212

ong Saud

No. 282 659

076

841

610

495

454

446

417

405

ong Saud

% Fem

16.5 Bre

8.1 Thy

7.0 Colo

5.8 Cor

5.1 NHL

5.0 Leu

4.6 Hod

3.9 Ova

3.8 Bra

3.7 Lun

di national

i nationals

male

ast

yroid

orectal

rpus Uteri

L

ukaemia

dgkin’s lymph

ary

in, CNS

ng

s, 2016.

11

8

6

4

3

3

3

3

3

s by sex, 2

homa

% 7.3 2.6

8.2

6.4

4.6

3.8

3.4

3.4

3.2

3.1

2016.

No

2240

854

704

454

372

276

230

219

155

148

%

30.4

11.6

9.6

6.2

5.1

3.8

3.1

3.0

2.1

2.0

19

29.6

2.2

2.5

2.8

5.6

5.9

6.0

6.1

8.7

14.3

16.4

10 30 40

Other Sites

Leukaemia

Oesophagus

Pancreas

Stomach

Bladder

NHL

Lung

Liver

Prostate

Colorectal

Male (1004 )

32.6

3.1

3.1

3.5

3.5

3.8

4.5

6.3

7.4

13.9

18.4

010203040

Other Sites

Ovary

Liver

Lung

Stomach

Gallbladder etc.

Thyroid

Corpus Uteri

NHL

Colorectal

Breast

Female (717 )

75+ Years

36.6

3.7

3.8

3.9

4.6

5.0

5.1

5.8

7.0

8.1

16.5

00 10 20 30 40

Other Sites

Brain, CNS

Thyroid

BladderHodgkin lymphoma

Liver

Lung

Leukaemia

Prostate

NHL

Colorectal

23.2

2.0

2.1

3.0

3.1

3.8

5.1

6.2

9.6

11.6

30.4

3040

Other Sites

Lung Brain, CNS

Ovary

Leukaemia

NHL

Corpus Uteri

Colorectal

Thyroid

Breast

All Ages

Female (7358 ) Male (5803 )

20

Hodgkin lymphoma

1020

20 20

TableSaud

ICD-

All

Not C44

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85

C88

C90

C91

C92-C94

C95

Other

e 2.6 : Numdi Nationa

-10 S

All sites Tota

All sites but C

Lip

Tongue

6 Mouth

Salivary gland

Tonsil

Other Oropha

Nasopharynx

Hypopharynx

Pharynx unsp

Oesophagus

Stomach

Small intestin

Colon

Rectum

Anus

Liver

4 Gallbladder e

Pancreas

Nose, sinuses

Larynx

4 Trachea,Bron

Other Thorac

Bone

Melanoma of

Other Skin

Mesothelioma

Kaposi sarco

Connective,S

Breast

Vulva

Vagina

Cervix Uteri

Corpus Uteri

Uterus unspe

Ovary

Other Female

Placenta

Penis

Prostate

Testis

Other male ge

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary

Eye

Brain, Nervou

Thyroid

Adrenal gland

Other Endocr

Hodgkin dise

5;C96 Non-Hodgkin

Immunoprolif

Multiple Myel

Lymphoid Le

4 Myeloid Leuk

Leukaemia un

Other & unsp

mber, perals by prim

Site N

l 58

C44 55

1

6

5

ds 2

3

arynx 4

x 15

x 7

pec. 2

7

20

ne 3

58

37

2

29

etc. 8

17

s etc. 1

6

nchus,Lung 29

cic organs 1

9

Skin 1

20

a 1

ma 2

Soft tissue 8

4

ec.

e Genital

4

40

12

enital 3

19

7

8

22

y organs 7

3

us system 2

22

d 2

rine 5

ease 26

lymphoma 46

ferative dis. 0

oma 7

ukaemia 16

kaemia 14

nspec. 2

pecified 13

centage, Cmary cance

o. % CR

803 100.00%

596 96.40%

6 0.30%

60 1.00%

59 1.00%

23 0.40%

3 0.10%

4 0.10%

54 2.70%

7 0.10%

2 0.00%

78 1.30%

07 3.60%

37 0.60%

81 10.00%

74 6.40%

24 0.40%

90 5.00%

80 1.40%

70 2.90%

8 0.30%

69 1.20%

98 5.10%

6 0.30%

93 1.60%

4 0.20%

07 3.60%

1 0.20%

27 0.50%

89 1.50%

42 0.70%

- -

- -

- -

- -

- -

- -

- -

- -

4 0.10%

05 7.00%

23 2.10%

3 0.10%

96 3.40%

7 0.10%

8 0.10%

29 3.90%

7 0.10%

30 0.50%

12 3.70%

22 3.80%

22 0.40%

5 0.10%

65 4.60%

69 8.10%

0 0.00%

72 1.20%

65 2.80%

42 2.40%

27 0.50%

37 2.40%

CIR, ASR er site and

Male

Crude Rate

ASR World

56.6 74.7

54.6 72

0.2 0.2

0.6 0.8

0.6 0.8

0.2 0.3

0 0

0 0.1

1.5 1.8

0.1 0.1

0 0

0.8 1.1

2 2.9

0.4 0.5

5.7 7.8

3.6 5.1

0.2 0.3

2.8 4.2

0.8 1.2

1.7 2.5

0.2 0.2

0.7 0.9

2.9 4.4

0.2 0.2

0.9 0.9

0.1 0.2

2 2.7

0.1 0.2

0.3 0.4

0.9 1

0.4 0.6

- -

- -

- -

- -

- -

- -

- -

- -

0 0

4 6.3

1.2 1.1

0 0

1.9 2.6

0.1 0.1

0.1 0.1

2.2 3.2

0.1 0.1

0.3 0.3

2.1 2.3

2.2 2.5

0.2 0.2

0 0.1

2.6 2.6

4.6 5.6

0 0

0.7 1

1.6 1.8

1.4 1.5

0.3 0.3

1.3 1.7

and Cumud gender,

e

d

Cumul

0-64

39.95

39.05

0.125

0.34

0.39

0.135

0.03

0.015

1.425

0.035

0.02

0.53

1.26

0.27

4.595

2.945

0.165

1.805

0.555

1.285

0.115

0.58

2.13

0.135

0.535

0.04

0.955

0.015

0.175

0.57

0.41

-

-

-

-

-

-

-

-

0.045

1.87

0.695

0.03

1.635

0.08

0.03

1.725

0.065

0.17

1.625

1.7

0.14

0.04

1.675

3.195

0

0.505

0.915

1.02

0.18

1.12

ulative Ra2016.

lative Rate

0-74

81.8

79.3

0.205

1.045

0.95

0.28

0.03

0.06

1.895

0.125

0.02

1.055

3.32

0.645

8.96

6.1

0.37

4.885

1.675

3.26

0.345

1.175

5.42

0.18

0.71

0.12

2.555

0.24

0.505

0.925

0.59

-

-

-

-

-

-

-

-

0.045

7.76

0.795

0.065

3.065

0.08

0.155

3.465

0.1

0.17

1.965

2.47

0.14

0.04

2.135

5.795

0

1.165

1.36

1.42

0.305

1.76

ates (per 1

No. %

7358 100.00%

7192 97.70%

6 0.10%

47 0.60%

60 0.80%

30 0.40%

2 0.00%

2 0.00%

59 0.80%

14 0.20%

1 0.00%

50 0.70%

111 1.50%

32 0.40%

447 6.10%

257 3.50%

11 0.10%

127 1.70%

113 1.50%

104 1.40%

5 0.10%

7 0.10%

148 2.00%

10 0.10%

53 0.70%

25 0.30%

166 2.30%

7 0.10%

4 0.10%

70 1.00%

2240 30.40%

9 0.10%

8 0.10%

111 1.50%

454 6.20%

40 0.50%

219 3.00%

18 0.20%

4 0.10%

- -

- -

- -

- -

138.0 0.0

2.0 0.0

0.0 0.0

59.0 0.0

2 0.00%

16 0.20%

155 2.10%

854 11.60%

19 0.30%

6 0.10%

230 3.10%

372 5.10%

0 0.00%

48 0.70%

105 1.40%

158 2.10%

13 0.20%

110 1.50%

00,000) am

Female

Crude Rate

ASWor

74.5 91.

72.9 89.

0.1 0.1

0.5 0.7

0.6 0.8

0.3 0.4

0 0

0 0

0.6 0.7

0.1 0.2

0 0

0.5 0.7

1.1 1.5

0.3 0.4

4.5 6.1

2.6 3.4

0.1 0.2

1.3 1.9

1.1 1.7

1.1 1.5

0.1 0.1

0.1 0.1

1.5 2

0.1 0.1

0.5 0.5

0.3 0.3

1.7 2.1

0.1 0.1

0 0.1

0.7 0.8

22.7 27.

0.1 0.1

0.1 0.1

1.1 1.4

4.6 6.6

0.4 0.5

2.2 2.7

0.2 0.2

0 0

- -

- -

- -

- -

1.4 1.8

0.0 0.0

0.0 0.0

0.6 0.8

0 0

0.2 0.2

1.6 1.8

8.7 8.9

0.2 0.2

0.1 0.1

2.3 2.3

3.8 4.9

0 0

0.5 0.6

1.1 1.2

1.6 1.7

0.1 0.1

1.1 1.5

mong

e

R rld

Cumulativ

0-64

3 62.75

2 61.7

1 0.025

7 0.435

8 0.46

4 0.255

0.005

0.015

7 0.535

2 0.08

0.01

7 0.275

5 0.765

4 0.27

1 4.09

4 2.34

2 0.15

9 1.005

7 0.73

5 0.71

1 0.055

1 0.025

1.185

1 0.095

5 0.305

3 0.125

1 1

1 0.085

1 0.01

8 0.415

2 21.46

1 0.1

1 0.06

4 0.83

6 4.76

5 0.345

7 1.755

2 0.17

0.02

-

-

-

-

8 1.16

0 0.02

0 0

8 0.39

0.035

2 0.095

8 1.16

9 7.005

2 0.095

1 0.035

3 1.535

9 3.01

0

6 0.455

2 0.635

7 1.275

1 0.05

5 0.805

ve Rate

0-74

99.35

97.2

0.055

0.83

0.925

0.33

0.05

0.015

0.745

0.2

0.01

0.69

1.615

0.44

7.13

3.685

0.18

2.585

2.305

1.985

0.1

0.1

2.355

0.17

0.35

0.28

2.135

0.085

0.055

0.645

29.67

0.145

0.06

1.475

8.475

0.605

3.075

0.245

0.02

-

-

-

-

1.89

0.065

0

0.89

0.035

0.14

1.755

7.985

0.095

0.035

1.825

5.435

0

0.775

0.97

1.62

0.095

1.895

Cancer In

Between

Cancer regi

Saudis and

7,566 (45.1

Table 2.7.1

Table 2.7to Saudi

AnalyMale Fem5409 707

Table 2.7

Sites Breast Colorecta

Thyroid

NHL

Corpus Ut

Lung

Hodgkin’s

Liver

Leukaemi

Prostate

Table 2.7

Male

Colorectal

NHL

Prostate

Lung

Liver

Bladder

Leukaemia

Thyroid

Hodgkin’s l

Stomach

ncidence a

January and

istry among

d 3,703 were

%) cases we

.

7.1 : DistribCancer Re

Saudi

yzed male Total 77 12486

7.2 : Most c

l

teri

s lymphoma

a

7.3 : Top te

a

lymphoma

among Ad

d December

adults aged

e among non

ere males an

bution of aegistry by

s

Non AnalyMale Female181 213

common c

en cancers

dults (>14

r 2016, the to

above 14 ye

n-Saudis, an

nd 9,210 (54

analyzed ay nationali

Un

yzed e Total Mal

394 103

cancers a

s reported

No %

950 17

427 7

405 7

297 5

287 5

227 4

223 4

219 4

214 4

207 3

years), 20

otal number

ears was 16,

nd unknown

.9%) were fe

and non-aty and ge

nknown Nation

le Female 3 90

mong Sau

A2216

10

78

45

44

41

41

41

40

d among S

% F

7.6 B

.9 T

.5 C

.5 C

.3 N

.2 O

.1 H

.0 L

.0 L

.8 L

016.

of cancer in

,776. Of thos

nationality w

emales with

analyzed ander, 2016

ality

Total Male 193 1799

udi adults

All 280 653

059

81

54

45

19

13

10

05

Saudi adu

Female

Breast

Thyroid

Colorectal

Corpus Uteri

NHL

Ovary

Hodgkin’s lym

Leukaemia

Lung

Liver

cidence cas

se,12,880 ca

was reported

a male to fem

adult canc6.

No

Analyzed Female To1768 35

, 2016.

lts by gen

mphoma

es reported

ancer cases w

d in 193 cas

male ratio of

cer cases

on –Saudis

Nonotal Male 567 74

% 18.3 13.2

8.5

6.3

3.6

3.6

3.4

3.3

3.3

3.2

nder, 2016

No

223

840

703

454

354

215

205

187

148

126

to the Saudi

were among

ses. Total of

f 100 to 121,

reported

n Analyzed Female Total

62 136

.

o %

38 31.6

0 11.9

3 9.9

4 6.4

4 5.0

5 3.0

5 2.9

7 2.6

8 2.1

6 1.8

21

i

g

f

,

22 22

Childhoo

Total of 8

4.6% of the

that cancer

340 (42.4%

were among

were786 inc

were girls, T

Table 2.8and gend

Analy

Boys Girl381 276

Childhoo

children wa

NHL (9.1%)

Table 2.8

Sites LeukaemiBrain CN

Hodgkin’s

NHL

Bone

Eye

Connectiv

Adrenal,g

Kidney

Thyroid

Table 2.8

Male

Leukaemia

Brain, CNS

Hodgkin's

NHL

Bone

Eye

Adrenal gl

Connectiv

Testis

Kidney

od cancers

803 cancer c

total numbe

was more c

%) were repor

g non-Saudi

cluding 657 S

Table 2.8.1.

8.1 : Distribder, 2016.

Saudyzed

ls Total B6 657

d cancers a

s leukemia (

), Table 2.8.2

8.2 : Top te

a S

s lymphoma

ve, soft tissue

land

8.3 : Distrib

a

S

lymphoma

and

e, Soft tissue

s reported

cases were

er of cancers

common amo

rted among g

s, and 10 ca

Saudis, and1

bution of r

is Non Analyz

Boys Girls 3 4

accounted fo

(30.4 %), foll

2.

en Cancer

e

bution of t

No

111

59

51

42

27

19

14

e 12

9

8

d to Saudi

diagnosed a

s reported to

ong boys tha

girls. Total of

ases were w

129 non-Sau

reported c

Unzed

Total Bo7 7

or 4.9% of a

lowed by bra

rs among

top ten ca

o %

1 29.1

15.5

13.4

11.0

7.1

5.0

3.7

3.1

2.4

2.1

Cancer re

among childr

Saudi Canc

an girls, 463

f 664 cancer

ith unknown

udis. Among

childhood

known Nati

oys Girls 7 3

all cancer am

ain tumors (1

Saudi chi

N29

7

6

4

2

2

2

2

ancer sites

Fe

Leu

Bra

Hod

Bon

Kid

NH

Co

Adr

Thy

Eye

egistry (≤

ren aged be

er Registry i

(57.6 %) ca

r cases were

nationality.

Saudi, 381(5

d cancer in

ionality

Total B10

mong Saudis

14.6 %), then

ldren, 201

No 200 96

76

60

48

29

27

27

26

15

s by gend

male

ukaemia

ain, CNS

dgkin's lymp

ne

dney

HL

nnective, So

renal gland

yroid

e

14 years)

tween 0 and

n 2016. The

ases were re

reported am

The total nu

58.0 %) were

n Saudi Ar

NAnalyzed

Boys Girls 72 57

s. The leadin

n Hodgkin’s

6.

ers, 2016.

phoma

oft tissue

, 2016.

d 14 years a

reported inc

eported amon

mong Saudi c

umber of ana

e boys and 2

rabia by n

Non –Saudis Non

Total Boys 129 0

ng cancer a

lymphoma (

% 30.4 14.6

11.6

9.1

7.3

4.4

4.1

4.1

4.0

2.3

No

89

37

25

21

18

18

15

13

12

10

accounted to

cidents show

ng boys and

children, 129

alyzed cases

276 (42.0 %)

ationality

n Analyzed

Girls Total 0 0

mong Saudi

11.6 %) and

%

32.2

13.4

9.1

7.6

6.5

6.5

5.4

4.7

4.3

3.6

o

w

d

9

s

)

i

d

P

Table 2.8reported

Primary Site

Leukaemia

Brain, CNS

Hodgkin's lymphoma

8.4 : Distribamong Sa

e Code 98363

98353

98613

98373

98013

98663

98263

98003

98913

99103

94703

94403

93803

93913

93923

94713

94003

94503

94243

95083

96633

96523

96593

96503

96673

96513

bution of maudi child

MorpholPrecursorPrecursor

Acute my

Precursor

Acute leu

Acute pro

Burkitt ce

Leukemia

Acute mo

Acute me

Others

Total

MedulloblGlioblasto

Glioma, m

Ependym

Ependym

Desmopla

Astrocyto

Oligodend

Pleomorp

Atypical te

Others

Total

Hodgkin l

Hodgkin l

Hodgkin lpredomin

Hodgkin l

Hodgkin l

Hodgkin l

Total

morpholoren by ge

logy r B-cell lympr cell lympho

yeloid leukem

r T-cell lymp

kemia, NOS

omyelocytic le

ll leukemia

a, NOS

onocytic leuke

egakaryoblas

lastoma, NOoma, NOS

malignant

moma, NOS

moma, anapla

astic nodular

ma, NOS

droglioma, N

phic xanthoas

eratoid/rhabd

ymphoma, n

ymphoma, m

ymphoma, nance

ymphoma, N

ymphoma, n

ymphoma, ly

ogical typender, 2016

hoblastic leuoblastic leuke

mia, NOS

hoblastic leu

S

eukemia,

emia

stic leukemia

OS

astic

r medulloblas

NOS

strocytoma

doid tumor

nodular sclero

mixed cellula

nodular lymp

NOS

nodular sclero

ymphocyte-r

es for the m6.

ukemia emia, NOS

ukemia

stoma

osis, NOS

rity, NOS

hocyte

osis, grade 2

ich

most com

Male 41

24

11

8

6

4

4

3

2

1

7

111

22

7

6

4

3

3

2

2

1

0

9

59

24

10

9

6

2 1

1

51

mmon canc

% Fem36.9 4

21.6

9.9

7.2

5.4

3.6

3.6

2.7

1.8

0.9

6.3

100.0 8

37.3

11.9

10.2

6.8

5.1

5.1

3.4

3.4

1.7

0.0

15.3

100.0 3

47.1

19.6

17.6

11.8

2.0

2.0

100.0 2

cers

male %41 46.

15 16.9

14 15.7

2 2.2

5 5.6

4 4.5

1 1.1

0 0.0

2 2.2

1 1.1

4 4.5

89 100

10 27.0

6 16.2

2 5.4

0 0.0

2 5.4

1 2.7

2 5.4

1 2.7

2 5.4

2 5.4

9 24.3

37 100

16 64.0

5 20.0

0 0.0

3 12.0

0 0.0

1 4.0

25 100

23

1

9

7

2

6

5

1

0

2

1

5

.0

0

2

4

0

4

7

4

7

4

4

3

.0

0

0

0

0

0

0

.0

24 24

P

Co

rimary Site

NHL

Bone

Eye

nnective,Sotissue

e Code

96873 97293

97143

97003

95913

96803

97543

97283

95903

97023

92603

91803

91813

92303

92313

93703

89203

91863

92503

95103

95133

89003

89103

89203

80713

oft

89003

90403

89103

88063

89023

89203

88003

88013

90803

95003

Morpho

Burkitt lymPrecurso

Anaplastcell type Mycosis f

Malignan

Malignan

Langerha

Precurso

Malignan

Mature T

Others

Total

Ewing sa

Osteosar

Chondrob

Chondrob

Myxoid c

Chordom

Alveolar

Central o

Giant cel

Total

Retinobla

Retinobla

Rhabdom

Embryon

Alveolar

Squamou

Total

Rhabdom

Synovial

Embryon

Desmopl

Mixed typ

Alveolar

Sarcoma

Spindle c

Teratoma

Neurobla

Others

Total

ology

mphoma, NOor T-cell lymp

ic large cell l

fungoides

nt lymphoma,

nt lymphoma,

ans cell histio

or B-cell lymp

nt lymphoma,

T-cell lympho

arcoma

rcoma, NOS

blastic osteo

blastoma, ma

hondrosarco

ma, NOS

rhabdomyos

osteosarcoma

l tumor of bo

astoma, NOS

astoma, diffu

myosarcoma,

al rhabdomy

rhabdomyos

us cell carcin

myosarcoma,

sarcoma, NO

al rhabdomy

astic small ro

pe rhabdomy

rhabdomyos

a, NOS

cell sarcoma

a, malignant,

astoma, NOS

OS phoblastic lym

lymphoma, T

, non-Hodgk

, large B-cell

ocytosis, diss

phoblastic lym

, NOS

ma, NOS

osarcoma

alignant

oma

sarcoma

a

one, maligna

S

se

, NOS

yosarcoma, N

sarcoma

noma, keratin

, NOS

OS

yosarcoma, N

ound cell tum

yosarcoma

sarcoma

, NOS

S

mphoma

T cell and Nu

in, NOS

l, diffuse, NO

seminated

mphoma

nt

NOS

nizing, NOS

NOS

mor

Male 14

6

ull 5

4

2

OS 2

2

2

2

1

2

42

16

5

3

1

1

1

0

0

0

27

14

2

1

1

1

0

19

2

2

1

1

1

1

1

1

0

0

2

12

% F33.3

14.3

11.9

9.5

4.8

4.8

4.8

4.8

4.8

2.4

4.8

100.0

59.3

18.5

11.1

3.7

3.7

3.7

0.0

0.0

0.0

100.0

73.7

10.5

5.3

5.3

5.3

0.0

100.0

16.7

16.7

8.3

8.3

8.3

8.3

8.3

8.3

0.0

0.0

16.7

100.0

Female %7 38

1 5

0 0

1 5

3 16

3 16

2 1

1 5

0 0

0 0

0 0

18 10

9 42

6 28

3 14

0 0

0 0

0 0

1 4

1 4

1 4

21 10

8 80

1 10

0 0

0 0

0 0

1 10

10 10

2 1

0 0

2 1

1 6

1 6

1 6

0 0

0 0

2 1

2 1

4 26

15 10

% 8.9

5.6

0.0

5.6

6.7

6.7

1.1

5.6

0.0

0.0

0.0

00.0

2.9

8.6

4.3

0.0

0.0

0.0

4.8

4.8

4.8

00.0

0.0

0.0

0.0

0.0

0.0

0.0

00.0

3.3

0.0

3.3

6.7

6.7

6.7

0.0

0.0

3.3

3.3

6.7

00.0

P

A

Primary Site

Adrenal glan

Kidney

Thyroid

e Code

d 95003

94903

80103

89603

83123

82603

83433

83403

85103

80103

MorpholNeuroblas

Ganglione

Carcinoma

Total

Nephrobla

Renal cell

Total

Papillary a

Papillary c

Papillary c

Medullary

Carcinoma

Total

ogy stoma, NOS

euroblastoma

a, NOS

astoma, NOS

carcinoma,

adeno carcin

carcinoma, e

carcinoma, fo

carcinoma,

a, NOS

a

S

NOS

noma, NOS

encapsulated

ollicular varia

NOS

d

ant

Male 12

2

0

14

7

1

8

2

1

0

0

0

3

% Fe85.7

14.3

0.0

100.0

87.5

12.5

100.0

66.7

33.3

0.0

0.0

0.0

100.0

emale %12 92

0 0

1 7

13 10

18 10

0 0

18 10

6 50

0 0

3 25

2 16

1 8

12 10

25

% 2.3

.0

.7

0.0

0.0

.0

0.0

0.0

.0

5.0

6.7

.3

0.0

26 26

Other sit

Brain, C

Liv

Stoma

Hodgkin's lympho

Bladd

Lu

NH

Leukaem

Prost

Colorec

Distributio

The follow

regions of S

site reporte

and thyroid

cancers am

cases. This

advanced c

regions see

Figure 2.5

Figure 2.5

Other s

Kid

Hodgkin's lymph

L

Leukaem

Brain, C

Thy

L

Pros

N

Colore

3.4

4.2

4.3

4.7

4.7

5.7

7.4

7.8

8.4

0 10

tes

NS

ver

ach

ma

der

ung

HL

mia

tate

ctal

Males ( 1352 ) M

on of Canc

wing bar cha

Saudi Arabia

d by perman

cancers we

mong men. It

s can be attri

cancer care c

eking for trea

5.1 : Riyadh

5.2 : Makka

4.1

4.2

4.3

4.4

4.4

5.1

6.3

6.4

8.0

0 10

sites

dney

oma

Lung

mia

CNS

yroid

Liver

state

NHL

ectal

Males ( 1604 )

33.7

15.6

20 30 40

Makkah Region

cer Cases in

arts show th

a by gender.

nent address

ere the leadi

is worth not

buted to the

centers whic

tment.

h Region, 2

h Region, 2

34

18.5

20 30 4Riyadh Region

7

0

Othe

Cervi

Hodgkin's lym

Leuk

Corpu

T

Col

n the 13 Ad

he distributio

These sites

s (region) of

ng cancers

ting that Riya

e high popula

h led to migr

2016 (Relat

2016 (Rela

Ot

Br

Hodgkin's ly

Leu

Corp

C

4.4

40

2.0

2.2

2.7

3.2

4.2

5.8

6.9

8.1

8.

0 10

er sites

ix Uteri

Kidney

mphoma

Ovary

kaemia

NHL

us Uteri

Thyroid

lorectal

Breast

Females (16

dministrati

n of the mos

are listed on

f the patient

among wom

adh, Makkah

ation density

ration of can

ive Freque

tive Freque

2.3

2.5

2.7

2.9

3.2

4.5

6.

0 10

ther sites

Lung

ain, CNS

ymphoma

ukaemia

Ovary

NHL

pus Uteri

Colorectal

Thyroid

Breast

Females ( 2

21.5

1

.8

34

20 30 40

673 ) Makkah Region

ve Regions

st common c

n the basis o

at the time

men, while C

h and Easter

in these reg

cer patients

ency Distrib

ency Distri

22.6

5

.2

9.8

16.3

26.9

0 20 30

2093 ) Riyadh Region

.5

0

n

Oth

Hodgkin's lym

Corp

Leu

C

s of Saudi

cancer sites

of the total n

of diagnosis

olorectal and

rn Province r

gions in addi

from remote

bution).

ibution).

40

n

O

Br

Hodgkin's ly

Cor

Le

C

2.7

3.4

3.6

3.8

3.8

5.5

5.

6

0 10

her sites

Kidney

Lung

mphoma

Prostate

pus Uteri

Thyroid

ukaemia

NHL

olorectal

Breast

All (3025 )

Arabia, 20

in the 13 ad

umber of cas

. In most reg

d NHL were

represent the

tion to the d

e areas to the

3.2

3.4

3.4

3.5

3.5

3.9

6

0 1

Other sites

Lung

rain, CNS

ymphoma

rpus Uteri

eukaemia

Liver

NHL

Thyroid

Colorectal

Breast

All ( 369

5

9

.5

11.9

19.4

0 20 30

) Makkah Region

16.

dministrative

ses for each

gions breast

e the leading

e majority of

istribution of

e three main

5

5

9

6.0

11.4

13.6

15.3

10 20 30

97 ) Riyadh Region

33.5

40

e

h

t

g

f

f

n

32.8

40

Other sit

Brain, CN

Kidn

Hodgkin's lymphom

Bladd

Thyro

Leukaemi

NH

Lu

Prosta

Colorect

Other site

Brain, CN

Bladd

Stomac

Nasopharyn

Lun

Hodgkin's lymphom

Leukaemia

Liv

NH

Colorect

Figure 2.5

Figure 2.5

Figure 2.5

Other site

Stoma

Oesophag

Hodgkin's lymphom

Kidn

Tes

Lun

Pancre

Prosta

colorect

NH

3.6

3.7

4.0

4.1

4.2

5.2

7.4

7.5

8.6

0 10

tes

NS

ney

ma

der

oid

ia

HL

ung

ate

tal

Males (1094 ) Ea

3.8

3.8

4.1

4.1

4.8

5.1

6.8

6.8

8.2

0 10 2

es

NS

der

ch

nx

ng

ma

a

ver

HL

tal

Males (293 ) Mad

5.3 : Easter

5.4 : Madina

5.5 : Northe

3.0

3.0

4.5

4.5

4.5

4.5

4.5

6.0

9.0

10.4

0 10 20

es

ch

gus

ma

ney

tis

ng

eas

ate

al

HL

Males (67 ) North

35.6

16.1

20 30 40

astern Region

31.7

20.8

20 30 40

dinah Region

rn Region, 2

ah Region,

ern Region

46.3

30 40 50

hern Region

6

Other

Hodgkin's lymp

O

Leuka

Brain

Th

Corpus

Colo

B

Other sites

Pancreas

Oesophagus

Salivary glands

NHL

Ovary

Lung

Leukaemia

Thyroid

colorectal

Breast

2016 (Rela

2016 (Rela

, 2016 (Rel

3

Females (144

2.4

3.0

3.0

4.3

4.6

5.2

7.3

7.6

9.

0

r sites

Liver

phoma

Ovary

emia

n, CNS

NHL

hyroid

s Uteri

orectal

Breast

Females (32

1.7

1.7

1.7

5.2

5.2

5.2

6.9

0 10Females (58 ) North

tive Freque

ative Frequ

ative Frequ

45 ) Eastern Region

25.0

5

28.0

20 4

28 ) Madinah Region

2

13.8

13.8

19.0

20hern Region

ency Distri

uency Distr

uency Dist

O

Cor

Hodgkin's l

Le

C

Oth

Nasop

Hodgkin's lym

Corpu

Brai

T

Leuk

Co

40

25.9

30

ibution).

ribution).

ribution).

O

O

Hodgkin's l

L

2.7

3.4

3.5

3.7

4.

4.

5

0 1

Other sites

Kidney

rpus Uteri

lymphoma

Prostate

eukaemia

Lung

NHL

Thyroid

Colorectal

Breast

All (2539

2.7

4.0

4.0

4.2

4.5

5.0

5.5

6.6

0 10

er sites

pharynx

mphoma

us Uteri

in, CNS

Liver

Thyroid

kaemia

NHL

lorectal

Breast

All (621 ) M

2.4

3.2

3.2

3.2

4.0

4.8

0 10

Other sites

esophagus

lymphoma

Prostate

Pancreas

Leukaemia

Lung

NHL

Thyroid

Breast

colorectal

All (125

3

4

5

7

6

.7

5.8

6.8

12.3

21.2

10 20 30

9 ) Eastern Region

6

14.8

15.1

20 30Madinah Region

0

8

8.0

8.0

8.8

11.2

0 20 30 40) Northern Region

27

31.3

40

33.5

40

43.2

0 50

20.7

2.0

2.4

2.6

3.1

4.1

4.5

6.0

8.8

9.4

36.4

0 40

Other sites

Cervix Uteri

Ovary

Lung

Hodgkin'slymphoma

Leukaemia

NHL

Corpus Uteri

Thyroid

Colorectal

BreastBreast

20 3010

28 28

Other site

Lun

Leukaemia

Liv

Prosta

Nasopharyn

NH

Stomac

Thyro

Hodgkin's lymphom

Colorecta

0

Other sites

Kidney

Stomach

Bladder

Prostate

Tongue

Leukaemia

Liver

Mouth

NHL

Colorectal

Males

Other

To

Pro

La

Hodgkin's lymph

Nasopha

Leukae

Th

Color

Figure 2.5

Figure 2.5

Figure 2.5

3.6

4.4

4.4

4.9

4.9

5.3

5.3

5.8

7.6

0 10

es

ng

a

ver

ate

nx

HL

ch

oid

ma

al

Males (225 ) Qass

3.4

3.4

4.0

5.4

5.4

6.0

6.0

8.7

11.4

11.4

10 20

s (149) Jazan Region

2.5

3.8

3.8

5.1

5.1

6.3

6.3

7.6

1

0 10

sites

ongue

ostate

arynx

homa

arynx

emia

Bone

yroid

NHL

rectal

Males (79 ) Ha

5.6 : Qassim

5.7 : Jazan

5.8 : Hail Re

33.3

20.4

20 30 40

sim Region

34.9

30 40

32.9

11.4

15.2

20 30 40ail Region

m Region, 2

Region, 20

egion, 2016

oth

Connective,So

P

Nasop

Hodgkin's lym

Corp

T

Col

Other

Salivary gl

Hodgkin's lymph

To

Leukae

N

M

Colore

Corpus U

Thy

B

0

2016 (Relat

016 (Relativ

6 (Relative

Ot

Br

Gallbla

Hodgkin's ly

Cor

C

1.5

1.5

1.8

2.1

5.5

5.8

6.7

7.3

9

0 10

her sites

oft tissue

Pancreas

Ovary

pharynx

NHL

mphoma

us Uteri

Thyroid

lorectal

Breast

Females (3

1.9

2.4

2.9

3.4

5.8

5.8

7.3

8.3

1

0 10

sites

lands

homa

ongue

emia

NHL

Mouth

ectal

Uteri

yroid

reast

Females (206)

tive Freque

ve Frequen

Frequency

2.0

2.0

2.0

2.0

2.6

5.3

6

0 10

ther sites

rain, CNS

Kidney

adder etc.

Stomach

Ovary

ymphoma

pus Uteri

Colorectal

Thyroid

Breast

Females (

18.8

7

3

9.4

3

20 30 40330 ) Qassim Region

24.3

1.2

26.7

20 30 40

Jazan Region

ency Distri

ncy Distribu

y Distributi

15.9

3

6.6

15.2

15.9

30.5

0 20 30(151 ) Hail Region

39.7

Oth

Hodgkin's lym

Leuk

Corpu

T

Col

0

O

Na

L

Co

Hodgkin's

bution).

ution).

ion).

Ot

Leu

Naso

Corp

Hodgkin's ly

Co

5

40

2.8

3.4

3.9

4.5

4.8

7.0

7.

8

9

0 10

her sites

mphoma

Liver

Tongue

kaemia

us Uteri

Mouth

Thyroid

NHL

lorectal

Breast

All (355) Ja

2.2

2.2

3.0

3.0

4

5

5

0

Other sites

Kidney

asopharynx

Leukaemia

Bone

orpus Uteri

NHL

lymphoma

Thyroid

Colorectal

Breast

All (230

2.3

2.5

2.7

3.2

4.0

5.

6

6

0 10

ther sites

ukaemia

Liver

Stomach

opharynx

pus Uteri

NHL

ymphoma

Thyroid

olorectal

Breast

All (555 )

3

0

3

8.2

9.0

16.1

20 30

azan Region

25.7

0

0

.3

5.2

5.2

13.0

15.2

20.9

10 20 30

0 ) Hail Region

28.

4

6.5

6.7

13.9

24.1

0 20 30 Qassim Region

33.0

40

40

.6

40

Other sit

L

Prosta

Hodgkin's lymphom

Liv

Colorect

Leukaemi

Other Sk

NH

Brain, CN

Thyro

Other s

B

To

Nasopha

L

Stom

Hodgkin's lymph

Bla

Oesoph

Color

N

Other

K

Bla

Pan

Hodgkin's lymp

Sto

Leukae

Pro

Colo

Figure 2.5

Figure 2.5

Figure 2.5

3.4

4.6

5.7

5.7

5.7

6.9

8.0

9.2

9.2

10.3

0 10

es

Lip

ate

ma

ver

tal

ia

kin

HL

NS

oid

Males (87 ) Najra

2.4

2.4

3.7

4.9

4.9

6.1

6.1

6.1

9.8

0 10

sites

Bone

ngue

arynx

Lung

mach

homa

adder

hagus

rectal

NHL

Males (82 ) Bah

2.2

3.2

4.0

4.6

5.6

6.8

7.0

8.6

9.4

0 10

r sites

Kidney

adder

ncreas

phoma

omach

emia

Liver

ostate

NHL

rectal

Males (498 ) A

5.9 : Najran

5.10 : Baha

5.11 : Asir R

31.0

20 30 40

an Region

3

14.6

20 30 40ha Region

30.9

6

4

17.5

20 30 4

Asir Region

Region, 20

Region, 20

Region, 201

Other

Pan

Corpus

Color

Leuka

O

Hodgkin's lymp

Th

B

Other sites

Tongue

Lip

Ovary

Stomach

Thyroid

Other Skin

Corpus Uteri

NHL

Colorectal

Breast

9.0

O

Hodgkin's l

Cor

Le

C

40

016 (Relati

016 (Relativ

16 (Relativ

2.5

2.5

3.3

4.1

4.9

5.7

5.7

7.4

0 10

r sites

ncreas

Liver

s Uteri

NHL

rectal

aemia

Ovary

phoma

hyroid

Breast

Females (122 )

2.5

2.5

3.8

5.0

6.3

6.3

8.8

10.0

0 10

e

p

y

h

d

n

i

L

t

Females (80 ) Bah

2.5

2.7

3.5

3.5

4.

5

0 1

Other sites

Stomach

lymphoma

Ovary

Liver

rpus Uteri

eukaemia

NHL

Colorectal

Thyroid

Breast

Females

ve Frequen

ve Frequen

e Frequenc

23.8

14.8

25.4

20 30 40) Najran Region

20.0

16.3

18.8

20 30ha Region

26.3

5

5

.8

5.6

6.7

11.7

12.9

19.8

10 20 30

(520) Asir Region

ncy Distrib

ncy Distrib

cy Distribu

Other

O

Brain,

Color

Other

Leukae

Hodgkin's lymp

Th

B

0

40

40

bution).

bution).

ution).

O

O

Nas

Hodgkin's l

Co

O

C

Hodgkin's

L

3.3

3.8

4.3

5.3

5.7

6.2

6.2

6.7

0 10

r sites

Ovary

Liver

, CNS

rectal

r Skin

emia

NHL

phoma

hyroid

Breast

All (209 ) Naj

3.1

3.1

3.7

4.

4.

4

0 1

Other sites

esophagus

sopharynx

lymphoma

Thyroid

rpus Uteri

Stomach

Breast

Other Skin

NHL

Colorectal

All (162

3

4

4

4

0

Other sites

lymphoma

Stomach

Other Skin

Prostate

Liver

Leukaemia

Thyroid

NHL

Breast

Colorectal

All (10

30.6

12.9

14.8

20 30 4

jran Region

1

1

7

3

3

.9

9.3

10.5

12.3

13.0

10 20 30) Baha Region

3.6

4.0

4.1

4.2

5.2

6.2

7.4

8.1

10.3

14.5

10 20 30

018) Asir Region

29

40

31.5

40

32.3

40

30 30

Other

Hodgkin's lymph

Brain,

L

Bla

Thy

Oesoph

Leukaem

Colore

L

N

Other

Leukae

Th

Brain,

Bla

Other

Hodgkin's lymp

Pro

Color

Figure 2.5

Figure 2.5

3.9

3.9

3.9

4.5

5.2

5.2

6.5

8.4

9.1

1

0 10

sites

homa

CNS

Liver

adder

yroid

hagus

mia

ectal

Lung

NHL

Males (154

4.3

4.3

4.3

4.3

4.3

5.4

5.4

6.5

0 10

r sites

emia

hyroid

CNS

adder

r Skin

homa

ostate

NHL

Lung

rectal

Females (92

5.12 : Tabuk

5.13 : Jouf R

3

1.7

20 30 40

4 ) Tabuk Region

3

12.0

12.0

20 30 4

) Jouf Region

k Region, 2

Region, 20

7.7

37.0

40

Other sites

Lung

Stomach

Kidney

NHL

Ovary

Other Skin

Leukaemia

Colorectal

Thyroid

Breast

2016 (Relat

016 (Relativ

Ot

Gallbla

Corp

Hodgkin's ly

Leu

Co

2.4

2.4

3.2

4.0

5.6

6.5

7.3

8.1

12.9

0 10

Males (124 ) Jouf Reg

tive Freque

ve Frequen

2.5

2.5

3.5

3.5

4.0

4.5

5.0

7

0 10

ther sites

Kidney

adder etc.

pus Uteri

Lung

NHL

ymphoma

ukaemia

olorectal

Thyroid

Breast

Females (

22.6

9

25.0

20 30

gion

ency Distri

cy Distribu

21.5

5

0

7.5

20.5

25.0

0 20 30

(200 ) Tabuk Region

40

bution).

ution).

40

O

Gallb

B

O

Hodgkin's

L

C

O

Hodgkin's

L

2.8

3.1

3.1

4

0

Other sites

bladder etc.

Brain, CNS

Oesophagus

lymphoma

eukaemia

Lung

NHL

Colorectal

Thyroid

Breast

All

2.8

3.

3

0

Other sites

Stomach

Ovary

lymphoma

NHL

Other Skin

Leukaemia

Lung

Thyroid

Colorectal

Breast

All (216

8

1

1

.2

5.6

5.9

7.3

7.9

13.8

14.7

10 20 30l (354 ) Tabuk Region

8

.2

.7

5.1

5.6

6.0

6.5

9.3

9.7

15.3

10 20 30

6 ) Jouf Region

31.4

40n

32.9

40

Saudi AraCamero

InOm

KuwMoro

UBahr

QaJord

Egch

SingapArgent

AustIrela

UNorw

Austra

Saudi ArabiOmaInd

CamerooMoroccBahraiKuwa

chinEgy

JordaSingapo

QatArgentin

UAAustri

UNorwa

AustralIrelan

US

Internatio

Figure 2.6

Figure 2.6

*ASR per 100,** Source for th

0

bia oondia

manwait occoUAEain atardan gypthinaporeina UK

tria andUSAway alia

0

ia ania oncoin

ait na

yptan oretarna AEia

UKay ia ndSA

nal Compa

6.1 : Compa

6.2 : Compa

000 his information i

74

50

50

arison of Ag

arison of A

arison of A

is summarized o

4.7

81.2

92.4

92.8

116.9

122

123

1

1

100

91.3

87.1

97.4

11

11

100

ge-Standar

ASR* for Sa

ASR* for Sa

on page 54.

9

.7

3.6

30.7

132.9

153.3

158.4

150 2

4.1

14.4

133.6

137.5

139.9

147.8

157

150

rdized Incid

audi males

audi female

211.2

218.8

230.4

200 25

.8

198.7

21

21

2

200

dence Rate

with selec

es with sele

4

284.0

29

0 300

10.1

11.8

214.9

222.7

250

es.

ted countr

ected coun

0

95.2

343.

347

0 350

267.3

277.1

278.6

278.9

297.4

300

ries**

ntries**

.3

7.0

368.7

373.9

400

4

350

31

32 32

I

CAN

NCIDE

CERS

PA

ENCE O

DIAGN

NATIO

ART

OF MO

NOSED

ONALS

T III

OST CO

D AMO

S,2016

OMMO

ONG SA

ON

AUDI

Cancer Inc

This sect

between Ja

geographica

presents co

developed a

Table 3.1

Site

Breast

Colorectal

Thyroid

NHL

Leukaemia

Hodgkin's

Corpus Ut

Lung

Liver

Prostate

cidence fo

tion demonst

anuary and D

al area. Dat

omparisons

and developi

: Most com

l

a

lymphoma

teri

r Most Com

trates the mo

December 20

ta presented

of cancer in

ing countries

mmon canc

mmon Sites

ost common

016. It shows

d as absolute

ncidence am

s.

cer among

Ma

42

95

22

46

33

26

0

29

29

40

s among S

cancers dia

s the distribu

e numbers,

mong Saudis

Saudis by

ale

2

55

22

69

34

65

0

98

90

05

Saudi Natio

gnosed amo

tion of the m

relative freq

s with cance

y gender, 20

Female

2240

704

854

372

276

230

454

148

127

0

onals, 2016

ong Saudi na

most common

quency, and

er incidence

016.

All

2282

1659

1076

841

610

495

454

446

417

405

.

ationals durin

n cancers by

incidence r

reported fro

ng the period

y gender and

rates. It also

om selected

%

17.3

12.6

8.2

6.4

4.6

3.8

3.4

3.4

3.2

3.1

33

d

d

o

d

34 34

Female Br

Breast ca

female brea

nationals, a

Saudi fema

at 46.7/100

and Jouf wi

and 103 yea

Figure 3.12016.

Table 3.1.

ICD-O-385003 85203

85223

80103

85233

80003

84803

85753

85103

90203

Total

Figure 3.1

reast Canc

ancer was ra

ast cancer c

and 30.4% fr

le population

,000, followe

ith 25.0/100,

ars).

.1 : Age-Sp

1 : Morpho

3 InfiltratingLobular c

Infiltrating

Carcinom

Infiltrating

Neoplasm

Mucinous

Metaplas

Medullary

Phyllode

Others

.2 : Stage d

cer (C50).

anked First a

cases. Breas

rom all cance

n. The five re

ed by Riyadh

,000 (Figure

pecific Inci

ological dis

Mg duct carcincarcinoma, N

g duct and lo

ma, NOS

g duct mixed

m, malignant

s adenocarc

stic carcinom

y carcinoma

s tumor, mal

distributio

Loca40

among femal

st cancer ac

ers reported

egions with th

h with 33.8/10

3.1.3). The

idence Rat

stribution o

Morthologynoma, NOS NOS

obular carcin

d with other t

t

inoma

ma, NOS

, NOS

lignant

n of breast

alised.8%

Unknown7.0%

es, between

ccounted to

among fem

he highest A

00,000, Qass

median age

e (AIR) for

of breast ca

y

oma

ypes of carc

t cancer am

n January an

17.3% from

ales at all a

ASR per 100

sim with 31.7

e at diagnosis

breast can

ancer amon

inoma

mong Saud

Distant 12.5%

Regional39.7%

d December

m all cancers

ges. The AS

0,000 populat

7/100,000 M

s was 50 ye

ncer among

ng Saudi fe

NO. 1745 139

85

48

38

27

22

21

20

13

82

2240

di females,

r 2016, there

s reported a

SR was 27.2

tion were Ea

akkah with 2

ears (ranged

g Saudi fem

emales, 20

7

1

2016.

e were 2,240

mong Saudi

2/100,000 for

astern region

29.7/100,000

between 17

males,

16.

% 77.9 6.2

3.8

2.1

1.7

1.2

1.0

0.9

0.9

0.6

3.7

00.0

0

i

r

n

0

7

0

1

10

100

00 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+Age Groups

Bah

Norther

Jaza

Asi

Madina

Najra

Ha

Tabu

Jou

Makka

Qassim

Riyad

Easter

chiOmInd

Saudi ArabCamero

MorocKuwa

EgyBahraJorda

SingapoAustr

ArgentinNorwa

UQat

AustralIrela

UU

Figure 3.1

*ASR per 100,

Figure 3.1

*ASR per 100,

** Source for th

0 5

a

n

n

ir

h

n

il

k

uf

h

m

h

n

0

inamandia bia on

ccoait yptain an oreria na ay AEtarlia ndSAUK

.3 : Region

000

.4 : Compa

000

his information i

7.0

9.4

1

5 10

10 20

nal distribu

arison of A

is summarized o

10.4

12.6

15.9

1

15

22.1

22.7

25.8

27.2

30

ution of bre

ASR* for Sa

on page 54.

9

17.4

19.0

19.8

20 2

35.2

40.8

40 5

east cancer

audi female

25.0

29.

5 30

49.1

49.5

53.8

6

50 60

r (ASR*) am

es breast ca

7

31.7

33.8

35

61.0

65.7

68.0

71.2

73

7

70

mong Saud

ancer with

40 4

3.1

73.9

75.3

86.

80 9

di females,

selected c

46.7

5 50

.0

92.3

92.9

95.0

0 100

2016.

countries.

35

36 36

Localised

29%

Un

Colorecta

There we

2016 amon

affected 955

12.9/100,00

Riyadh at

12.7/100,00

/100,000, f

and Qassim

between 20

Figure 3.2nationals,

Table 3.2.

Code 81403

84803

84903

82633

82613

80103

80003

81443

82463

82103

Total

Figure 3.2

known5%

l cancer (C

ere 1,659 ca

g Saudi nati

5 (57.6%) m

00 for males

18.9 /100,00

00, and Mad

followed by E

m at 8.6/100

0 and 96 yea

2.1 : Age-Sp 2016.

1 : Morpho

Adenocarci

Mucinous a

Signet ring

Adenocarci

Adenocarci

Carcinoma,

Neoplasm,

Adenocarci

Neuroendo

Adenocarci

Others

2.2 : Stage d

MaleDistant

24%

Regional42%

C18-C20).

ases of color

ionals. Color

males and 70

and 9.5/100

00 Eastern r

inah at 12.5/

Eastern regio

,000 (Figur

rs) and 57 ye

pecific Inci

ological dis

Morp

noma, NOS

adenocarcino

cell carcinom

noma in tubu

noma in villo

, NOS malignant

noma, intest

crine carcino

noma in ade

distributio

e

rectal cancer

rectal cancer

4 (42.4%) fe

0,000 for fem

region at 17.

/100,000. In

on at 13.6/10

re 3.2.3). Th

ears in fema

idence Rat

stribution o

hology

oma

ma

ulovillous ad

ous adenoma

tinal type

oma, NOS

enomatous p

n of colore

Localised24%

Unkno8%

Age Groups

r accounting

r was ranked

emales with a

males. The f

3/100,000, f

females, reg

00,000, then

e median ag

les (ranged b

e (AIR) for

of colorecta

enoma

a

olyp

ectal cance

D

own Female

for 12.6% o

d first among

a male to fem

five regions w

followed by A

gions with th

n Hail at 10.2

ge at diagno

between 14 a

colorectal

al cancer a

Male 748

61

27

25

18

13

11

11

9

6

26

955

er among S

Distant31%

Regional37%

of all newly d

g males and

male ratio of

with the high

Asir at 12.9/1

he highest A

2/100,000, th

osis was 59

and 95 years

cancer am

among Sau

% Fe78.3

6.4

2.8

2.6

1.9

1.4

1.2

1.2

0.9

0.6

2.7

100

Saudi natio

Localised

27%

Unknow6%

diagnosed ca

d third among

f 136:100. Th

hest ASR in

100,000, the

ASR were Riy

hen Jouf at 9

years in ma

s).

mong Saud

di national

emale 577

44

12

23

9

8

7

5

4

6

9

704

nals, 2016.

D

Reg4

wn All

ases in year

g females. It

he ASR was

males were

n Qassim at

yadh at 14.0

9.2/100,000,

ales (ranged

di

ls, 2016.

% 82.0

6.3

1.7

3.3

1.3

1.1

1.0

0.7

0.6

0.9

1.3

100

.

Distant27%

gional40%

r

t

s

e

t

0

,

d

0

1

10

100Male Female

0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+

Najran

Jazan

Baha

Hai

Tabuk

Northern

Jou

Makkah

Madinah

Qassim

Asi

Eastern

Riyadh

CameroEgyInd

MorocOm

UASaudi Arab

chiKuwa

BahraQat

UArgentin

JordaAustr

USingapo

NorwaIrela

Austral

Figure 3.22016.

*ASR per 100,

Figure 3.2countries*

*ASR per 100,

** Source for th

0 2

n

n

a

il

k

n

uf

h

h

m

r

n

h

33.

0

onyptdia ccoanAE

bia na

ait in tarSAna an ria UKoreay ndlia

2.3 : Region

000

2.4 : Compa**

000

his information i

3.6

3.13.2

3.9

2 4

3.3

5.2

5.1

7.3

8.5

9.5

2

6.1

7.2

9

5 10

nal distribu

arison of A

is summarized o

5.7

6.2

6.4

4.5

5.3

5.8

6.

6

5

11.6

14.2

13.2

9.9

10.6

12.6

12.9

1

15

ution of col

ASR* for co

on page 54.

8.2

9.2

8.4

8.6

8.2

8

8.9

8 10Male Fem

20.6

21.1

22.0

19.1

21.2

19.6

16.9

17.8

21.3

23

20 2Male Fem

lorectal can

olorectal ca

10.2

11.3

0 12ale

24.4

28.0

27.7

3.4

28.5

29

29

25 30ale

ncer (ASR*

ancer amon

13.6

14.0

12.5

12.7

12.9

14

35.8

32.0

.8

.8

34.0

36

35

*) among S

ng Saudis w

17.

16 18

6.8

40.1

42.6

43.

40 45

Saudi natio

with ASR in

3

18.9

8 20

1

45.5

5 50

nals,

n selected

37

38 38

Localised52%

Unk

Thyroid ca

Thyroid c

1076 thyroi

nationals. T

of 385:100.

highest AS

Najran at 9.

regions with

region at 3

age at diag

between 9 a

Figure 3.32016.

Table 3.3

Code

82603 83403

83413

83433

80503

83353

83303

85103

83443

82903

Total

Figure 3.3

Distan8%

known6%

Male

ancer (C73

cancer was

id cases can

Thyroid cance

. The ASR w

R for female

.9/100,000, t

h the highes

.4/100,000, t

nosis was 4

and 92 years

3.1 : Age-Sp

.1 : Morpho

Papillary Papillary

Papillary

Papillary

Papillary

Follicular

Follicular

Medullary

Papillary

Oxyphilic

Others

3.2 : Stage d

nt

Regional34%

3).

ranked seco

ncer accoun

er affected 8

was 8.9/100

es were Riy

then Jouf at

t ASR were

then Qassim

1 years in fe

s).

pecific Inci

ological dis

Mo

adenocarcincarcinoma,

microcarcino

carcinoma,

carcinoma,

r carcinoma,

r adenocarcin

y carcinoma

carcinoma,

c adenocarci

distributio

Localised66%

U

ond among

nting to 8.2%

854 (79.4%)

,000 for fem

yadh region

9.8/100,000

Najran at 4.

m at 3.1/100

emales (rang

idence Rat

stribution o

rphology

noma, NOS follicular var

oma

encapsulate

NOS

minimally in

noma, NOS

, NOS

columnar ce

noma

n of thyroid

Distant 3%

nknown6%

Female

Saudi fema

% from all n

females and

males and 2

at 16.6/100

, then Hail a

.8/100,000, f

,000, and Ta

ged between

e (AIR) for

of thyroid c

iant

d

vasive

ell

d cancer a

Regional25%

les and nint

ewly diagno

d 222 (20.6%

.5/100,000 f

0,000, followe

nd Eastern r

followed by R

abuk at 2.5/

3 and 93 ye

thyroid ca

cancer amo

Male

125 29

18

7

4

5

6

6

10

3

9

222

mong Saud

th among Sa

osed cancers

%) males, wit

for males. T

ed by Tabu

region both a

Riyadh at 4.

100,000 (Fig

ears) and 48

ancer amon

ong Saudi

e %

56.3 13.1

8.1

3.2

1.8

2.3

2.7

2.7

4.5

1.4

4.1

100.0

di national

Localised63%

Unknow6%

audi males.

s in 2016 a

th a female t

he five regio

k at 12.9/10

at 9.6/100,00

4/100,000, t

gure 3.3.3).

8 years in ma

ng Saudi na

nationals,

Female

438 132

116

26

24

22

19

18

18

16

25

854

s, 2016.

Distant 4%

wn

All

There were

mong Saudi

to male ratio

ons with the

00,000, then

00. In males,

then Eastern

The median

ales (ranged

ationals,

2016.

%

51.3 15.5

13.6

3.0

2.8

2.6

2.2

2.1

2.1

1.9

2.9

100.0

Regional27%

e

i

o

e

n

,

n

n

d

Age Groups

0

1

10

100Male Female

0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+

Ba

Madin

Jaz

Qass

North

Makk

A

East

H

J

Naj

Tab

Riya

Camero

Ind

Eg

Irela

Bahra

ch

Moro

Singap

Norw

Aust

Jord

Austra

Argenti

Om

Qa

Saudi Arab

Kuw

U

U

Figure 3.3

*ASR per 100,

Figure 3.3countries*

*ASR per 100,

** Source for th

1

0.

1

0

aha

nah

zan

sim

ern

kah

Asir

ern

Hail

ouf

ran

buk

adh

1.0.2

0.7

1

1

1

1

1.1

0.8

0

oon

dia

ypt

and

ain

hina

UK

cco

ore

way

tria

dan

alia

ina

man

atar

bia

wait

UAE

USA

3.3 : Region

000

3.4 : Compa**

000

his information i

2.21.0

1.2

.9

3.1

1.4

1.5

1.0

3

2.4

2.3

2.5

2

2

1.7

3.8

4.1

4.1

4.4

4

1.5

1.5

1.9

.3

1.5

1

2.1

2.3

1.9

4.1

1.7

2.1

2.5

2.0

1.9

5

nal distribu

arison of A

is summarized o

3.7

4.1

5.5

5.7

5

.4

4.8

4.4

4 6

4

4.9

5.5

6.0

6.0

6.0

7.2

7.2

7.4

7.6

5.6

6.4

ution of thy

ASR* for thy

on page 54.

7

5.9

7.4

8Male

8.5

8.9

10.1

10male Fem

yroid cance

yroid cance

9.6

9.6

9.8

9.9

10Female

15male

er (ASR*) a

er among S

12.9

12

17.5

among Sau

Saudis with

9

14 16

20.0

20

di national

h ASR in s

16.6

6 18

25

ls, 2016.

elected

39

40 40

Non-Hodg

Non-Hod

841 cases a

(55.8%) ma

for males a

7.5/100,000

and Asir at

by Riyadh a

(Figure 3.4.

57 years in

Figure 3.4

Table 3.4.

Code 96803 M

96873 B

95913 M

97003 M

97143 A

96913 F

96983 F

95903 M

96993 M

96903 F

OTotal

Figure 3.4

Localised38%

U

gkin Lymph

gkin Lympho

accounted to

ales, and 372

and 4.9/100,

0, followed b

6.5/100,000

at 6.3/100,00

.3). The med

females (ran

4.1 : Age-Sp

1 : Morpho

Malignant lymp

Burkitt lympho

Malignant lymp

Mycosis fungo

Anaplastic larg

ollicular lymp

ollicular lymp

Malignant lymp

Marginal zone

ollicular lymp

Others

4.2 : Stage d

Re1

Unknown6%

Male

homa (C82-

oma (NHL) w

o 6.4% from

2 (44.2%) fem

,000 for fem

y Baha at 7.

. In females,

00, then Asir

dian age at d

nged betwee

pecific Inci

ological dis

Morpphoma, large

oma, NOS

phoma, non-H

ides

ge cell lympho

phoma, grade

phoma, grade

phoma, NOS

B-cell lymph

phoma, NOS

distributio

Distant 44%

gional12%

Localised37%

Unknow10%

-C85; C96)

was ranked

all cancers d

males, with a

males. The fi

.2/100,000, t

regions with

r at 5.3/100,0

diagnosis wa

en 1 and 115

idence Rat

stribution o

phology B-cell, diffus

Hodgkin, NOS

oma, T cell an

2

3

oma, NOS

n of NHL a

Regional12%

wnFemale

.

second amo

diagnosed am

a male to fem

ive regions

then Riyadh

h the highest

000, then Ma

as 50 years i

years).

e (AIR) for

of NHL amo

e, NOS

S

nd Null cell ty

among Sau

Distant 41%

ong males a

mong Saudi

male ratio of

with the hig

at 7.0/100,0

t ASR were E

akkah at 5.2/

in males (ran

NHL amon

ong Saudi

Male236

31

23

20

ype 19

19

13

12

11

10

75

469

di national

Localised38%

Unkno8%

nd fifth amo

nationals in

126:100. Th

ghest ASR in

000, then Eas

Eastern regio

/100,000 and

nged betwee

ng Saudi na

nationals,

e % 50.3

6.6

4.9

4.3

4.1

4.1

2.8

2.6

2.3

2.1

16.0

100.0

ls, 2016.

Region12%

own%

All

ong females.

2016. NHL a

he ASR was

n males we

stern region

on 6.4/100,0

d Qassim at

en 1 and 105

ationals, 2

2016.

Female 211

8

26

20

3

10

7

14

16

7

50

372

Distant 42%

al

There were

affected 469

5.6/100,000

re Tabuk at

6.6/100,000

000, followed

4.5/100,000

5 years) and

016.

% 56.7

2.2

7.0

5.4

0.8

2.7

1.9

3.8

4.3

1.9

13.4

100.0

e

9

0

t

0

d

0

d

Age Groups

0

1

10

100Male Female

0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+

Qa

N

Mad

J

Nort

Ma

Ea

Ri

T

I

c

Saudi Ar

Jor

Q

O

Argen

Ku

Mor

Came

E

Au

Bah

Singa

Nor

Ire

Aust

Figure 3.4

*ASR per 100,

Figure 3.4

*ASR per 100,

** Source for th

0

assim

ajran

Hail

dinah

Jazan

Jouf

thern

akkah

Asir

stern

iyadh

Baha

Tabuk

0

ndia

china

rabia

rdan

Qatar

Oman

ntina

wait

rocco

UAE

eroon

Egypt

stria

hrain

apore

UK

rway

eland

ralia

USA

4.3 : Region

000

4.4 : Compa

000

his information i

1.2

1

1.5

2.02

2

nal distribu

arison of A

is summarized o

2

4.9

4.3

5

4.6

2.9

3.1

4

ution of NH

ASR* for NH

on page 54.

3.4

2.6

2.8

3.5

3.3

2.8

3

Male Fe

9

6.0

.0

5.3

7.0

6.1

5.6

6.3

5.6

5.8

6.2

7.

7

7

6male Fem

HL (ASR*) a

HL among S

4.5

3.8

4.1

5

3.8

3.9

4.0

4.3

4.6

4

emale

8.3

8.0

0

8.5

8.9

9.2

1

.2

7.3

7.7

8.0

8.2

8.6

8.6

8.7

8 1male

among Sau

Saudis wit

5.2

5.3

6

5.0

5.2

5

10.1

2

10.2

10.2

10.1

10 12

di national

h selected

6.4

6.3

6.5

6.6

6 7

11.9

12.3

12.5

2 14

ls, 2016.

countries*

7.0

7.2

7.5

8

14.4

14.7

16

*

41

42 42

Leukaemi

Leukaem

to 4.6% of

males and 2

and 3.0/100

5.3/100,000

both at 3.4/

at 4.9/100,0

median age

(ranged bet

Figure 3.5

Table 3.5.

Code 98363

98613

98353

98233

98633

98663

98013

98003

98373

99403

Total

a (C91-C95

mia was ranke

all cancer c

276 (45.2%)

0,000 for fe

0, followed b

100,000. In f

000, then A

e at diagnosi

tween 1 and

5.1 : Age-Sp

1 : Morpho

Precursor B-c

Acute myeloid

Precursor cel

B-cell chronic

Chronic myelo

Acute promye

Acute leukem

Leukemia, NO

Precursor T-c

Hairy cell leuk

Others

5).

ed third amo

cases diagno

females wit

emales. The

y Asir at 4.3

females, reg

Asir and Najra

is was 27 ye

87 years).

pecific Inci

ological dis

Mocell lymphobla

d leukemia, N

l lymphoblasti

c lymphocytic l

oid leukemia,

elocytic leukem

mia, NOS

OS

cell lymphobla

kemia

ong males an

osed among

h a male to f

five regions

3/100,000, th

gions with the

an both at 3

ears in males

idence Rat

stribution o

orphologyastic leukemia

OS

ic leukemia, N

leukemia/sma

NOS

mia, t(15;17) (

stic leukemia

nd the sixth a

Saudi natio

female ratio

s with the h

en Eastern r

e highest AS

3.7/100,000,

s (ranged be

e (AIR) for

of leukaem

y

NOS

all lymphocytic

q22;q11-12)

among femal

onals in 201

of 121:100.

highest ASR

region at 4.2

SR were Jouf

and Makkah

etween 0 and

leukaemia

ia among S

M

c lymphom

les, there we

6. Leukaem

The ASR wa

R in males w

2/100,000, th

f at 5.7/100,0

h at 3.4/100,

d 98 years)

a among Sa

Saudi natio

Male %62 18.

57 17.

40 12.

37 11.

37 11.

16 4.8

14 4.2

13 3.9

11 3.3

7 2.1

40 12.

334 100

ere 610 case

ia affected 3

as 3.6/100,00

were Makka

hen Madinah

000, then Ea

000 (Figure

and 31 year

audi nation

onals, 2016

% Fema.6 52

.1 70

.0 21

.1 20

.1 49

8 11

2 9

9 3

3 5

1 2

.0 34

0.0 276

es accounted

334 (54.8%)

00 for males

ah region at

and Riyadh

astern region

3.5.2 ). The

rs in females

nals, 2016.

6.

ale % 18.8

25.4

7.6

7.2

17.8

4.0

3.3

1.1

1.8

0.7

12.3

100.0

d

)

s

t

h

n

e

s

Age Groups

0

1

10

100

Male Female

0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+

Northern

Baha

Jazan

Hai

Qassim

Jouf

Tabuk

Najran

Riyadh

Madinah

Eastern

Asir

Makkah

Camer

In

Saudi ar

Moro

Om

c

Eg

Argent

Singap

Kuw

Bahr

Jor

Aus

Norw

Austr

Ire

Q

Figure 3.5

*ASR per 100,

Figure 3.5countries*

* ASR per 100

** Source for th

0.00

0

n

a

n

l

m

f

k

n

h

h

n

r

h

0.3

0

roon

ndia

abia

occo

man

hina

gypt

tina

pore

wait

rain

dan

stria

UK

way

USA

UAE

ralia

land

Qatar

5.2 : Region

000

5.3 : Compa**

,000

his information i

1

0.9

0.7

0.5

1.0

1

1.3

2.2

3

2.2

2.4

2.4

2

nal distribu

arison of A

is summarized o

1.31.8

1.9

2.0

2Mal

3.0

3.2

3.7

4.0

3.3

4.3

3.3

3.6

3.8

4.1

5.0

4m

ution of leu

ASR* for leu

on page 54.

2

2.2

0

2.6

2.8

3e Female

5.4

5.3

6.0

5.8

6.2

7.1

6.5

0

6.3

6.3

6.7

6male Fema

ukaemia (AS

ukaemia am

2.9

3.0

3

3.1

3

3.4

8

3.1

3.4

3.4

3

1

7.5

7.6

7.8

8.5

9.3

9.

8 1ale

SR*) amon

mong Saud

3.7

3.74.2

4.3

4

10.0

.5

10.3

11.4

11

10 12

ng Saudi na

dis with AS

4.9

5

5

12.74

1.7

12.5

2 14

ationals, 20

SR in select

5.7

5.3

6

15.1

16

016.

ted

43

44 44

Localised38%

Unkn6%

Hodgkin’s

Hodgkin’s

cases of Ho

2016. Hodg

female of 1

the highest

3.0/100,000

were Qassi

then Riyadh

years (rang

Figure 3.6nationals,

Table 3.6.2016.

Code

96633

96503

'96593

96523

96513

96673

96533

96653

96643

Total

Figure 3.6

Region21%

own%

Male

s Lymphom

s lymphoma

odgkin’s lym

gkin’s Lymph

15:100. The

t ASR in ma

0, then Hail a

m at 3.1/100

h and Easte

ed between

6.1 : Age-Sp 2016.

1 : Morpho

Hodgkin lym

Hodgkin lym

Hodgkin lym

Hodgkin lym

Hodgkin lym

Hodgkin lym

Hodgkin lym

Hodgkin lym

Hodgkin lym

6.2 : Stage d

Distant 35%

nal%

ma (C 81).

a was ranked

phoma acco

homa affecte

ASR was 2

ales were Q

at 2.6/100,00

0,000, follow

ern region bo

3 and 88 yea

pecific Inci

ological dis

M

mphoma, nod

mphoma, NO

mphoma, nod

mphoma, mix

mphoma, lym

mphoma, nod

mphoma, lym

mphoma, nod

mphoma, nod

distributio

d the sevent

ounted to 3.8

ed 265 (53.5%

2.6/100,000 f

Qassim and

00, and Riya

wed by Jouf a

oth at 2.7/10

ars) in males

idence Rat

stribution o

Morphology

dular scleros

OS

dular lympho

xed cellularit

mphocyte-ric

dular scleros

mphocyte dep

dular scleros

dular scleros

n of Hodgk

Localised32%

Unk1

th among Sa

8% of all can

%) males an

for males an

Najran both

adh at 2.5/10

at 3.0/100,00

00,000 (Figu

s and 25 yea

e (AIR) for

of Hodgkin

sis, NOS

ocyte predom

ty, NOS

h

sis, grade 2

pletion, NOS

sis, grade 1

sis, cellular p

kin’s lymph

Region26%

known0%

Fema

Loc

audi males a

ncer cases d

nd 230 (46.5

d 2.3/100,00

at 3.9/100,

00,000. In fem

00, then Ma

re 3.6.3). Th

ars (ranged b

Hodgkin’s

’s lymphom

minance

S

phase

homa amon

Distant 32%

al

le

calised35%

Unknow8%

and Saudi fe

diagnosed am

5%) females,

00 for female

000, followe

males, regio

kkah and Ba

he median a

between 4 an

s lymphom

ma among

Male

123 4

42 1

40 1

38 1

14

3

2

2

l

265 1

ng Saudi n

Dista33%

Regiona24%

wnAll

emales. The

mong Saudi

with a ratio

es. The five

ed by Easte

ns with the h

aha both at 2

age at diagn

nd 90) in fem

a among S

Saudi nati

% Fem

46.4 129

15.8 48

15.1 5

14.3 33

5.3 9

1.1 4

0.8 2

0.8 0

0.4 0

00.0 230

ationals, 2

ant %

al

re were 495

nationals in

n of male to

regions with

rn region at

highest ASR

2.9/100,000,

osis was 28

males.

Saudi

onals,

ale %

9 56.1

8 20.9

2.2

3 14.3

3.9

1.7

0.9

0.0

0.0

0 100.0

2016.

5

n

o

h

t

R

,

8

0

1

10Male Female

-30 -35 -400 -5 -10 -15 -20 -25 -45 -50 -55 -60 -65 -70 75+Age Groups

Bah

Jaza

Norther

Madina

Jou

As

Makka

Tabu

Riyad

Ha

Easter

Qassim

Najra

CCame

ISingaArgen

AusE

MorJor

AustO

Saudi Ar

Ire

NorBah

QKuw

Figure 3.62016.

*ASR per 100,

Figure 3.6selected c

*ASR per 100,

** Source for th

0

ha

n

rn

h

uf

ir

h

uk

h

ail

rn

m

n

0.10

0

Chinaeroonndia

aporentina stria

Egyptroccordan ralia

Omanrabia

UAEeland

UKUSA

rway hrain Qatarwait

6.3 : Region

000

6.4 : Compacountries**

000

his information i

0.70.4

0.8

1 1

1

0.5

0.5

0.7

0

0.7

0.2

0

1

nal distribu

arison of A*

is summarized o

1.3

1.1

1

1

1 2

1.0

1.1

0.8

0.8

0.9

1.0

1 2

ution of Ho

ASR* for Ho

on page 54.

2

1.7

.5

.5

1.6

2

2Male Fem

1.5

1.6

1.9

1.8

1.9

1.9

1.9

1.9

1.9

2Male Fem

dgkin’s lym

odgkin’s ly

.1

2.2

2.6

2

2

2.2

.1

2.2

2.5

2.6

3male

2.3

2.3

2.3

2.2

2.2

2.3

2.5

2.5

2.6

2.6

2.6

3male

mphoma (A

mphoma a

2.9

3.0

2.9

2.7

2.7

3.13.0

3

2.9

6

6

6

2.8

2.8

2.9

3.1

3

ASR*) amon

among Sau

3

3

4 4

4 4

ng Saudi n

dis with AS

3.9

3.9

4 5

4.0

4.1

4.2

4 5

nationals,

SR in

45

46 46

Corpus Ut

Corpus U

cancer cas

population.

region at

5.2/100,000

Figure 3.7females, 2

Table 3.7.

Code 83803 81403

84413

80103

89503

89313

89803

88903

84613

80003

Total

Figure 3.7

teri Cancer

Uteri cancer

ses diagnose

The five reg

9.1/100,000

0(Figure 3.7.3

7.1 : Age-Sp2016.

1 : Morpho

EndomeAdenoca

Serous c

Carcinom

Mulleria

Endome

Carcinos

Leiomyo

Serous s

Neoplas

Other

7.2 : Stage d

r (C54).

was ranked

ed among S

gions with the

0, then M

3). The med

pecific Inci

ological dis

Moretrioid adenoarcinoma, NO

cystadenoca

ma, NOS

n mixed tum

etrial stroma

sarcoma NO

osarcoma, N

surface papi

sm, maliqnan

distributio

Localised65.4%

Un5

fourth amo

Saudi female

e highest AS

Makkah at

ian age at di

idence Rat

stribution o

rthology ocarcinoma OS

arcinoma NO

or

l sarcoma lo

OS

OS

llary carcino

nt

n of corpus

Dista10.8

known5.5%

ng Saudi fem

es in 2016.

SR were Riy

6.7/100,000

agnosis was

e (AIR) for

of corpus u

NOS

OS

ow grade

ma

s uteri can

ant 8%

Regional18.3%

males with 4

The ASR

adh region a

0,Qassim a

s 60 years (ra

corpus ute

uteri cance

N24

2

1

1

3

4

cer among

454 cases ac

was 6.6/100

at 10.6/100,0

t 6.1/100,0

anged betwe

eri cancer

r among Sa

No 99 44

23

13

10

9

7

7

6

5

31

54

g Saudi fem

ccounted to

0,000 for S

000, followed

000, and M

een 18 and 9

among Sau

audi femal

% 65.99.7

5.1

2.9

2.2

2.0

1.5

1.5

1.3

1.1

6.8

100.0

males, 2016

6.2 % of all

audi female

d by Eastern

Madinah at

96 years).

udi

es, 2016.

9

0

6.

l

e

n

t

0

1

10

100

Age Groups

0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+

Figure 3.72016.

*ASR per 100,

Figure 3.7in selected

*ASR per 100,

** Source for th

NorthNaj

JTaJa

AB

HMadi

QasMakEastRiya

InOm

MoroEg

BahrJord

Saudi AraKuw

Argentch

AustIrela

AustraU

Singap

NorwU

Camero

7.3 : Region

000

7.4 : Compad countries

000

his information i

0

hernjranJoufbuk

azanAsirahaHailnah

ssimkkahternadh

0

dia manoccogyptain

dan bia

wait ina

hinatria andalia UAEpore

UKway USAoon

nal distribu

arison of As**

is summarized o

1.2

2

2.3

2.4

3.0

3.8

4.1

5.2

6.6

6.

5

ution of cor

ASR* for co

on page 54.

2.7

3.1

3.3

3.5

3.7

3.

4

6

7

7.8

8.6

10.4

11.1

1

10

rpus uteri c

orpus uteri

7

8

4.8

5.2

1

12.1

13.3

13.9

13.9

16

15

cancer (AS

cancer am

6.1

6.7

6

6.9

19.5

20

SR*) among

mong Saudi

8

25

g Saudi fem

females w

9.1

10

30.0

30

males,

with ASR

10.6

12

35

47

48 48

Regional 17%

Localised16%

Un

Lung Can

Lung can

of lung can

affected 298

4.4/100,000

Jouf at 10.1

4.6/100,000

regions eac

Riyadh at 3

males (rang

Figure 3.82016.

Table 3.8.

Code 81403 A80703 S80413 S80463 N80003 N80103 C85503 A80723 S

84803 M85603 A

OTotal

Figure 3.8

nknown7%

Male

cer (C33 - C

ncer was ran

ncer accoun

8 (66.8%) m

0 for males a

1/100,000, fo

0 and Makka

ch at 4.1/100

.4/100,000,

ged between

8.1 : Age-Sp

1 : Morpho

AdenocarcinoSquamous ceSmall cell carNon-small ceNeoplasm, mCarcinoma, NAcinar cell caSquamous cell

Mucinous adeAdenosquamOthers

8.2 : Stage d

Distant 60%

e

C34)

ked fifth amo

ted to 3.4 %

males and 14

and 2.0 /100

ollowed by E

ah at 4.5/100

0,000 and 4.

and Jouf at 2

22 and 94 y

pecific Inci

ological dis

Moma, NOS ell carcinomarcinoma, NOll carcinoma alignant

NOS arcinoma

carcinoma, lar

enocarcinomous carcinom

distributio

Regional 10%

Localised22%

U

ong Saudi m

% of all new

8 (33.2%) fe

0,000 for fem

Eastern regio

,000. In fema

.0/100,000 re

2.3/100,000

years) and 59

idence Rat

stribution o

Morpholog

a, NOS S

rge cell, nonke

ma ma

n of lung c

Unknown9%

Fem

males and ten

wly diagnose

emales with a

males. The fiv

n at 9.6/100

ales, regions

espectively,

(Figure 3.7.3

9 years in fem

e (AIR) for

of lung can

gy

ratinizing, NOS

cancer amo

Distant 59%

male

nth among S

ed cases am

a male to fem

ve regions w

,000, then T

s with the hig

followed by

3). The med

males (range

lung canc

cer among

Male 98 51 33 25 15 14 8

S 7 6 5 36

298

ong Saudi n

Regional 15%

Localised18%

U

audi females

mong Saudis

male ratio of

with the high

Tabuk at 8.0/

ghest ASR w

Eastern reg

ian age at di

ed between 2

er among S

g Saudi nat

% F32.9 17.1 11.1 8.4 5.0 4.7 2.7 2.3 2.0 1.7 12.1

100.0

nationals, 2

nknown7%

All

s. There wer

s in 2016. L

f 201:100. Th

est ASR for

/100,000, the

were Tabuk a

gion at 3.7/10

iagnosis was

20 and 94 ye

Saudi natio

tionals, 201

Female 67 11 5 7 14 10 3 1 3 2 25

148

2016.

Distant 60%

re 446 cases

Lung cancer

he ASR was

males were

en Riyadh at

and Northern

00,000, then

s 64 years in

ears).

onals,

16.

% 45.3 7.4 3.4 4.7 9.5 6.8 2.0 0.7 2.0 1.4 16.9

100.0

s

r

s

e

t

n

n

n

Age Groups

0

1

10

Male Female

0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+

100

Hai

Najran

Jazan

Asi

Qassim

Baha

Madinah

Northern

Makkah

Riyadh

Tabuk

Eastern

Jou

Came

Saudi A

O

Ku

Ba

Mo

Jo

Arge

Aus

No

Sing

Ir

Au

Figure 3.8

*ASR per 100,

Figure 3.8Countries

*ASR per 100,

** Source for th

1

0

0.4

1

0.6

0.5

0.5

0.6

0.8

0

il

n

n

r

m

a

h

n

h

h

k

n

uf

1.0

2

1.

2

0

eroon

Arabia

Oman

UAE

uwait

India

Egypt

Qatar

hrain

orocco

ordan

ntina

tralia

orway

UK

apore

reland

ustria

USA

China

8.3 : Region

000

8.4 : Compa**

000

his information i

1

1.4

1

1.4

2.3

8

1.1

2

.0

3.2

.4

2.7

3.1

3.8

5.3

5.1

2.8

4.1

2.0

4.4

4.9

8.9

9.

10

nal distribu

arison of A

is summarized o

4

3.4

4.

3.7

2.7

3.2

3.3

4

4

11.8

15.5

5

11.0

11.2

14.0

14.1

2

ution of lun

ASR* for lun

on page 54.

.1

4.2

4.5

4.6

6Male Fem

21.5

26

25.

19.5

20.4

25.4

2

20male Fem

ng cancer (

ng cancer a

6male

6.1

.8

27.4

33.7

4

27.0

32.5

33.3

3

3

30male

ASR*) amo

among Sau

8

8

7

3

4.8

34.9

35.7

36.1

37.1

40

ong Saudi n

udis with A

9.6

10.1

10

44.2

50

nationals, 2

ASR in Sele

12

52.8

60

2016.

ected

49

50 50

Localised41%

Unknown22%

Liver Canc

Liver can

cancer case

affected 290

4.2/100,000

Riyadh regi

4.3/100,000

were Riyad

at 2.0/100,0

was 67 yea

100 years).

Figure 3.9.

Table 3.9.

Code

81703 80003

81603

81723

81403

19703

91203

82463

85503

88943

Total

Figure 3.9

Dista17%

Male

cer (C22)

ncer was rank

es accounted

0 (69.5%) m

0 for males a

ion at 7.2/10

0 for each re

h at 3.7/100,

000 and Mad

ars in males

1 : Age-Spe

1 : Morpho

HepatocellNeoplasm

Cholangioc

Hepatocell

Adenocarc

Hepatobla

Hemangio

Neuroendo

Acinar cell

Angiomyos

Others

9.2 : Stage d

ant %

Regional20%

ked sixth am

d to 3.2% of

males and 12

and 1.9/100,

00,000, follow

egion, and E

,000, followe

dinah and M

(ranged betw

ecific Inciden

ological dis

Morpho

lular carcino, malignant

carcinoma

lular carcino

cinoma, NOS

stoma

sarcoma

ocrine carcin

carcinoma

sarcoma

distributio

Localised46%

Unknown19%

mong Saudi m

all cancer ca

7 (30.5%) fe

,000 for fem

wed by Asir

Eastern regio

ed by Asir at

Makkah both

ween 0 and

nce Rate (A

stribution o

ology

ma, NOS

ma, scirrhou

S

noma, NOS

n of liver c

Distan18%

Female

males and tw

ases diagnos

emales with a

ales. The fiv

at 5.1/100,0

on at 4.1/100

2.5/100,000,

at 1.5/100,0

116 years) a

IR) for liver

of liver can

s

cancer amo

nt %

Regional17%

welfth among

sed among S

a male to fem

ve regions w

000, followed

0,000. In fem

, then Easter

000 (Figure 3

and 64 years

cancer amo

cer among

Male

220 30

15

12

3

3

2

2

1

1

1

290

ong Saudi n

Localised42%

Unknown21%

Saudi femal

Saudi nationa

male ratio of

with the highe

d by Madina

males, region

rn region at

3.9.3). The m

s in females

ong Saudi n

g Saudi nat

%

75.9 10.3

5.2

4.1

1.0

1.0

0.7

0.7

0.3

0.3

0.3

100.0

nationals, 2

Distant18%

All

les. There w

als in 2016.

f 228:100. Th

est ASR for

h and Najra

ns with the h

2.1/100,000

median age

(ranged bet

ationals, 20

tionals, 201

Female

82 6

19

2

6

0

0

3

0

0

9

127

2016

t

Regional19%

ere 417 liver

Liver cancer

he ASR was

males were

an regions at

highest ASR

, and Najran

at diagnosis

tween 8 and

016

16

%

64.6 4.7

15.0

1.6

4.7

0.0

0.0

2.4

0.0

0.0

7.1

100.0

r

r

s

e

t

R

n

s

d

Age Groups

0

1

10

100Male Female

-5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+0

MorBah

NorInQ

Saudi Ar

Argen

OKuwIre

JorAustr

CameAus

SingacE

Figure 3.9

*ASR per 100,

Figure 3.9countries*

* ASR per 100** Source for th

Ha

Bah

Norther

Jou

Jaza

Qassim

Makka

Tabu

Easter

Madina

Najra

Asi

Riyad

1.0

1.4

1

1

1

1.

1

2

1.

0

roccohrain

rway ndia

Qatar

abia UAE

ntina

Omanwait

eland

UKrdan ralia

roonstria USA

porechinaEgypt

9.3 : Region

000

9.4 : Compa**

,000 his information i

0.5

0

0

0.5

0.5

0

0

0

il

a

n

uf

n

m

h

k

n

h

n

ir

h

5.8

4

1.9

7.

1.9

3.1

2.5

1.8

5

2.2

1.9

3.0

2.1

2.5

2.8

2.8

4.1

5

2.5

2.9

3.5

3.6

4.2

4.4

4.4

4.4

4.4

4.5

4.6

5.4

6.4

7.3

8

5

nal distribu

arison of A

is summarized o

5

5

5

1.2

1.5

0.6

1.5

0.6

0.7

1

1.6

1

7

10.9

14

3

8.1

9.8

10 15

ution of live

ASR* for liv

on page 54.

2.1

2

2.5

6

1.8

2

4.1

15.8

5 20male Fem

er cancer (A

er cancer a

3.7

2.8

3.3

3.3

3 4Male Fem

25male

ASR*) amo

among Sau

7

4.1

4.3

4.3

4 5male

30

ong Saudi n

udis with A

5.1

6

33.7

38.1

35 40

nationals, 2

ASR in sele

7

1

0 45

2016

ected

7.1

8

51

52 52

Prostate C

Prostate

cancers cas

The five re

7.9/100,000

median age

Figure 3.12016.

Table 3.10

Code 81403

85503

80003

80103

84803

89103

84903

Total

Figure 3.1

Cancer (C6

cancer was

ses diagnose

egions with

0, then Makk

e at diagnosis

0.1 : Age-S

0.1 : Morph

Adenocar

Acinar ce

Neoplasm

Carcinom

Mucinous

Embryon

Signet rin

0.2 : Stage

61)

s ranked the

ed among Sa

the highest

kah at 7.5/10

s was 70 yea

Specific Inc

hological di

Morrcinoma, NO

ell carcinoma

m, malignant

ma, NOS

s adenocarci

al rhabdomy

ng cell carcin

e distributio

Localised49.9%

e tenth amo

audi Males in

t ASR were

00,000, Asir

ars (ranged b

cidence Ra

istribution

rphology OS

a

noma

yosarcoma, N

noma

on of prost

Unknown4.2%

ong Saudi m

n 2016. The

e Eastern re

at 6.6/100,0

between 15 a

ate (AIR) pr

of prostate

NOS

tate cancer

Distant35.1%

Regional10.9%

males with 40

ASR was 6.3

egion at 11

000, and Jou

and 101 yea

r

e cancers a

rs among S

05 cases ac

3/100,000 fo

.2/100,000,

uf at 5.0/100,

rs).

ostate cancer amon

among Sau

NO. 367

18

9

7

2

1

1

405

Saudi natio

ccounted to

or Saudi male

followed by

,000 (Figure

ng Saudi n

udi nationa

%90

4.4

2.

1.

0.

0.

0.

100

onals, 2016

3.1% of all

e population.

y Riyadh at

3.10.3).The

ationals,

als, 2016

% .6

4

2

7

5

2

2

0.0

6.

l

.

t

e

0

1

10

100

0 -5 -10 -15 -20 -25 -30 -35 -

Age Groups

40 -45 -50 -55 -60 -65 -70 75+

Baha

Hail

Madinah

Jazan

Tabuk

Qassim

Najran

Northern

Jouf

Asir

Makkah

Riyadh

Eastern

IndiaChina

Saudi ArabiaEgyptOmanQata

JordanBahrain

UAEKuwait

MoroccoCameroonSingaporeArgentina

UKAustria

USAIreland

AustraliaNorway

Figure 3.1

*ASR per 100,

Figure 3.1ASR in Se

*ASR per 100,

** Source for th

0.8

0.0

a

l

h

n

k

m

n

n

f

r

h

h

n

4.2

5.3

6.3

7.8

1

0

a a

a tnr

n n Et onea Ka Ada y

0.3 : Regio

000

0.4 : Compelected Cou

000

his information i

1.7

2.0

2.3

2

2.0

12.2

12.3

15.3

16.3

16.5

18

18.5

23

20

onal distrib

parison of Auntries**

is summarized o

2.7

3.1

3.7

4.0

33.1

44.1

40

bution of pr

ASR* for o

on page 54.

4.7

5.0

6.0

60

rostate can

of prostate

6.6

7.5

8

73.2

74.7

80

ncers(ASR*

cancers am

5

7.9

8.0

98.2

100

*) among S

mong Saud

10.0

114.2

115.1

120

Saudi natio

di nationals

11.2

12.0

129.7

140

onals, 2016

s with

53

54 54

1.

2.

Reference

GLOBOCAN

Research o

15- Year Ca

http://

es :

N 2012, Canc

on Cancer. Av

ancer Inciden

/ghc.sa/ar-s

cer Incidence

vailable from

nce among N

sa/Documen

e and Mortal

m: http://globo

Nationals of t

nts/GCCCP

ity Worldwid

ocan.iarc.fr/P

the GCC Sta

P/GCCCP%

e, IARC, Lyo

Pages/online

tes, 1998-20

%20-%20Re

on: Internatio

e.aspx

012

port%20-%

onal agency f

20Pages.pd

for

df

CANC

PACER IN

NON

ART CIDEN

N-SAU

2016

IV NCE AM

UDIS

MONGG

55

56 56

Cancer Inc

Between

population,

10 codes. T

and 1,826 (

The ratio of

and the fac

differences.

represented

During 2016

ages 15 to

median age

(ranged bet

Table 4.1

Breast

Colorecta

Thyroid

NHL

Skin

Lung

Prostate

Leukaem

Kidney

Stomach

Total

cidence Am

January and

147cases w

Therefore, th

51.4 %) were

f male to fem

ct that cance

. Those who

d 3.8%, and t

6, approxima

39 years, 5

e at diagnosi

tween 0 and

: Ten most

al

mia

mong Non-

d December

were excluded

he total numb

e females.

male was 10

er is primari

were under

the 15 to 59

ately 3.5 % o

5.9% were b

s was 54 ye

106).

t common c

Site

-Saudi Pop

2016, a tota

d from analy

ber of cases

02:100. Takin

ly a disease

15 represen

age group re

of all cancers

between the

ars in males

cancers am

pulation, 20

al of 3,845 ca

ysis due to In

analyzed w

ng into cons

e of the elde

nted 15.2% o

epresented 8

s occurred be

ages 40-64

s (ranged bet

mong Non-

3

016.

ancer cases

n Situ and m

was 3,698 Ou

sideration the

erly; the patt

of the populat

81% of Non-

efore the age

4, and 11.2 %

tween 0 and

-Saudi pop

NO. 807

421

214

198

171

157

144

133

115

112

3698

were reporte

mismatch bet

ut of this 1,8

e population

tern of canc

tion, those a

Saudi popula

e of 15, 29.4

% occurred a

103 years)

ulation, 20

ed among the

tween ICD-O

72 (48.6 %)

structure of

cer had som

aged 60 year

ation.

% occurred

after the age

and 49 year

016.

% 21.8

11.4

5.8

5.4

4.6

4.2

3.9

3.6

3.1

3.0

100.0

e Non-Saudi

O-3 and ICD-

were males

f non-Saudis

e significant

rs and above

between the

e of 64. The

rs in females

i

-

s

s

t

e

e

e

s

Table 4.2

NationaliYemen

Syrian Arab

Egypt

Sudan

Philippines

Pakistan

Gaza Strip(

India

Jordan

Bangladesh

Eritrea

Indonesia

Myanmar

United State

Ethiopia

Non-Saudi,

Lebanon

United King

Afghanistan

Bahrain

Sri Lanka

Morocco

Somalia

Canada

Chad

Others Nati

TOTAL

: Distributi

ty

b Republic

(Palestine)

h

es of Americ

NOS

gdom

n

onalities

on of canc

M

ca

1

cer cases a

Male 391

227

228

198

129

106

82

84

49

58

19

12

22

42

14

17

17

21

11

11

12

7

9

10

6

90

1872

among Non

% 20.9

12.1

12.2

10.6

6.9

5.7

4.4

4.5

2.6

3.1

1.0

0.6

1.2

2.2

0.7

0.9

0.9

1.1

0.6

0.6

0.6

0.4

0.5

0.5

0.3

4.8

100

n-Saudi by

Female 334

218

209

165

226

82

72

55

51

16

39

40

29

9

33

22

14

10

18

17

13

17

0

7

10

120

1826

nationality

% 18.3

11.9

11.4

9.0

12.4

4.5

3.9

3.0

2.8

0.9

2.1

2.2

1.6

0.5

1.8

1.2

0.8

0.5

1.0

0.9

0.7

0.9

0.0

0.4

0.5

6.6

100

y and gend

Total 725

445

437

363

355

188

154

139

100

74

58

52

51

51

47

39

31

31

29

28

25

24

19

17

16

200

3698

er, 2016.

% 19.6

12.0

11.8

9.8

9.6

5.1

4.2

3.8

2.7

2.0

1.6

1.4

1.4

1.4

1.3

1.1

0.8

0.8

0.8

0.8

0.7

0.6

0.5

0.5

0.4

5.4

100

57

58 58

Table 4.3

Male Colorecta

Prostate

Skin

NHL

Lung

Bladder

Kidney

Leukemia

Stomach

Brain,CNS

Figure 4.12016.

0

10

1000

: Most com

l

S

: Age-Spe

mmon canc

1872

299

144

135

133

124

92

89

84

73

73

ecific Incide

Ag

cers among

%

15.9

7.7

7.2

7.1

6.6

4.9

4.8

4.5

3.9

3.9

ence Rate

Male

ge Groups

g Non-Saud

Fem

9 Breas

7 Thyro

2 Color

Corp

6 Ovar

9 NHL

8 Cerv

5 Leuk

9 Stom

9 Skin

(AIR) for a

Female

di populatio

male

st

oid

rectal

us Uteri

y

ix Uteri

emia

mach

ll cancers a

on by gend

1826

787

146

122

78

77

65

51

49

39

36

among No

der, 2016.

6

7

6

2

n-Saudi po

%

43.1

8

6.6

4.3

4.2

3.6

2.8

2.7

2.1

2

opulation,

100

0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+

INC

PACIDEN

ARTNCE T

T VTABLLES

59

60 60

Table

ICD (10th)

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C96

C88

C90

C91

C92-C94

C95

Other

All

Not C44

5.1.1 : Numb

Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharynx

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchus,Lung

Other Thoracic organs

Bone

Melanoma of Skin

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft tissue

Breast

Penis

Prostate

Testis

Other male genital

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary organs

Eye

Brain, Nervous system

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

Non-Hodgkin lymphoma Immunoproliferative dis.

Multiple Myeloma

Lymphoid Leukaemia

Myeloid Leukaemia

Leukaemia unspec.

Other & unspecified

All sites Total

All sites but C44

ber Of Cases

All Ages

Age unk

16 0

60 0

59 0

23 0

3 0

4 0

154 0

7 0

2 0

78 1

207 0

37 0

581 5

374 0

24 0

290 0

80 0

170 1

18 0

69 0

298 1

16 0

93 1

14 0

207 1

11 0

27 0

89 1

42 0

4 0

405 0

123 1

3 0

196 0

7 0

8 0

229 0

7 0

30 0

212 0

222 0

22 0

5 0

265 0

469 0

0 0

72 0

165 0

142 0

27 0

137 1

----- -----

5803 13

5596 12

Among Saud

0-4 5-9 10-14

0 0 1

0 0 0

1 0 1

0 0 0

0 0 0

0 0 0

0 0 4

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 1

3 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

1 0 0

4 10 13

0 0 0

1 1 1

0 0 0

0 0 0

5 2 5

0 0 0

0 0 0

0 0 0

6 1 2

0 0 0

4 3 1

0 0 0

0 0 0

2 0 0

0 0 0

18 1 0

24 23 12

0 1 2

12 1 1

0 0 2

4 23 24

14 17 11

0 0 0

0 0 0

36 23 19

14 5 5

4 3 2

5 1 1

----- ----- -----

158 115 108

157 114 107

di Males by P

4 15-19 20-24

0 0

0 0

0 2

0 4

0 0

0 0

4 4

0 0

0 0

0 0

1 3

0 0

0 5

0 1

0 0

0 0

0 1

0 0

0 1

0 0

0 1

0 3

20 11

0 0

1 6

0 0

0 0

2 11

0 1

0 0

1 0

12 17

0 0

0 0

0 0

0 0

0 0

0 0

1 1

2 16

4 6

2 1

0 1

24 33

16 25

0 0

0 0

15 8

11 12

2 0

1 4

----- -----

119 178

118 172

Primary Site A

25-29 30-34

0 0

1 1

1 1

4 3

0 0

0 0

3 12

0 0

0 0

1 2

2 8

1 0

7 16

6 10

0 0

1 4

0 0

5 2

2 1

1 0

4 5

1 0

6 6

0 1

9 7

0 1

0 0

9 6

2 0

0 0

0 0

23 32

0 0

8 6

0 0

0 0

1 3

0 0

0 0

10 14

17 21

1 0

1 0

33 38

29 30

0 0

0 5

3 5

7 14

0 2

1 5

----- -----

200 261

191 254

And Age Gro

35-39 40-44

0 0

4 4

1 5

1 1

0 0

1 0

13 17

0 0

0 0

0 2

10 8

1 2

20 33

18 24

0 3

4 7

1 3

2 8

0 3

2 4

5 6

3 0

4 3

0 0

10 9

0 0

2 0

8 4

2 2

1 0

0 1

6 8

0 0

12 16

0 0

0 0

8 13

0 0

1 0

15 9

25 20

0 1

0 0

16 6

28 30

0 0

3 3

4 1

13 11

1 1

5 6

----- -----

250 274

240 265

oups, 2016.

45-49 50-54 55

0 1

3 6

2 7

0 1

0 1

1 0

25 19

0 0

2 0

5 11

7 14

3 4

56 77

34 47

3 1

3 28

8 9

12 15

0 1

7 10

10 27

1 2

6 1

0 0

8 13

0 1

0 2

5 7

8 3

1 1

6 10

4 4

0 1

24 18

1 0

0 1

11 14 3

0 1

0 1

16 17

24 25

0 1

0 0

15 17

34 34 3

0 0

3 4

3 10

9 12

1 0

13 20

----- ----- -

374 499 6

366 486 5

5-59 60-64 65-6

6 1 1

5 5 10

6 6 3

1 2 3

0 1 0

0 0 0

15 19 3

1 1 0

0 0 0

7 11 6

26 22 20

3 6 7

74 76 42

49 47 39

1 4 2

41 35 38

9 10 10

20 29 19

0 3 0

15 6 8

51 41 54

1 2 0

1 2 1

1 1 1

16 11 16

0 0 4

5 3 3

4 5 5

2 11 4

0 1 0

43 51 79

0 1 3

0 1 1

24 26 22

2 2 0

0 1 1

37 36 27

1 2 1

1 2 0

22 14 6

21 14 16

1 1 0

0 1 0

10 5 4

33 41 39

0 0 0

10 10 10

6 5 5

10 6 5

2 3 1

18 16 8

---- ----- ----

601 599 527

585 588 511

69 70-74 75+

1 5

0 8 13

10 13

1 2

0 1

1 1

8 8

2 3

0 0

7 25

0 30 56

3 7

2 64 106

9 40 59

3 6

8 39 87

0 17 12

9 29 28

5 2

7 9

4 32 61

1 1

3 1

1 9

6 23 74

2 3

5 7

4 6

1 6

0 0

9 70 144

0 3

0 0

2 15 17

0 2

2 3

7 18 59

0 2

0 4

3 9

6 5 21

0 0

0 0

7 6

9 28 60

0 0

0 7 17

6 16

5 3

2 3

8 24

-- ----- -----

7 523 1004

1 500 930

Total (%)

0.30%

1.00%

1.00%

0.40%

0.10%

0.10%

2.70%

0.10%

0.00%

1.30%

3.60%

0.60%

10.00%

6.40%

0.40%

5.00%

1.40%

2.90%

0.30%

1.20%

5.10%

0.30%

1.60%

0.20%

3.60%

0.20%

0.50%

1.50%

0.70%

0.10%

7.00%

2.10%

0.10%

3.40%

0.10%

0.10%

3.90%

0.10%

0.50%

3.70%

3.80%

0.40%

0.10%

4.60%

8.10%

0.00%

1.20%

2.80%

2.40%

0.50%

2.40%

-----

100.00%

96.40%

Table

ICD (10th)

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C96

C88

C90

C91

C92-C94

C95

Other

All

Not C44

5.1.2 : Numb

Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharynx

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchus,L

Other Thoracic orga

Bone

Melanoma of Skin

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft tissu

Breast

Vulva

Vagina

Cervix Uteri

Corpus Uteri

Uterus unspec.

Ovary

Other Female Genita

Placenta

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary organ

Eye

Brain, Nervous syste

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

Non-Hodgkin lymph

Immunoproliferative

Multiple Myeloma

Lymphoid Leukaem

Myeloid Leukaemia

Leukaemia unspec.

Other & unspecified

All sites Total

All sites but C44

ber Of Cases

All Ages

6

47

60

30

2

2

59

14

1

50

111

32

447

257

11

127

113

104

5

7

Lung 148

ans 10

53

25

166

7

4

ue 70

2240

9

8

111

454

40

219

al 18

4

138

2

0

59

ns 2

16

em 155

854

19

6

230

homa 372

e dis. 0

48

mia 105

158

13

d 110

-----

7358

7192

Among Saud

Age unk 0-4 5

0 0

0 0

0 0

1 0

0 1

0 0

0 1

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 1

0 1

0 0

0 0

0 0

0 0

0 11

2 0

0 0

0 2

0 0

0 0

0 0

0 2

0 0

0 0

0 15

0 0

0 0

0 0

0 0

0 7

0 15 1

2 1

0 12

0 0

0 4

0 5

0 0

0 0

0 33 1

0 10

0 1

0 4

----- ----- --

5 126 6

5 126 6

di Females by

5-9 10-14 15-19

0 0 0

0 0 1

0 0 0

0 0 2

0 0 0

0 0 0

0 0 2

0 0 0

0 0 0

0 0 0

0 0 0

0 1 0

0 1 1

0 0 0

0 0 0

1 0 1

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

6 14 7

1 0 1

0 1 2

0 0 0

0 0 0

1 3 7

0 0 2

0 0 0

0 0 0

0 0 0

0 0 1

0 0 0

1 1 8

0 0 2

0 0 0

2 1 2

0 0 0

0 0 0

0 0 1

0 0 0

1 2 0

13 9 6

2 9 21

1 0 0

0 0 1

8 13 40

5 8 5

0 0 0

0 0 0

14 13 5

7 7 5

3 1 3

0 0 0

---- ----- -----

66 84 126

66 83 124

y Primary Sit

20-24 25-29 3

0 1

0 2

0 0

3 1

0 0

1 0

4 2

0 1

0 0

0 1

2 2

0 2

1 3

1 4

0 0

0 1

2 0

0 2

0 0

0 0

1 6

1 0

4 6

0 1

0 8

1 0

0 0

9 1

22 53

1 0

1 0

4 3

1 2

0 2

14 16

1 0

0 1

1 1

0 0

0 0

1 1

0 0

1 0

4 9

58 87

2 0

1 1

45 32

25 7

0 0

0 0

3 2

5 12

1 0

2 7

----- -----

223 280

223 272

te And Age G

30-34 35-39 40-44

0 0 0

0 0 2

3 1 2

2 2 1

0 0 0

0 0 0

3 8 4

0 1 0

0 0 0

7 0 2

3 5 14

1 1 2

11 21 31

8 16 18

0 0 0

1 2 2

0 1 1

3 4 6

0 0 1

0 0 0

5 8 6

0 1 1

2 5 1

1 2 4

15 6 6

0 0 1

0 0 0

8 1 4

124 227 315

0 1 0

0 1 0

5 9 10

7 18 17

0 2 5

9 8 21

0 0 3

2 1 0

5 7 12

0 0 0

0 0 0

4 0 6

0 0 0

0 0 1

7 11 9

101 116 117

2 1 0

1 0 0

22 10 12

14 23 17

0 0 0

1 7 2

4 2 1

19 19 8

1 0 0

4 3 1

----- ----- -----

405 551 666

390 545 660

Groups, 2016

4 45-49 50-54

0 0

6 7

6 5

3 3

0 0

1 0

9 9

3 1

0 1

0 6

5 13

4 3

41 70

33 43

3 2

6 8

6 7

10 7

0 0

0 1

12 17

0 1

1 1

0 1

16 9

1 2

1 0

4 8

319 341

0 1

0 1

14 20

29 51

3 9

20 19

4 2

0 0

17 16

0 0

0 0

2 5

0 0

0 1

15 14

106 80

0 1

0 0

9 8

24 36

0 0

3 11

4 3

13 16

0 0

7 9

----- -----

760 869

744 860

55-59 60-64 65

0 1 1

8 6 4

9 7 9

5 2 1

0 0 0

0 0 0

6 4 1

2 0 1

0 0 0

2 5 6

9 10 1

4 4 4

60 63 4

29 32 2

3 2 1

22 20 2

13 16 1

11 11 1

0 2 0

1 0 1

21 16 1

1 2 1

2 0 0

2 1 2

16 11 1

1 1 0

0 0 0

1 1 3

288 198 11

1 3 0

2 0 0

11 3 9

86 98 5

6 2 4

25 19 1

0 3 1

0 0 0

12 15 6

0 1 0

0 0 0

4 7 3

1 1 0

0 1 0

12 8 6

61 34 1

0 0 0

1 0 0

11 5 2

32 53 3

0 0 0

6 6 3

3 5 2

17 6 8

0 0 0

15 12 1

----- ----- --

822 697 50

806 686 48

-69 70-74 75+

1 0 3

4 6 5

9 4 14

1 1 3

0 1 0

0 0 0

1 4 2

1 2 3

0 0 0

6 5 16

14 9 25

4 1 5

46 35 63

21 15 37

1 0 0

20 21 22

17 23 27

16 17 17

0 1 1

1 1 3

17 14 25

1 1 0

0 1 2

2 2 7

13 16 47

0 0 0

0 1 2

3 3 5

18 99 132

0 1 1

0 0 1

9 8 15

56 43 45

4 3 4

16 18 22

1 1 1

0 0 0

6 12 14

0 1 0

0 0 0

3 9 16

0 0 0

0 1 1

6 9 8

18 9 32

0 0 0

0 0 1

2 5 4

38 27 53

0 0 0

3 5 4

2 6 5

8 2 4

0 1 2

13 15 18

--- ----- -----

02 459 717

89 443 670

61

Total (%)

0.10%

0.60%

0.80%

0.40%

0.00%

0.00%

0.80%

0.20%

0.00%

0.70%

1.50%

0.40%

6.10%

3.50%

0.10%

1.70%

1.50%

1.40%

0.10%

0.10%

2.00%

0.10%

0.70%

0.30%

2.30%

0.10%

0.10%

1.00%

30.40%

0.10%

0.10%

1.50%

6.20%

0.50%

3.00%

0.20%

0.10%

1.90%

0.00%

0.00%

0.80%

0.00%

0.20%

2.10%

11.60%

0.30%

0.10%

3.10%

5.10%

0.00%

0.70%

1.40%

2.10%

0.20%

1.50%

-----

100.00%

97.70%

62 62

Table (per 1

ICD (10th)

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C60

2

C62

C63

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C96

C88

C90

C91

C92-C94

C95

Other

All

Not C44

5.1.3 : Age-S00,000) by Pr

Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharynx

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchus,Lung

Other Thoracic organs

Bone

Melanoma of Skin

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft tissue

Breast

Penis

Prostate

Testis

Other male genital

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary organs

Eye

Brain, Nervous system

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

Non-Hodgkin lymphoma

Immunoproliferative dis

Multiple Myeloma

Lymphoid Leukaemia

Myeloid Leukaemia

Leukaemia unspec.

Other & unspecified

All sites Total

All sites but C44

Spesific Inciderimary Site a

All Ages

Age unk

16 0

60 0

59 0

23 0

3 0

4 0

154 0

7 0

2 0

78 1

207 0

37 0

581 5

374 0

24 0

290 0

80 0

170 1

18 0

69 0

298 1

16 0

93 1

14 0

207 1

11 0

27 0

89 1

42 0

4 0

405 0

123 1

3 0

196 0

7 0

8 0

229 0

7 0

30 0

212 0

222 0

22 0

5 0

265 0

a 469 0

. 0 0

72 0

165 0

142 0

27 0

137 1

----- -----

5803 13

5596 12

ence Rate (Aand Age grou

0-4 5-9 10

0 0 0

0 0

0.1 0 0

0 0

0 0

0 0

0 0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0 0

0.3 0

0 0

0 0

0 0

0 0

0 0

0.1 0

0.4 0.9 1

0 0

0.1 0.1 0

0 0

0 0

0.5 0.2 0

0 0

0 0

0 0

0.6 0.1 0

0 0

0.4 0.3 0

0 0

0 0

0.2 0

0 0

1.7 0.1

2.2 2.2 1

0 0.1 0

1.1 0.1 0

0 0 0

0.4 2.2 2

1.3 1.6 1

0 0

0 0

3.3 2.2

1.3 0.5 0

0.4 0.3 0

0.5 0.1 0

----- ----- --

14 11

14 11

IR), Age Stanps, 2016.

0-14 15-19 20-24

0.1 0 0

0 0 0

0.1 0 0.2

0 0 0.4

0 0 0

0 0 0

0.4 0.4 0.4

0 0 0

0 0 0

0 0 0

0 0.1 0.3

0 0 0

0 0 0.5

0 0 0.1

0.1 0 0

0 0 0

0 0 0.1

0 0 0

0 0 0.1

0 0 0

0 0 0.1

0 0 0.3

1.4 2.2 1.1

0 0 0

0.1 0.1 0.6

0 0 0

0 0 0

0.5 0.2 1.1

0 0 0.1

0 0 0

0 0.1 0

0.2 1.3 1.6

0 0 0

0.1 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0.1 0.1

1.3 0.2 1.5

0.2 0.4 0.6

0.1 0.2 0.1

0.2 0 0.1

2.5 2.7 3.2

1.2 1.8 2.4

0 0 0

0 0 0

2 1.7 0.8

0.5 1.2 1.2

0.2 0.2 0

0.1 0.1 0.4

---- ----- -----

11 13 17

11 13 17

ndardised In

25-29 30-34

0 0

0.1 0.1

0.1 0.1

0.4 0.3

0 0

0 0

0.3 1.4

0 0

0 0

0.1 0.2

0.2 0.9

0.1 0

0.7 1.8

0.6 1.2

0 0

0.1 0.5

0 0

0.5 0.2

0.2 0.1

0.1 0

0.4 0.6

0.1 0

0.6 0.7

0 0.1

0.9 0.8

0 0.1

0 0

0.9 0.7

0.2 0

0 0

0 0

2.4 3.7

0 0

0.8 0.7

0 0

0 0

0.1 0.3

0 0

0 0

1 1.6

1.8 2.4

0.1 0

0.1 0

3.4 4.4

3 3.5

0 0

0 0.6

0.3 0.6

0.7 1.6

0 0.2

0.1 0.6

----- -----

21 30

20 29

cidence Rate

35-39 40-44 45-4

0 0 0

0.5 0.6 0.6

0.1 0.8 0.4

0.1 0.2 0

0 0 0

0.1 0 0.2

1.7 2.6 4.6

0 0 0

0 0 0.4

0 0.3 0.9

1.3 1.2 1.3

0.1 0.3 0.6

2.6 5.1 10.

2.4 3.7 6.3

0 0.5 0.6

0.5 1.1 0.6

0.1 0.5 1.5

0.3 1.2 2.2

0 0.5 0

0.3 0.6 1.3

0.7 0.9 1.8

0.4 0 0.2

0.5 0.5 1.1

0 0 0

1.3 1.4 1.5

0 0 0

0.3 0 0

1 0.6 0.9

0.3 0.3 1.5

0.1 0 0.2

0 0.2 1.1

0.8 1.2 0.7

0 0 0

1.6 2.5 4.4

0 0 0.2

0 0 0

1 2 2

0 0 0

0.1 0 0

2 1.4 3

3.3 3.1 4.4

0 0.2 0

0 0 0

2.1 0.9 2.8

3.7 4.6 6.3

0 0 0

0.4 0.5 0.6

0.5 0.2 0.6

1.7 1.7 1.7

0.1 0.2 0.2

0.7 0.9 2.4

----- ----- ----

33 42 69

31 41 67

(ASR) Amon

49 50-54 55-59

0.2 1.8

6 1.4 1.5

4 1.6 1.8

0.2 0.3

0.2 0

2 0 0

6 4.4 4.5

0 0.3

4 0 0

9 2.5 2.1

3 3.2 7.7

6 0.9 0.9

.3 17.8 22

3 10.9 14.5

6 0.2 0.3

6 6.5 12.2

5 2.1 2.7

2 3.5 5.9

0.2 0

3 2.3 4.5

8 6.2 15.1

2 0.5 0.3

1 0.2 0.3

0 0.3

5 3 4.7

0.2 0

0.5 1.5

9 1.6 1.2

5 0.7 0.6

2 0.2 0

1 2.3 12.8

7 0.9 0

0.2 0

4 4.2 7.1

2 0 0.6

0.2 0

3.2 11

0.2 0.3

0.2 0.3

3.9 6.5

4 5.8 6.2

0.2 0.3

0 0

8 3.9 3

3 7.9 9.8

0 0

6 0.9 3

6 2.3 1.8

7 2.8 3

2 0 0.6

4 4.6 5.3

-- ----- -----

9 115 178

7 112 174

ng Saudi Mal

60-64 65-69 7

0.4 0.7

2 6.7

2.5 2

0.8 2

0.4 0

0 0

7.8 2

0.4 0

0 0

4.5 4

9 13.5 2

2.5 4.7

31.1 28.3

19.2 26.2 3

1.6 1.3

14.3 25.6

4.1 6.7 1

11.9 12.8 2

1.2 0

2.5 5.4

16.8 36.3 2

0.8 0

0.8 0.7

0.4 0.7

4.5 10.8 2

0 2.7

1.2 2

2 3.4

4.5 2.7

0.4 0

20.9 53.2 6

0.4 2

0.4 0.7

10.6 14.8 1

0.8 0

0.4 0.7

14.7 18.2 1

0.8 0.7

0.8 0

5.7 4

5.7 10.8

0.4 0

0.4 0

2 2.7

16.8 26.2 2

0 0

4.1 6.7

2 3.4

2.5 3.4

1.2 0.7

6.6 5.4

----- ----- -

245 355 4

241 344 4

les

0-74 75+ CrudRate

0.9 3.3 0.2

7.4 8.5 0.6

9.2 8.5 0.6

0.9 1.3 0.2

0 0.7 0

0.9 0.7 0

7.4 5.2 1.5

1.8 2 0.1

0 0 0

6.5 16.3 0.8

27.7 36.4 2

2.8 4.6 0.4

59 68.9 5.7

36.9 38.4 3.6

2.8 3.9 0.2

36 56.6 2.8

15.7 7.8 0.8

26.7 18.2 1.7

4.6 1.3 0.2

6.5 5.9 0.7

29.5 39.7 2.9

0.9 0.7 0.2

2.8 0.7 0.9

0.9 5.9 0.1

21.2 48.1 2

1.8 2 0.1

4.6 4.6 0.3

3.7 3.9 0.9

0.9 3.9 0.4

0 0 0

64.6 93.6 4

0 2 1.2

0 0 0

13.8 11.1 1.9

0 1.3 0.1

1.8 2 0.1

16.6 38.4 2.2

0 1.3 0.1

0 2.6 0.3

2.8 5.9 2.1

4.6 13.7 2.2

0 0 0.2

0 0 0

6.5 3.9 2.6

25.8 39 4.6

0 0 0

6.5 11.1 0.7

5.5 10.4 1.6

4.6 2 1.4

1.8 2 0.3

7.4 15.6 1.3

----- ----- -----

482 653 56.6

461 605 54.6

de e

ASR World

0.2

0.8

0.8

0.3

0

0.1

1.8

0.1

0

1.1

2.9

0.5

7.8

5.1

0.3

4.2

1.2

2.5

0.2

0.9

4.4

0.2

0.9

0.2

2.7

0.2

0.4

1

0.6

0

6.3

1.1

0

2.6

0.1

0.1

3.2

0.1

0.3

2.3

2.5

0.2

0.1

2.6

5.6

0

1

1.8

1.5

0.3

1.7

- -----

6 74.7

6 72

Table 100,00

ICD (10th)

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C96

C88

C90

C91

C92-C94

C95

Other

All

Not C44

5.1.4 : Age-S00) by Primar

Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharynx

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchus,Lung Other Thoracic organs

Bone

Melanoma of Skin

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft tissue

Breast

Vulva

Vagina

Cervix Uteri

Corpus Uteri

Uterus unspec.

Ovary

Other Female Genital

Placenta

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary organs

Eye

Brain, Nervous system

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

Non-Hodgkin lymphoma Immunoproliferative dis.

Multiple Myeloma

Lymphoid Leukaemia Myeloid Leukaemia Leukaemia unspec. Other & unspecified

All sites Total

All sites but C44

Spesific Incidery Site and A

All Ages

Age unk

0

6 0

47 0

60 0

30 1

2 0 0

2 0

59 0 0

14 0

1 0

50 0

111 0

32 0

447 0

257 0

11 0

127 0

113 0

104 0

5 0

7 0

148 0

10 0 0

53 0 0

25 0

166 0

7 0

4 0

70 0

2240 2

9 0

8 0 0

111 0

454 0

40 0

219 0 0

18 0

4 0

138 0 1

2 0

0 0

59 0

2 0

16 0 0

155 0 1

854 2 0

19 0 1

6 0

230 0 0

372 0 0

0 0

48 0

105 0 3

158 0

13 0 0

110 0 0

----- ----- --

7358 5 1

7192 5 1

ence Rate (AAge groups, 20

0-4 5-9 10-14

0 0 0

0 0 0

0 0 0

0 0 0

0.1 0 0

0 0 0

0.1 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0.1

0 0 0.1

0 0 0

0 0 0

0 0.1 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0.1 0 0

0.1 0.6 1.5

0 0.1 0

0 0 0.1

0 0 0

0 0 0

1 0.1 0.3

0 0 0

0 0 0

0.2 0 0

0 0 0

0 0 0

0 0 0

0.2 0.1 0.1

0 0 0

0 0 0

1.4 0.2 0.1

0 0 0

0 0 0

0 0 0

0 0 0

0.7 0.1 0.2

1.4 1.3 1

0.1 0.2 1

1.1 0.1 0

0 0 0

0.4 0.8 1.4

0.5 0.5 0.9

0 0 0

0 0 0

3.1 1.4 1.4

1 0.7 0.8

0.1 0.3 0.1

0.4 0 0

---- ----- -----

12 6 9

12 6 9

IR), Age Stan016

15-19 20-24 2

0 0

0.1 0

0 0

0.2 0.3

0 0

0 0.1

0.2 0.4

0 0

0 0

0 0

0 0.2

0 0

0.1 0.1

0 0.1

0 0

0.1 0

0 0.2

0 0

0 0

0 0

0 0.1

0 0.1

0.8 0.4

0.1 0

0.2 0

0 0.1

0 0

0.8 0.9

0.2 2.3

0 0.1

0 0.1

0 0.4

0.1 0.1

0 0

0.9 1.5

0.2 0.1

0 0

0.2 0.1

0 0

0 0

0.1 0.1

0 0

0 0.1

0.7 0.4

2.4 6.1

0 0.2

0.1 0.1

4.6 4.7

0.6 2.6

0 0

0 0

0.6 0.3

0.6 0.5

0.3 0.1

0 0.2

----- -----

15 23

14 23

ndardised In

25-29 30-34 35-3

0.1 0 0

0.2 0 0

0 0.4 0.1

0.1 0.2 0.3

0 0 0

0 0 0

0.2 0.4 1.1

0.1 0 0.1

0 0 0

0.1 0.8 0

0.2 0.4 0.7

0.2 0.1 0.1

0.3 1.3 2.8

0.4 0.9 2.2

0 0 0

0.1 0.1 0.3

0 0 0.1

0.2 0.4 0.5

0 0 0

0 0 0

0.6 0.6 1.1

0 0 0.1

0.6 0.2 0.7

0.1 0.1 0.3

0.8 1.8 0.8

0 0 0

0 0 0

0.1 0.9 0.1

5.6 14.5 30.

0 0 0.1

0 0 0.1

0.3 0.6 1.2

0.2 0.8 2.4

0.2 0 0.3

1.7 1.1 1.1

0 0 0

0.1 0.2 0.1

0.1 0.6 0.9

0 0 0

0 0 0

0.1 0.5 0

0 0 0

0 0 0

1 0.8 1.5

9.2 11.8 15.

0 0.2 0.1

0.1 0.1 0

3.4 2.6 1.3

0.7 1.6 3.1

0 0 0

0 0.1 0.9

0.2 0.5 0.3

1.3 2.2 2.6

0 0.1 0

0.7 0.5 0.4

----- ----- ----

30 47 74

29 46 73

cidence Rate

39 40-44 45-49

0 0

0.3 1.2

1 0.3 1.2

3 0.2 0.6

0 0

0 0.2

1 0.6 1.8

1 0 0.6

0 0

0.3 0

7 2.3 1

1 0.3 0.8

8 5 8

2 2.9 6.4

0 0.6

3 0.3 1.2

1 0.2 1.2

5 1 2

0.2 0

0 0

1 1 2.3

1 0.2 0

7 0.2 0.2

3 0.6 0

8 1 3.1

0.2 0.2

0 0.2

1 0.6 0.8

.5 50.7 62.2

1 0 0

1 0 0

2 1.6 2.7

4 2.7 5.7

3 0.8 0.6

1 3.4 3.9

0.5 0.8

1 0 0

9 1.9 3.3

0 0

0 0

1 0.4

0 0

0.2 0

5 1.4 2.9

.6 18.8 20.7

1 0 0

0 0

3 1.9 1.8

1 2.7 4.7

0 0

9 0.3 0.6

3 0.2 0.8

6 1.3 2.5

0 0

4 0.2 1.4

-- ----- -----

4 107 148

3 106 145

(ASR) Amon

50-54 55-59

0 0

1.7 2.6

1.2 2.9

0.7 1.6

0 0

0 0

2.2 1.9

0.2 0.6

0.2 0

1.5 0.6

3.2 2.9

0.7 1.3

17.1 19.4

10.5 9.4

0.5 1

2 7.1

1.7 4.2

1.7 3.6

0 0

0.2 0.3

4.2 6.8

0.2 0.3

0.2 0.6

0.2 0.6

2.2 5.2

0.5 0.3

0 0

2 0.3

83.5 93

0.2 0.3

0.2 0.6

4.9 3.6

12.5 27.8

2.2 1.9

4.7 8.1

0.5 0

0 0

3.9 3.9

0 0

0 0

1.2 1.3

0 0.3

0.2 0

3.4 3.9

19.6 19.7

0.2 0

0 0.3

2 3.6

8.8 10.3

0 0

2.7 1.9

0.7 1

3.9 5.5

0 0

2.2 4.8

----- -----

213 266

211 260

ng Saudi Fem

60-64 65-69 70

0.4 0.6

2.6 2.5

3.1 5.7

0.9 0.6

0 0

0 0

1.8 0.6

0 0.6

0 0

2.2 3.8

4.4 8.9

1.8 2.5

27.6 29.3 3

14 13.4 1

0.9 0.6

8.8 12.7 1

7 10.8 2

4.8 10.2 1

0.9 0

0 0.6

7 10.8 1

0.9 0.6

0 0

0.4 1.3

4.8 8.3 1

0.4 0

0 0

0.4 1.9

86.7 75.1 8

1.3 0

0 0

1.3 5.7

42.9 35.6 3

0.9 2.5

8.3 10.2 1

1.3 0.6

0 0

6.6 3.8 1

0.4 0

0 0

3.1 1.9

0.4 0

0.4 0

3.5 3.8

14.9 11.5

0 0

0 0

2.2 1.3

23.2 24.2 2

0 0

2.6 1.9

2.2 1.3

2.6 5.1

0 0

5.3 8.3 1

----- ----- -

305 319 4

300 311 3

males (per

0-74 75+ CrudRate

0 1.9 0.1

5.4 3.1 0.5

3.6 8.7 0.6

0.9 1.9 0.3

0.9 0 0

0 0 0

3.6 1.2 0.6

1.8 1.9 0.1

0 0 0

4.5 9.9 0.5

8.1 15.4 1.1

0.9 3.1 0.3

31.5 38.9 4.5

13.5 22.9 2.6

0 0 0.1

18.9 13.6 1.3

20.7 16.7 1.1

15.3 10.5 1.1

0.9 0.6 0.1

0.9 1.9 0.1

12.6 15.4 1.5

0.9 0 0.1

0.9 1.2 0.5

1.8 4.3 0.3

14.4 29 1.7

0 0 0.1

0.9 1.2 0

2.7 3.1 0.7

89.1 81.6 22.7

0.9 0.6 0.1

0 0.6 0.1

7.2 9.3 1.1

38.7 27.8 4.6

2.7 2.5 0.4

16.2 13.6 2.2

0.9 0.6 0.2

0 0 0

10.8 8.7 1.4

0.9 0 0

0 0 0

8.1 9.9 0.6

0 0 0

0.9 0.6 0.2

8.1 4.9 1.6

8.1 19.8 8.7

0 0 0.2

0 0.6 0.1

4.5 2.5 2.3

24.3 32.8 3.8

0 0 0

4.5 2.5 0.5

5.4 3.1 1.1

1.8 2.5 1.6

0.9 1.2 0.1

13.5 11.1 1.1

----- ----- -----

413 443 74.5

399 414 72.9

63

de e

ASR World

0.1

0.7

0.8

0.4

0

0

0.7

0.2

0

0.7

1.5

0.4

6.1

3.4

0.2

1.9

1.7

1.5

0.1

0.1

2

0.1

0.5

0.3

2.1

0.1

0.1

0.8

27.2

0.1

0.1

1.4

6.6

0.5

2.7

0.2

0

1.8

0

0

0.8

0

0.2

1.8

8.9

0.2

0.1

2.3

4.9

0

0.6

1.2

1.7

0.1

1.5

-----

91.3

89.2

64 64

Ta(AS

ICD

C00

C01-C

C03-C

C07-C

C09

C10

C11

C12-C

C14

C15

C16

C17

C18

C19-C

C21

C22

C23-C

C25

C30-C

C32

C33-C

C37-C

C40-C

C43

C44

C45

C46

C47;C

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70-C

C73

C74

C75

C81

C82-C

C88

C90

C91

C92-C

C95

Othe

All

Not C

able 5.2.1 : NuSR) Among S

D (10th)

Lip

C02 Tongue

C06 Mouth

C08 Salivary

Tonsil

Other O

Nasoph

C13 Hypoph

Pharyn

Oesoph

Stomac

Small in

Colon

C20 Rectum

Anus

Liver

C24 Gallbla

Pancrea

C31 Nose, si

Larynx

C34 Trache

C38 Other T

C41 Bone

Melano

Other S

Mesoth

Kaposi

C49 Connec

Breast

Penis

Prostat

Testis

Other m

Kidney

Renal P

Ureter

Bladder

Other U

Eye

C72 Brain, N

Thyroid

Adrena

Other E

Hodgki

C85;C96 Non-Ho

Immun

Multipl

Lymph

C94 Myeloid

Leukae

r Other &

All sites

C44 All sites

umber Of CaSaudi Males (

Site

e

y glands

Oropharynx

harynx

harynx

nx unspec.

hagus

ch

ntestine

m

adder etc.

as

inuses etc.

x

a,Bronchus,Lung

Thoracic organs

oma of Skin

Skin

helioma

sarcoma

ctive,Soft tissue

te

male genital

y

Pelvis

r

Urinary organs

Nervous system

d

al gland

Endocrine

in disease

odgkin lymphoma

noproliferative dis.

le Myeloma

oid Leukaemia

d Leukaemia

emia unspec.

& unspecified

s Total

s but C44

ases, Relative ( per 100,000

All Ages Total (%)

0 0.00%

2 0.40%

8 1.60%

1 0.20%

0 0.00%

0 0.00%

9 1.80%

1 0.20%

1 0.20%

5 1.00%

28 5.60%

8 1.60%

51 10.20%

36 7.20%

2 0.40%

35 7.00%

9 1.80%

20 4.00%

2 0.40%

5 1.00%

8 1.60%

2 0.40%

9 1.80%

0 0.00%

21 4.20%

0 0.00%

5 1.00%

7 1.40%

2 0.40%

1 0.20%

43 8.60%

7 1.40%

1 0.20%

11 2.20%

0 0.00%

0 0.00%

16 3.20%

1 0.20%

2 0.40%

10 2.00%

8 1.60%

3 0.60%

0 0.00%

23 4.60%

47 9.40%

0 0.00%

7 1.40%

19 3.80%

7 1.40%

8 1.60%

7 1.40%

----- -----

498 100.00%

477 95.80%

Frequency, C0) by Primary

Asir

Crude Rate ASR

0

0.2

0.9

0.1

0

0

1.1

0.1

0.1

0.6

3.3

0.9

6

4.2

0.2

4.1

1.1

2.3

0.2

0.6

0.9

0.2

1.1

0

2.5

0

0.6

0.8

0.2

0.1

5

0.8

0.1

1.3

0

0

1.9

0.1

0.2

1.2

0.9

0.4

0

2.7

5.5

0

0.8

2.2

0.8

0.9

0.8

-----

58.4

55.9

Crude Incidey Site, Age Gr

R World All Ages

0 0

0.2 2

0.9 0

0.1 0

0 0

0 0

1.2 3

0.2 0

0.1 0

0.5 5

3.9 4

1.1 0

7.5 5

5.4 3

0.2 0

5.1 1

1.4 1

2.8 0

0.2 0

0.7 1

1.1 4

0.2 0

1.1 2

0 0

2.8 12

0 0

0.7 2

1.1 2

0.3 0

0.1 0

6.6 2

0.7 0

0.2 0

1.5 2

0 0

0 0

2.5 5

0.1 0

0.2 1

1.2 2

1 2

0.4 0

0 0

2.6 5

6.5 12

0 0

0.9 1

2.3 0

1 2

1 0

1 1

----- -----

68.7 82

65.9 70

ence Rate (CIroups and Re

Baha

Total (%) Crude R

0.00% 0

2.40% 1.1

0.00% 0

0.00% 0

0.00% 0

0.00% 0

3.70% 1.7

0.00% 0

0.00% 0

6.10% 2.8

4.90% 2.2

0.00% 0

6.10% 2.8

3.70% 1.7

0.00% 0

1.20% 0.6

1.20% 0.6

0.00% 0

0.00% 0

1.20% 0.6

4.90% 2.2

0.00% 0

2.40% 1.1

0.00% 0

14.60% 6.6

0.00% 0

2.40% 1.1

2.40% 1.1

0.00% 0

0.00% 0

2.40% 1.1

0.00% 0

0.00% 0

2.40% 1.1

0.00% 0

0.00% 0

6.10% 2.8

0.00% 0

1.20% 0.6

2.40% 1.1

2.40% 1.1

0.00% 0

0.00% 0

6.10% 2.8

14.60% 6.6

0.00% 0

1.20% 0.6

0.00% 0

2.40% 1.1

0.00% 0

1.20% 0.6

----- -----

100.00% 45.2

85.40% 38.5

IR) Age-Standegions 2016

Rate ASR World

0

0.9

0

0

0

0

1.8

0

0

2.2

2.9

0

2.3

2.2

0

0.7

0.9

0

0

0.8

3.2

0

1.1

0

6.5

0

1.8

1.4

0

0

0.8

0

0

1.4

0

0

3.2

0

0.7

1

1

0

0

2.9

7.2

0

0.7

0

1

0

0.4

- -----

2 49.3

5 42.8

dardised Inci

J

All Ages Total (%)

2 1.30%

8 5.40%

13 8.70%

3 2.00%

0 0.00%

0 0.00%

3 2.00%

0 0.00%

0 0.00%

1 0.70%

5 3.40%

0 0.00%

10 6.70%

7 4.70%

0 0.00%

9 6.00%

2 1.30%

3 2.00%

0 0.00%

1 0.70%

3 2.00%

0 0.00%

3 2.00%

1 0.70%

9 6.00%

0 0.00%

0 0.00%

2 1.30%

2 1.30%

0 0.00%

8 5.40%

3 2.00%

0 0.00%

5 3.40%

0 0.00%

0 0.00%

6 4.00%

0 0.00%

1 0.70%

2 1.30%

3 2.00%

0 0.00%

0 0.00%

5 3.40%

17 11.40%

0 0.00%

0 0.00%

6 4.00%

2 1.30%

1 0.70%

3 2.00%

----- -----

149 100.00%

140 94.00%

idence Rate

Jazan

Crude Rate ASR

0.3

1.3

2.2

0.5

0

0

0.5

0

0

0.2

0.8

0

1.7

1.2

0

1.5

0.3

0.5

0

0.2

0.5

0

0.5

0.2

1.5

0

0

0.3

0.3

0

1.3

0.5

0

0.8

0

0

1

0

0.2

0.3

0.5

0

0

0.8

2.8

0

0

1

0.3

0.2

0.5

----- -

24.7 3

23.2 3

R World

0.4

1.9

3.6

0.6

0

0

0.5

0

0

0.2

1.2

0

2.5

1.4

0

1.8

0.4

0.6

0

0.1

0.8

0

0.5

0.4

2.1

0

0

0.3

0.6

0

2.3

0.4

0

0.9

0

0

1.5

0

0.1

0.3

0.9

0

0

0.7

4.3

0

0

1.1

0.5

0.2

0.7

-----

33.7

31.5

Tabl(ASR

ICD (1

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C

C88

C90

C91

C92-C94

C95

Other

All

Not C44

le 5.2.2 : NumR) Among Sa

10th) Si

Lip

Tongue

Mouth

Salivary glan

Tonsil

Other Oroph

Nasopharynx

Hypopharynx

Pharynx unsp

Oesophagus

Stomach

Small intestin

Colon

Rectum

Anus

Liver

Gallbladder e

Pancreas

Nose, sinuses

Larynx

Trachea,Bron

Other Thorac

Bone

Melanoma of

Other Skin

Mesothelioma

Kaposi sarcom

Connective,So

Breast

Penis

Prostate

Testis

Other male ge

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinar

Eye

Brain, Nervou

Thyroid

Adrenal gland

Other Endocr

Hodgkin dise

C96 Non-Hodgkin

Immunoproli

Multiple Mye

Lymphoid Le

Myeloid Leuk

Leukaemia un

Other & unsp

All sites Total

All sites but C

mber Of Caseaudi Males ( p

ite All A

0

1

0

ds 0

0

arynx 1

x 12

x 0

pec. 0

1

12

ne 2

44

17

2

20

etc. 3

8

etc. 2

1

nchus,Lung 14

cic organs 1

6

f Skin 0

8

a 1

ma 0

oft tissue 8

2

1

8

3

enital 0

9

0

0

11

ry organs 0

1

us system 11

7

d 2

rine 1

ase 15

n lymphoma 24

iferative dis. 0

eloma 5

eukaemia 7

kaemia 9

nspec. 4

pecified 9

----

l 293

C44 285

es, Relative Fper 100,000) b

Mad

Ages Total (%)

0.00%

0.30%

0.00%

0.00%

0.00%

0.30%

2 4.10%

0.00%

0.00%

0.30%

2 4.10%

0.70%

4 15.00%

7 5.80%

0.70%

0 6.80%

1.00%

2.70%

0.70%

0.30%

4 4.80%

0.30%

2.00%

0.00%

2.70%

0.30%

0.00%

2.70%

0.70%

0.30%

2.70%

1.00%

0.00%

3.10%

0.00%

0.00%

1 3.80%

0.00%

0.30%

1 3.80%

2.40%

0.70%

0.30%

5 5.10%

4 8.20%

0.00%

1.70%

2.40%

3.10%

1.40%

3.10%

-- -----

3 100.00%

5 97.30%

Frequency, Crby Primary S

dinah

Crude Rate ASR W

0 0

0.1 0.2

0 0

0 0

0 0

0.1 0.2

1.8 2

0 0

0 0

0.1 0.3

1.8 2.4

0.3 0.3

6.5 9

2.5 3.5

0.3 0.4

2.9 4.3

0.4 0.5

1.2 1.3

0.3 0.2

0.1 0.2

2.1 3.3

0.1 0.2

0.9 0.9

0 0

1.2 1.7

0.1 0.1

0 0

1.2 1.3

0.3 0.3

0.1 0.2

1.2 2

0.4 0.5

0 0

1.3 1.6

0 0

0 0

1.6 1.8

0 0

0.1 0.1

1.6 1.7

1 1.2

0.3 0.3

0.1 0.1

2.2 2.2

3.5 4

0 0

0.7 1.3

1 1.2

1.3 1.4

0.6 0.8

1.3 1.5

----- ----

43 54.7

41.8 53

rude IncidencSite, Age Gro

World All Ages

0

2 2

0

2

0

2 0

4

0

0

3 1

4 1

3 1

5

5 7

4 0

3 1

5 0

3 1

2 0

2 3

3 1

2 1

9 5

0

7 2

1 0

1

3 1

3 2

2 0

3

5 2

0

6 2

0

0

8 2

0

1 1

7 2

2 6

3 0

1 0

2 4

9

0

3 0

2 4

4 1

8 0

5 2

-- -----

7 79

3 77

ce Rate (CIRoups and Reg

Hail

Total (%) Crude Ra

0.00% 0

2.50% 0.8

0.00% 0

2.50% 0.8

0.00% 0

0.00% 0

5.10% 1.5

0.00% 0

0.00% 0

1.30% 0.4

1.30% 0.4

1.30% 0.4

6.30% 1.9

8.90% 2.7

0.00% 0

1.30% 0.4

0.00% 0

1.30% 0.4

0.00% 0

3.80% 1.1

1.30% 0.4

1.30% 0.4

6.30% 1.9

0.00% 0

2.50% 0.8

0.00% 0

1.30% 0.4

1.30% 0.4

2.50% 0.8

0.00% 0

3.80% 1.1

2.50% 0.8

0.00% 0

2.50% 0.8

0.00% 0

0.00% 0

2.50% 0.8

0.00% 0

1.30% 0.4

2.50% 0.8

7.60% 2.3

0.00% 0

0.00% 0

5.10% 1.5

11.40% 3.4

0.00% 0

0.00% 0

5.10% 1.5

1.30% 0.4

0.00% 0

2.50% 0.8

----- -----

100.00% 30.1

97.50% 29.3

R) Age-Standaions 2016

ate ASR World

0

0.8

0

1.1

0

0

1.6

0

0

0.6

0.4

0.6

2.3

3

0

0.6

0

0.4

0

1.3

0.5

0.6

1.9

0

0.8

0

0.5

0.3

1.1

0

1.7

0.8

0

0.6

0

0

0.8

0

0.4

0.8

2.4

0

0

1.3

3.9

0

0

1.5

0.4

0

0.9

-----

33.7

33

ardised Incid

All Ages Total (%

0 0.00%

2 0.90%

0 0.00%

2 0.90%

0 0.00%

0 0.00%

11 4.90%

0 0.00%

0 0.00%

4 1.80%

12 5.30%

1 0.40%

29 12.90%

17 7.60%

0 0.00%

10 4.40%

3 1.30%

6 2.70%

0 0.00%

3 1.30%

8 3.60%

1 0.40%

5 2.20%

1 0.40%

11 4.90%

0 0.00%

0 0.00%

1 0.40%

3 1.30%

0 0.00%

11 4.90%

5 2.20%

0 0.00%

7 3.10%

0 0.00%

0 0.00%

6 2.70%

0 0.00%

2 0.90%

7 3.10%

13 5.80%

0 0.00%

0 0.00%

17 7.60%

12 5.30%

0 0.00%

1 0.40%

4 1.80%

6 2.70%

0 0.00%

4 1.80%

----- -----

225 100.00%

214 95.10%

dence Rate

Qassim

) Crude Rate

0

0.4

0

0.4

0

0

2.2

0

0

0.8

2.4

0.2

5.8

3.4

0

2

0.6

1.2

0

0.6

1.6

0.2

1

0.2

2.2

0

0

0.2

0.6

0

2.2

1

0

1.4

0

0

1.2

0

0.4

1.4

2.6

0

0

3.4

2.4

0

0.2

0.8

1.2

0

0.8

-----

% 44.7

42.5

65

ASR World

0

0.6

0

0.6

0

0

2.8

0

0

1

2.8

0.4

7.9

4.8

0

2.8

1.2

1.9

0

0.9

2.7

0.2

1.1

0.2

2.7

0

0

0.2

0.8

0

3.1

0.8

0

1.7

0

0

1.5

0

0.4

1.3

3.1

0

0

3.1

2.8

0

0.3

0.8

1.2

0

0.7

-----

56.5

53.9

66 66

Table (ASR)

ICD (10th)

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C96

C88

C90

C91

C92-C94

C95

Other

All

Not C44

5.2.3 : Numb) Among Sau

Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharynx

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchus,L

Other Thoracic orga

Bone

Melanoma of Skin

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft tissu

Breast

Penis

Prostate

Testis

Other male genital

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary organ

Eye

Brain, Nervous syste

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

Non-Hodgkin lymphoma Immunoproliferativdis.

Multiple Myeloma

Lymphoid Leukaem

Myeloid Leukaemia

Leukaemia unspec.

Other & unspecified

All sites Total

All sites but C44

ber Of Cases,di Males ( pe

All Ages

Tota

3 3.4

2 2.3

0 0.0

1 1.1

0 0.0

0 0.0

0 0.0

0 0.0

0 0.0

1 1.1

3 3.4

2 2.3

2 2.3

3 3.4

1 1.1

5 5.7

1 1.1

3 3.4

0 0.0

0 0.0

Lung 1 1.1

ans 1 1.1

0 0.0

1 1.1

7 8.0

0 0.0

0 0.0

ue 0 0.0

0 0.0

0 0.0

4 4.6

1 1.1

0 0.0

1 1.1

0 0.0

0 0.0

2 2.3

ns 0 0.0

1 1.1

em 8 9.2

9 10.3

0 0.0

0 0.0

5 5.7

8 9.2

ve 0 0.0

0 0.0

mia 2 2.3

a 3 3.4

1 1.1

d 5 5.7

----- --

87 100.

80 92.0

, Relative Freer 100,000) by

Najran

al (%) Crude Rate

40% 1.4

30% 0.9

00% 0

10% 0.5

00% 0

00% 0

00% 0

00% 0

00% 0

10% 0.5

40% 1.4

30% 0.9

30% 0.9

40% 1.4

10% 0.5

70% 2.3

10% 0.5

40% 1.4

00% 0

00% 0

10% 0.5

10% 0.5

00% 0

10% 0.5

00% 3.2

00% 0

00% 0

00% 0

00% 0

00% 0

60% 1.8

10% 0.5

00% 0

10% 0.5

00% 0

00% 0

30% 0.9

00% 0

10% 0.5

20% 3.7

30% 4.1

00% 0

00% 0

70% 2.3

20% 3.7

00% 0

00% 0

30% 0.9

40% 1.4

10% 0.5

70% 2.3

---- -----

.00% 40

00% 36.8

equency, Cruy Primary Sit

ASR World

All Ages

T

2.3 2

1.6 0

0 2

0.6 1

0 0

0 0

0 3

0 0

0 0

0.9 0

1.9 3

1.5 0

1.3 7

1.9 4

0.5 1

4.3 2

0.6 3

3.3 2

0 1

0 3

0.6 11 1

0.4 0

0 1

0.6 0

4.7 4

0 1

0 0

0 1

0 2

0 0

3.7 5

0.4 0

0 0

0.4 2

0 0

0 0

1.3 4

0 0

0.4 2

4 4

4.8 4

0 0

0 0

2.2 5

3.8 6

0 0

0 0

0.9 3

1.2 0

1 1

2.9 2

----- -----

53.9 92 1

49.2 88 9

ude Incidencete, Age.

Jouf

otal (%) Crude Rate

2.20% 1.1

0.00% 0

2.20% 1.1

1.10% 0.5

0.00% 0

0.00% 0

3.30% 1.6

0.00% 0

0.00% 0

0.00% 0

3.30% 1.6

0.00% 0

7.60% 3.7

4.30% 2.1

1.10% 0.5

2.20% 1.1

3.30% 1.6

2.20% 1.1

1.10% 0.5

3.30% 1.6

12.00% 5.8

0.00% 0

1.10% 0.5

0.00% 0

4.30% 2.1

1.10% 0.5

0.00% 0

1.10% 0.5

2.20% 1.1

0.00% 0

5.40% 2.6

0.00% 0

0.00% 0

2.20% 1.1

0.00% 0

0.00% 0

4.30% 2.1

0.00% 0

2.20% 1.1

4.30% 2.1

4.30% 2.1

0.00% 0

0.00% 0

5.40% 2.6

6.50% 3.2

0.00% 0

0.00% 0

3.30% 1.6

0.00% 0

1.10% 0.5

2.20% 1.1

----- -----

00.00% 48.4

95.70% 46.3

e Rate (CIR) A

ASR World

All Ages

1.6 1

0 0

1.7 0

0.4 1

0 0

0 0

2.4 5

0 1

0 0

0 8

2.9 4

0 1

5.7 11

3.2 2

0.5 0

1.6 6

3.1 5

1.8 1

1.2 0

2.3 3

10.1 14

0 0

0.4 3

0 0

3.7 6

1.2 0

0 1

0.5 4

1.3 2

0 0

5 5

0 4

0 0

1.6 3

0 1

0 1

2.4 7

0 0

0.9 0

2.3 6

2.3 8

0 1

0 0

3 6

4.6 18

0 0

0 2

1.4 5

0 4

1.2 1

1.2 3

----- -----

71.4 154

67.7 148

Age-Standar

Tabuk

Total (%)

Crude Rate

0.60% 0.3

0.00% 0

0.00% 0

0.60% 0.3

0.00% 0

0.00% 0

3.20% 1.4

0.60% 0.3

0.00% 0

5.20% 2.2

2.60% 1.1

0.60% 0.3

7.10% 3

1.30% 0.5

0.00% 0

3.90% 1.6

3.20% 1.4

0.60% 0.3

0.00% 0

1.90% 0.8

9.10% 3.8

0.00% 0

1.90% 0.8

0.00% 0

3.90% 1.6

0.00% 0

0.60% 0.3

2.60% 1.1

1.30% 0.5

0.00% 0

3.20% 1.4

2.60% 1.1

0.00% 0

1.90% 0.8

0.60% 0.3

0.60% 0.3

4.50% 1.9

0.00% 0

0.00% 0

3.90% 1.6

5.20% 2.2

0.60% 0.3

0.00% 0

3.90% 1.6

11.70% 4.9

0.00% 0

1.30% 0.5

3.20% 1.4

2.60% 1.1

0.60% 0.3

1.90% 0.8

----- -----

100.00% 42.1

96.10% 40.4

dised Inciden

ASR World

All Ages

0.6 1

0 0

0 1

0.2 0

0 1

0 0

1.8 0

0.6 0

0 0

4.2 2

2.2 2

0.5 0

4.9 3

0.9 3

0 2

3.3 1

2.1 2

0.6 3

0 1

2 0

8 3

0 0

0.8 2

0 0

3.1 7

0 0

0.6 0

1.2 2

0.9 0

0 0

2.7 4

1.6 3

0 0

1.3 3

0.3 0

0.4 0

3.8 2

0 0

0 0

1.9 2

2.5 2

0.3 1

0 0

1.7 3

7.5 7

0 0

0.7 2

1.4 0

1.2 1

0.2 0

1.4 1

----- -----

67.1 67

64 60

nce Rate

Northern Regio

Total (%) Crude Rate

1.50% 0.7

0.00% 0

1.50% 0.7

0.00% 0

1.50% 0.7

0.00% 0

0.00% 0

0.00% 0

0.00% 0

3.00% 1.4

3.00% 1.4

0.00% 0

4.50% 2.1

4.50% 2.1

3.00% 1.4

1.50% 0.7

3.00% 1.4

4.50% 2.1

1.50% 0.7

0.00% 0

4.50% 2.1

0.00% 0

3.00% 1.4

0.00% 0

10.40% 4.9

0.00% 0

0.00% 0

3.00% 1.4

0.00% 0

0.00% 0

6.00% 2.8

4.50% 2.1

0.00% 0

4.50% 2.1

0.00% 0

0.00% 0

3.00% 1.4

0.00% 0

0.00% 0

3.00% 1.4

3.00% 1.4

1.50% 0.7

0.00% 0

4.50% 2.1

10.40% 4.9

0.00% 0

3.00% 1.4

0.00% 0

1.50% 0.7

0.00% 0

1.50% 0.7

----- -----

100.00% 46.5

89.60% 41.7

on

ASR World

1.6

0

0.9

0

1.1

0

0

0

0

2.1

2

0

3.5

3.3

3.1

1

2.6

4.1

1.5

0

4.2

0

1.1

0

6.7

0

0

1.1

0

0

4.7

3.5

0

3.3

0

0

2.9

0

0

1.1

1.4

0.7

0

2.1

5

0

2.5

0

0.5

0

0.6

-----

69

62.2

Table (ASR)

ICD (10th)

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C96

C88

C90

C91

C92-C94

C95

Other

All

Not C44

5.2.4 : Numb) Among Sau

Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharynx

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchus,Lu

Other Thoracic organ

Bone

Melanoma of Skin

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft tissue

Breast

Penis

Prostate

Testis

Other male genital

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary organs

Eye

Brain, Nervous system

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

Non-Hodgkin lympho

Immunoproliferative

Multiple Myeloma

Lymphoid Leukaemia

Myeloid Leukaemia

Leukaemia unspec.

Other & unspecified

All sites Total

All sites but C44

ber Of Cases,di Males ( pe

All Ages

1

15

13

4

1

1

50

1

1

23

44

6

183

113

7

101

20

49

3

17

ung 69

ns 3

33

5

55

1

7

e 19

4

0

103

38

2

65

1

5

57

s 4

8

m 71

82

6

1

68

oma 128

dis. 0

13

a 28

40

2

33

-----

1604

1549

, Relative Freer 100,000) by

Riyadh

Total (%) Crude

0.10% 0

0.90% 0.6

0.80% 0.5

0.20% 0.2

0.10% 0

0.10% 0

3.10% 2.1

0.10% 0

0.10% 0

1.40% 1

2.70% 1.8

0.40% 0.3

11.40% 7.7

7.00% 4.7

0.40% 0.3

6.30% 4.2

1.20% 0.8

3.10% 2.1

0.20% 0.1

1.10% 0.7

4.30% 2.9

0.20% 0.1

2.10% 1.4

0.30% 0.2

3.40% 2.3

0.10% 0

0.40% 0.3

1.20% 0.8

0.20% 0.2

0.00% 0

6.40% 4.3

2.40% 1.6

0.10% 0.1

4.10% 2.7

0.10% 0

0.30% 0.2

3.60% 2.4

0.20% 0.2

0.50% 0.3

4.40% 3

5.10% 3.4

0.40% 0.3

0.10% 0

4.20% 2.9

8.00% 5.4

0.00% 0

0.80% 0.5

1.70% 1.2

2.50% 1.7

0.10% 0.1

2.10% 1.4

----- ----

100.00% 67.

96.60% 65

equency, Cruy Primary Sit

Rate ASR World

0

6 1.1

5 0.7

2 0.2

0.1

0.1

1 2.6

0.1

0

1.6

8 2.8

3 0.4

7 11.7

7 7.2

3 0.5

2 7.1

8 1.4

1 3.3

1 0.2

7 1

9 4.6

1 0.1

4 1.4

2 0.3

3 3.3

0.1

3 0.5

8 1

2 0.3

0

3 7.9

6 1.4

1 0.1

7 4

0.1

2 0.4

4 3.8

2 0.3

3 0.4

3.4

4 4.4

3 0.3

0

9 2.7

4 7

0

5 0.8

2 1.4

7 1.9

1 0.1

4 2

-- -----

4 96.4

5 93

ude Incidencete, Age Group

All Ages Tota

3 0.2

14 1.0

14 1.0

3 0.2

0 0.0

2 0.1

29 2.1

1 0.1

0 0.0

20 1.5

58 4.3

7 0.5

119 8.8

92 6.8

5 0.4

57 4.2

23 1.7

42 3.1

4 0.3

14 1.0

77 5.7

6 0.4

9 0.7

3 0.2

33 2.4

2 0.1

7 0.5

23 1.7

10 0.7

1 0.1

114 8.4

23 1.7

0 0.0

45 3.3

3 0.2

2 0.1

64 4.7

2 0.1

5 0.4

46 3.4

32 2.4

5 0.4

2 0.1

63 4.7

100 7.4

0 0.0

21 1.6

59 4.4

41 3.0

6 0.4

41 3.0

----- --

1352 100

1319 97.

e Rate (CIR) Aps and Regio

Makkah

al (%) Crude Rate

20% 0.1

00% 0.6

00% 0.6

20% 0.1

00% 0

10% 0.1

10% 1.3

10% 0

00% 0

50% 0.9

30% 2.6

50% 0.3

80% 5.3

80% 4.1

40% 0.2

20% 2.5

70% 1

10% 1.9

30% 0.2

00% 0.6

70% 3.4

40% 0.3

70% 0.4

20% 0.1

40% 1.5

10% 0.1

50% 0.3

70% 1

70% 0.4

10% 0

40% 5

70% 1

00% 0

30% 2

20% 0.1

10% 0.1

70% 2.8

10% 0.1

40% 0.2

40% 2

40% 1.4

40% 0.2

10% 0.1

70% 2.8

40% 4.4

00% 0

60% 0.9

40% 2.6

00% 1.8

40% 0.3

00% 1.8

---- -----

0.00% 59.9

.60% 58.4

Age-Standarons 2016.

ASR World

0.2

0.8

0.8

0.2

0

0.1

1.4

0

0

1.1

3.3

0.4

6.3

5

0.2

3.3

1.3

2.5

0.2

0.8

4.5

0.3

0.4

0.2

1.9

0.2

0.4

1

0.5

0

7.5

0.9

0

2.4

0.1

0.1

3.6

0.1

0.3

2.3

1.5

0.3

0.1

2.9

5.2

0

1.2

3

2

0.3

2.3

-----

73.2

71.3

dised Inciden

East

All Ages Total (%)

3 0.30%

12 1.10%

8 0.70%

5 0.50%

1 0.10%

0 0.00%

25 2.30%

3 0.30%

0 0.00%

6 0.50%

29 2.70%

9 0.80%

109 10.00%

67 6.10%

4 0.40%

38 3.50%

8 0.70%

31 2.80%

5 0.50%

18 1.60%

82 7.50%

1 0.10%

14 1.30%

3 0.30%

31 2.80%

6 0.50%

4 0.40%

19 1.70%

13 1.20%

1 0.10%

94 8.60%

33 3.00%

0 0.00%

41 3.70%

2 0.20%

0 0.00%

45 4.10%

0 0.00%

6 0.50%

39 3.60%

46 4.20%

4 0.40%

1 0.10%

44 4.00%

81 7.40%

0 0.00%

20 1.80%

28 2.60%

26 2.40%

3 0.30%

26 2.40%

----- -----

1094 100.00%

1063 97.20%

nce Rate

tern Province

) Crude Rate

0.2

0.7

0.5

0.3

0.1

0

1.6

0.2

0

0.4

1.8

0.6

6.8

4.2

0.2

2.4

0.5

1.9

0.3

1.1

5.1

0.1

0.9

0.2

1.9

0.4

0.2

1.2

0.8

0.1

5.8

2

0

2.5

0.1

0

2.8

0

0.4

2.4

2.9

0.2

0.1

2.7

5

0

1.2

1.7

1.6

0.2

1.6

-----

67.9

66

67

ASR World

0.3

1.4

1

0.2

0.1

0

1.9

0.5

0

0.6

2.9

1

10.9

6.4

0.5

4.1

0.9

3.3

0.6

1.8

9.6

0.1

0.9

0.4

3.1

0.8

0.6

1.4

1.3

0.1

11.2

1.8

0

3.9

0.2

0

5.2

0

0.5

2.9

3.4

0.3

0

2.7

6.6

0

2.1

2.5

1.5

0.2

2.4

-----

104.3

101.2

68 68

Table (ASR)

ICD (10th)

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C96

C88

C90

C91

C92-C94

C95

Other

All

Not C44

5.3.1 : Numb) Among Sau

Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharynx

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchus,Lu

Other Thoracic organ

Bone

Melanoma of Skin

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft tissue

Breast

Vulva

Vagina

Cervix Uteri

Corpus Uteri

Uterus unspec.

Ovary

Other Female Genita

Placenta

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary organ

Eye

Brain, Nervous system

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

Non-Hodgkin lympho

Immunoproliferative

Multiple Myeloma

Lymphoid Leukaemia

Myeloid Leukaemia

Leukaemia unspec.

Other & unspecified

All sites Total

All sites but C44

ber Of Cases,di Females (

All Ages

0

8

11

0

1

0

6

3

0

4

13

3

43

18

0

18

13

4

1

0

ung 11

ns 0

2

1

21

0

0

e 4

103

1

2

2

25

0

18

al 1

1

3

0

0

7

s 0

4

m 12

67

2

0

14

oma 35

dis. 0

4

a 13

14

2

5

-----

520

499

, Relative Freper 100,000)

Asir

Total (%) Crude

0.00% 0

1.50% 0.

2.10% 1.

0.00% 0

0.20% 0.

0.00% 0

1.20% 0.

0.60% 0.

0.00% 0

0.80% 0.

2.50% 1.

0.60% 0.

8.30% 4.

3.50% 2.

0.00% 0

3.50% 2.

2.50% 1.

0.80% 0.

0.20% 0.

0.00% 0

2.10% 1.

0.00% 0

0.40% 0.

0.20% 0.

4.00% 2.

0.00% 0

0.00% 0

0.80% 0.

19.80% 11

0.20% 0.

0.40% 0.

0.40% 0.

4.80% 2.

0.00% 0

3.50% 2.

0.20% 0.

0.20% 0.

0.60% 0.

0.00% 0

0.00% 0

1.30% 0.

0.00% 0

0.80% 0.

2.30% 1.

12.90% 7.

0.40% 0.

0.00% 0

2.70% 1.

6.70% 4

0.00% 0

0.80% 0.

2.50% 1.

2.70% 1.

0.40% 0.

1.00% 0.

----- ---

100.00% 59

96.00% 57

equency, Cruby Primary

e Rate ASR World

0 0

.9 1.1

.3 1.6

0 0

.1 0.1

0 0

.7 0.8

.3 0.4

0 0

.5 0.4

.5 1.6

.3 0.4

.9 5.9

.1 2.3

0 0

.1 2.5

.5 1.8

.5 0.4

.1 0.1

0 0

.3 1.4

0 0

.2 0.2

.1 0.1

.4 2.6

0 0

0 0

.5 0.5

.8 12.6

.1 0.2

.2 0.3

.2 0.2

.9 3.7

0 0

.1 2

.1 0.1

.1 0.1

.3 0.3

0 0

0 0

.8 0.8

0 0

.5 0.5

.4 1.5

.7 7.4

.2 0.3

0 0

.6 1.6

4 5.3

0 0

.5 0.6

.5 1.7

.6 1.8

.2 0.2

.6 0.7

--- -----

9.6 66.2

7.2 63.7

ude IncidenceSite, Age Gro

All Ages Tot

2 2.

2 2.

2 2.

0 0.

0 0.

0 0.

2 2.

0 0.

0 0.

0 0.

4 5.

0 0.

10 12

3 3.

0 0.

0 0.

0 0.

2 2.

0 0.

0 0.

1 1.

0 0.

0 0.

0 0.

5 6.

0 0.

0 0.

1 1.

15 18

0 0.

1 1.

1 1.

7 8.

0 0.

3 3.

1 1.

0 0.

0 0.

0 0.

0 0.

0 0.

0 0.

1 1.

2 2.

5 6.

0 0.

0 0.

1 1.

8 10

0 0.

0 0.

0 0.

0 0.

0 0.

1 1.

----- -

80 100

75 93

e Rate (CIR) Aoups and Reg

Baha

tal (%) Crude Rate

.50% 1

.50% 1

.50% 1

.00% 0

.00% 0

.00% 0

.50% 1

.00% 0

.00% 0

.00% 0

.00% 2

.00% 0

2.50% 5.1

.80% 1.5

.00% 0

.00% 0

.00% 0

.50% 1

.00% 0

.00% 0

.20% 0.5

.00% 0

.00% 0

.00% 0

.20% 2.6

.00% 0

.00% 0

.20% 0.5

8.80% 7.7

.00% 0

.20% 0.5

.20% 0.5

.80% 3.6

.00% 0

.80% 1.5

.20% 0.5

.00% 0

.00% 0

.00% 0

.00% 0

.00% 0

.00% 0

.20% 0.5

.50% 1

.20% 2.6

.00% 0

.00% 0

.20% 0.5

0.00% 4.1

.00% 0

.00% 0

.00% 0

.00% 0

.00% 0

.20% 0.5

----- -----

0.00% 40.9

3.80% 38.3

Age-Standargions 2016

e ASR World

0.7

1.1

1.2

0

0

0

0.8

0

0

0

1.6

0

4.4

1.3

0

0

0

1.1

0

0

0.6

0

0

0

2

0

0

0.6

7

0

0.7

0.3

3.8

0

1.6

0.3

0

0

0

0

0

0

0.6

1.1

2.2

0

0

0.4

3.5

0

0

0

0

0

0.5

-----

37.5

35.5

dised Inciden

All Ages Total (%

1 0.50%

6 2.90%

12 5.80%

4 1.90%

0 0.00%

0 0.00%

0 0.00%

3 1.50%

1 0.50%

3 1.50%

4 1.90%

1 0.50%

6 2.90%

9 4.40%

1 0.50%

3 1.50%

4 1.90%

1 0.50%

0 0.00%

0 0.00%

2 1.00%

0 0.00%

2 1.00%

0 0.00%

6 2.90%

1 0.50%

0 0.00%

2 1.00%

55 26.70%

0 0.00%

0 0.00%

2 1.00%

17 8.30%

2 1.00%

3 1.50%

0 0.00%

0 0.00%

2 1.00%

0 0.00%

0 0.00%

1 0.50%

0 0.00%

0 0.00%

3 1.50%

23 11.20%

0 0.00%

0 0.00%

5 2.40%

12 5.80%

0 0.00%

0 0.00%

4 1.90%

3 1.50%

0 0.00%

2 1.00%

----- -----

206 100.00%

200 97.10%

nce Rate

Jazan

%) Crude Rate

0.2

1

2

0.7

0

0

0

0.5

0.2

0.5

0.7

0.2

1

1.5

0.2

0.5

0.7

0.2

0

0

0.3

0

0.3

0

1

0.2

0

0.3

% 9.4

0

0

0.3

2.9

0.3

0.5

0

0

0.3

0

0

0.2

0

0

0.5

% 3.9

0

0

0.9

2

0

0

0.7

0.5

0

0.3

-----

% 35

% 34

ASR World

0.2

1.3

2.6

0.8

0

0

0

0.5

0.2

0.6

0.8

0.2

1.1

2

0.2

0.5

0.8

0.2

0

0

0.4

0

0.3

0

1.4

0.2

0

0.3

10.4

0

0

0.3

3.5

0.4

0.6

0

0

0.4

0

0

0.2

0

0

0.6

4.1

0

0

0.8

2.6

0

0

0.8

0.5

0

0.4

-----

40.6

39.2

Ta(AS

IC(1

C00

C01-C0

C03-C0

C07-C0

C09

C10

C11

C12-C1

C14

C15

C16

C17

C18

C19-C2

C21

C22

C23-C2

C25

C30-C3

C32

C33-C3

C37-C3

C40-C4

C43

C44

C45

C46

C47;C4

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70-C7

C73

C74

C75

C81

C82-C8

C88

C90

C91

C92-C9

C95

Other

All

Not C4

ble 5.3.2 : NuSR) Among S

CD 0th)

Lip

02 Tongue

06 Mouth

08 Salivary g

Tonsil

Other Oro

Nasophary

13 Hypophar

Pharynx u

Oesophagu

Stomach

Small inte

Colon

20 Rectum

Anus

Liver

24 Gallbladd

Pancreas

31 Nose, sinu

Larynx

34 Trachea,B

38 Other Tho

41 Bone

Melanoma

Other Skin

Mesothelio

Kaposi sar

49 Connectiv

Breast

Vulva

Vagina

Cervix Ute

Corpus Ut

Uterus un

Ovary

Other Fem

Placenta

Kidney

Renal Pelv

Ureter

Bladder

Other Uri

Eye

72 Brain, Ner

Thyroid

Adrenal gl

Other End

Hodgkin d

85;C96 Non-Hodg

Immunopr

Multiple M

Lymphoid

94 Myeloid L

Leukaemi

Other & u

All sites T

44 All sites bu

umber Of CaSaudi Female

Site

glands

opharynx

ynx

rynx

unspec.

us

stine

er etc.

uses etc.

Bronchus,Lung

oracic organs

a of Skin

n

oma

rcoma

ve,Soft tissue

eri

teri

spec.

male Genital

vis

nary organs

rvous system

land

docrine

disease

gkin lymphoma

roliferative dis.

Myeloma

d Leukaemia

Leukaemia

a unspec.

unspecified

otal

ut C44

ses, Relative es ( per 100,0

M

All Ages Total (%

0 0.00%

2 0.60%

1 0.30%

0 0.00%

0 0.00%

0 0.00%

5 1.50%

2 0.60%

0 0.00%

5 1.50%

3 0.90%

2 0.60%

17 5.20%

14 4.30%

1 0.30%

8 2.40%

4 1.20%

2 0.60%

0 0.00%

0 0.00%

3 0.90%

1 0.30%

5 1.50%

3 0.90%

6 1.80%

0 0.00%

0 0.00%

2 0.60%

92 28.00%

0 0.00%

0 0.00%

8 2.40%

25 7.60%

3 0.90%

10 3.00%

0 0.00%

1 0.30%

7 2.10%

0 0.00%

0 0.00%

2 0.60%

0 0.00%

2 0.60%

15 4.60%

24 7.30%

3 0.90%

1 0.30%

10 3.00%

17 5.20%

0 0.00%

2 0.60%

3 0.90%

10 3.00%

1 0.30%

6 1.80%

----- -----

328 100.00

322 98.20%

Frequency, C00) by Prima

Madinah

%) Crude Rate

% 0

% 0.3

% 0.1

% 0

% 0

% 0

% 0.7

% 0.3

% 0

% 0.7

% 0.4

% 0.3

% 2.5

% 2.1

% 0.1

% 1.2

% 0.6

% 0.3

% 0

% 0

% 0.4

% 0.1

% 0.7

% 0.4

% 0.9

% 0

% 0

% 0.3

% 13.6

% 0

% 0

% 1.2

% 3.7

% 0.4

% 1.5

% 0

% 0.1

% 1

% 0

% 0

% 0.3

% 0

% 0.3

% 2.2

% 3.6

% 0.4

% 0.1

% 1.5

% 2.5

% 0

% 0.3

% 0.4

% 1.5

% 0.1

% 0.9

-----

% 48.5

% 47.6

Crude Incideary Site, Age

ASR World

All Ages

0 0

0.5 0

0.2 0

0 1

0 0

0 0

0.9 1

0.5 0

0 0

1.2 0

0.6 3

0.4 1

3.5 13

2.9 10

0.2 0

1.5 1

0.9 3

0.3 2

0 0

0 0

0.5 2

0.1 0

0.7 2

0.4 0

1 2

0 0

0 0

0.3 0

15.9 46

0 0

0 0

1.7 0

5.2 10

0.6 2

1.9 4

0 0

0.1 0

1.8 3

0 0

0 0

0.4 2

0 0

0.3 0

2.5 3

3.7 24

0.5 0

0.2 0

1.5 8

3.8 3

0 0

0.4 0

0.4 0

1.7 2

0.1 0

1.4 3

----- -----

60.6 151

59.6 149

nce Rate (CIGroups and

Hail

Total (%) CR

0.00%

0.00%

0.00%

0.70%

0.00%

0.00%

0.70%

0.00%

0.00%

0.00%

2.00%

0.70%

8.60%

6.60%

0.00%

0.70%

2.00%

1.30%

0.00%

0.00%

1.30%

0.00%

1.30%

0.00%

1.30%

0.00%

0.00%

0.00%

30.50% 1

0.00%

0.00%

0.00%

6.60%

1.30%

2.60%

0.00%

0.00%

2.00%

0.00%

0.00%

1.30%

0.00%

0.00%

2.00%

15.90%

0.00%

0.00%

5.30%

2.00%

0.00%

0.00%

0.00%

1.30%

0.00%

2.00%

-----

100.00% 5

98.70% 5

IR) Age-StandRegions 2016

Crude Rate

ASR World

0 0

0 0

0 0

0.4 0.4

0 0

0 0

0.4 0.3

0 0

0 0

0 0

1.1 1.5

0.4 0.6

4.9 5.6

3.7 4.6

0 0

0.4 0.5

1.1 1.8

0.7 0.8

0 0

0 0

0.7 1

0 0

0.7 0.8

0 0

0.7 0.8

0 0

0 0

0 0

17.2 19

0 0

0 0

0 0

3.7 4.8

0.7 0.9

1.5 1.8

0 0

0 0

1.1 1.5

0 0

0 0

0.7 0.9

0 0

0 0

1.1 1.2

9 9.6

0 0

0 0

3 2.6

1.1 1.2

0 0

0 0

0 0

0.7 0.9

0 0

1.1 1.4

----- -----

56.4 64.6

55.6 63.8

dardised Inci6

Q

All Ages Total (%

1 0.30%

0 0.00%

1 0.30%

3 0.90%

0 0.00%

0 0.00%

7 2.10%

0 0.00%

0 0.00%

2 0.60%

3 0.90%

0 0.00%

22 6.70%

9 2.70%

0 0.00%

4 1.20%

3 0.90%

5 1.50%

0 0.00%

0 0.00%

3 0.90%

1 0.30%

4 1.20%

1 0.30%

4 1.20%

0 0.00%

0 0.00%

5 1.50%

131 39.70%

0 0.00%

1 0.30%

4 1.20%

22 6.70%

2 0.60%

6 1.80%

0 0.00%

0 0.00%

5 1.50%

0 0.00%

0 0.00%

1 0.30%

0 0.00%

2 0.60%

5 1.50%

24 7.30%

1 0.30%

0 0.00%

19 5.80%

18 5.50%

0 0.00%

0 0.00%

1 0.30%

2 0.60%

0 0.00%

8 2.40%

----- -----

330 100.00%

326 98.80%

idence Rate

Qassim

%) Crude Rate

% 0.2

% 0

% 0.2

% 0.6

% 0

% 0

% 1.4

% 0

% 0

% 0.4

% 0.6

% 0

% 4.5

% 1.8

% 0

% 0.8

% 0.6

% 1

% 0

% 0

% 0.6

% 0.2

% 0.8

% 0.2

% 0.8

% 0

% 0

% 1

% 26.7

% 0

% 0.2

% 0.8

% 4.5

% 0.4

% 1.2

% 0

% 0

% 1

% 0

% 0

% 0.2

% 0

% 0.4

% 1

% 4.9

% 0.2

% 0

% 3.9

% 3.7

% 0

% 0

% 0.2

% 0.4

% 0

% 1.6

-----

% 67.2

% 66.4

69

ASR World

0.3

0

0.2

0.7

0

0

1.5

0

0

0.6

0.7

0

6.2

2.4

0

1.2

0.9

1.5

0

0

1

0.4

0.8

0.3

0.9

0

0

1.1

31.7

0

0.2

0.8

6.1

0.4

1.2

0

0

1.1

0

0

0.2

0

0.4

1.1

5.5

0.2

0

3.9

4.5

0

0

0.2

0.5

0

2

-----

80.8

79.9

70 70

Table (ASR)

ICD (10th)

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C96

C88

C90

C91

C92-C94

C95

Other

All

Not C44

5.3.3 : Numb) Among Sau

Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharynx

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchus,Lu

Other Thoracic organ

Bone

Melanoma of Skin

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft tissue

Breast

Vulva

Vagina

Cervix Uteri

Corpus Uteri

Uterus unspec.

Ovary

Other Female Genital

Placenta

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary organs

Eye

Brain, Nervous system

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

Non-Hodgkin lympho

Immunoproliferative

Multiple Myeloma

Lymphoid Leukaemia

Myeloid Leukaemia

Leukaemia unspec.

Other & unspecified

All sites Total

All sites but C44

ber Of Cases,di Females (

All Ages

T

0

0

0

1

0

0

2

0

0

1

1

1

6

0

0

3

2

3

1

0

ung 0

ns 0

2

1

5

0

1

e 0

31

0

0

1

4

1

7

l 0

0

2

0

0

1

s 0

0

m 1

18

0

0

9

oma 5

dis. 0

1

a 3

4

0

4

-----

122 1

117

, Relative Freper 100,000)

Najran

Total (%) Crude Rate

0.00% 0

0.00% 0

0.00% 0

0.80% 0.5

0.00% 0

0.00% 0

1.60% 0.9

0.00% 0

0.00% 0

0.80% 0.5

0.80% 0.5

0.80% 0.5

4.90% 2.8

0.00% 0

0.00% 0

2.50% 1.4

1.60% 0.9

2.50% 1.4

0.80% 0.5

0.00% 0

0.00% 0

0.00% 0

1.60% 0.9

0.80% 0.5

4.10% 2.3

0.00% 0

0.80% 0.5

0.00% 0

25.40% 14.5

0.00% 0

0.00% 0

0.80% 0.5

3.30% 1.9

0.80% 0.5

5.70% 3.3

0.00% 0

0.00% 0

1.60% 0.9

0.00% 0

0.00% 0

0.80% 0.5

0.00% 0

0.00% 0

0.80% 0.5

14.80% 8.4

0.00% 0

0.00% 0

7.40% 4.2

4.10% 2.3

0.00% 0

0.80% 0.5

2.50% 1.4

3.30% 1.9

0.00% 0

3.30% 1.9

----- -----

100.00% 56.9

95.90% 54.6

equency, Cruby Primary

ASR World

All Ages

0 0

0 0

0 0

0.5 0

0 0

0 0

1.5 2

0 0

0 0

0.7 0

0.8 3

0.7 2

3.6 5

0 5

0 1

2 1

1.4 1

2.5 0

0.8 0

0 0

0 3

0 0

0.8 3

0.8 0

3.3 8

0 1

0.8 0

0 2

17.4 31

0 0

0 0

0.5 0

2.7 3

0.6 1

3.9 7

0 0

0 0

1.5 4

0 0

0 0

0.7 0

0 0

0 1

0.4 1

9.9 16

0 0

0 0

3.9 3

3.4 5

0 0

0.4 0

1.6 3

2.1 6

0 0

2.6 6

----- -----

71.7 124

68.5 116

ude IncidenceSite, Age Gro

Jouf

Total (%) Crude Rate

0.00% 0

0.00% 0

0.00% 0

0.00% 0

0.00% 0

0.00% 0

1.60% 1.1

0.00% 0

0.00% 0

0.00% 0

2.40% 1.6

1.60% 1.1

4.00% 2.7

4.00% 2.7

0.80% 0.5

0.80% 0.5

0.80% 0.5

0.00% 0

0.00% 0

0.00% 0

2.40% 1.6

0.00% 0

2.40% 1.6

0.00% 0

6.50% 4.3

0.80% 0.5

0.00% 0

1.60% 1.1

25.00% 16.8

0.00% 0

0.00% 0

0.00% 0

2.40% 1.6

0.80% 0.5

5.60% 3.8

0.00% 0

0.00% 0

3.20% 2.2

0.00% 0

0.00% 0

0.00% 0

0.00% 0

0.80% 0.5

0.80% 0.5

12.90% 8.7

0.00% 0

0.00% 0

2.40% 1.6

4.00% 2.7

0.00% 0

0.00% 0

2.40% 1.6

4.80% 3.3

0.00% 0

4.80% 3.3

----- -----

100.00% 67.2

93.50% 62.9

e Rate (CIR) Aoups and Reg

ASR World

All Ages

0 0

0 1

0 2

0 1

0 0

0 0

2.1 2

0 0

0 0

0 3

2 3

1.5 2

4.6 13

4.6 2

0.7 0

0.5 2

1.1 5

0 2

0 0

0 0

2.3 7

0 1

1.5 0

0 0

7.3 5

1.1 0

0 0

1.2 3

25 50

0 0

0 0

0 2

3.1 7

1.1 1

4.9 1

0 0

0 1

2.5 5

0 0

0 0

0 2

0 0

0.5 1

0.9 5

9.8 41

0 1

0 0

1.5 9

4.1 8

0 0

0 1

2.2 4

3.5 5

0 1

6 1

----- -----

95.5 200

88.3 195

Age-Standargions 2016.

Tabuk

Total (%) CrudRat

0.00% 0

0.50% 0.3

1.00% 0.6

0.50% 0.3

0.00% 0

0.00% 0

1.00% 0.6

0.00% 0

0.00% 0

1.50% 0.9

1.50% 0.9

1.00% 0.6

6.50% 3.8

1.00% 0.6

0.00% 0

1.00% 0.6

2.50% 1.4

1.00% 0.6

0.00% 0

0.00% 0

3.50% 2

0.50% 0.3

0.00% 0

0.00% 0

2.50% 1.4

0.00% 0

0.00% 0

1.50% 0.9

25.00% 14.4

0.00% 0

0.00% 0

1.00% 0.6

3.50% 2

0.50% 0.3

0.50% 0.3

0.00% 0

0.50% 0.3

2.50% 1.4

0.00% 0

0.00% 0

1.00% 0.6

0.00% 0

0.50% 0.3

2.50% 1.4

20.50% 11.8

0.50% 0.3

0.00% 0

4.50% 2.6

4.00% 2.3

0.00% 0

0.50% 0.3

2.00% 1.2

2.50% 1.4

0.50% 0.3

0.50% 0.3

----- -----

100.00% 57.7

97.50% 56.3

dized Inciden

de e

ASR World

All Ages

0 0

3 0.8 0

6 0.7 0

3 0.2 1

0 0

0 0

6 0.9 0

0 0

0 0

9 1.9 1

9 1.3 0

6 1 0

8 5.6 7

6 0.6 1

0 0

6 0.6 0

4 2.5 0

6 1.2 1

0 0

0 1

4.1 3

3 0.4 0

0 0

0 0

4 2.5 5

0 0

0 0

9 0.8 1

4 19.8 11

0 0

0 0

6 1 1

3.3 1

3 0.3 1

3 0.8 3

0 1

3 0.2 0

4 2.3 0

0 0

0 0

6 0.8 1

0 0

3 0.3 0

4 1.7 1

8 12.9 8

3 0.3 0

0 0

6 2.2 1

3 3.3 3

0 0

3 0.4 0

2 1.1 1

4 1.7 3

3 0.2 0

3 0.2 1

- ----- ----

7 78.1 58

3 75.5 53

nce Rate

Northern Reg

Total (%) CrudRat

0.00% 0

0.00% 0

0.00% 0

1.70% 0.7

0.00% 0

0.00% 0

0.00% 0

0.00% 0

0.00% 0

1.70% 0.7

0.00% 0

0.00% 0

12.10% 4.9

1.70% 0.7

0.00% 0

0.00% 0

0.00% 0

1.70% 0.7

0.00% 0

1.70% 0.7

5.20% 2.1

0.00% 0

0.00% 0

0.00% 0

8.60% 3.5

0.00% 0

0.00% 0

1.70% 0.7

19.00% 7.7

0.00% 0

0.00% 0

1.70% 0.7

1.70% 0.7

1.70% 0.7

5.20% 2.1

1.70% 0.7

0.00% 0

0.00% 0

0.00% 0

0.00% 0

1.70% 0.7

0.00% 0

0.00% 0

1.70% 0.7

13.80% 5.6

0.00% 0

0.00% 0

1.70% 0.7

5.20% 2.1

0.00% 0

0.00% 0

1.70% 0.7

5.20% 2.1

0.00% 0

1.70% 0.7

----- ----

100.00% 40.7

91.40% 37.2

ion de te

ASR World

0

0

0

7 0

0

0

0

0

0

7 0.7

0

0

9 6.8

7 1.4

0

0

0

7 1.4

0

7 0.9

1 4

0

0

0

5 4.4

0

0

7 0.5

7 9.4

0

0

7 1

7 1.2

7 0.9

1 3.4

7 1

0

0

0

0

7 1.1

0

0

7 0.6

6 5.7

0

0

7 1.1

1 2.8

0

0

7 0.8

1 2.1

0

7 1.1

- -----

7 53.8

2 49.5

Tabl(ASR

ICD (1

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C

C88

C90

C91

C92-C94

C95

Other

All

Not C44

le 5.3.4 : NumR) Among Sa

10th) Si

Lip

Tongue

Mouth

Salivary glan

Tonsil

Other Oroph

Nasopharynx

Hypopharyn

Pharynx uns

Oesophagus

Stomach

Small intestin

Colon

Rectum

Anus

Liver

Gallbladder

Pancreas

Nose, sinuses

Larynx

Trachea,Bro

Other Thora

Bone

Melanoma of

Other Skin

Mesotheliom

Kaposi sarco

Connective,S

Breast

Vulva

Vagina

Cervix Uteri

Corpus Uter

Uterus unspe

Ovary

Other Femal

Placenta

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinar

Eye

Brain, Nervo

Thyroid

Adrenal glan

Other Endoc

Hodgkin dise

C96 Non-Hodgkin

Immunoprol

Multiple My

Lymphoid L

Myeloid Leu

Leukaemia u

Other & uns

All sites Tota

All sites but C

mber Of Caseaudi Females

ite All Ag

1

7

10

nds 8

0

harynx 1

x 15

nx 2

spec. 0

8

29

ne 9

126

79

1

43

etc. 42

32

s etc. 0

4

onchus,Lung 48

acic organs 5

12

f Skin 11

31

ma 3

oma 1

Soft tissue 21

563

5

1

27

i 129

ec. 15

68

le Genital 6

1

42

1

0

15

ry organs 2

2

ous system 53

341

nd 8

crine 1

ease 57

n lymphoma 95

liferative dis. 0

yeloma 17

eukaemia 24

ukaemia 35

unspec. 2

pecified 34

-----

al 2093

C44 2062

es, Relative F( per 100,000

Riya

es Total (%) C

0.00%

0.30%

0.50%

0.40%

0.00%

0.00%

0.70%

0.10%

0.00%

0.40%

1.40%

0.40%

6.00%

3.80%

0.00%

2.10%

2.00%

1.50%

0.00%

0.20%

2.30%

0.20%

0.60%

0.50%

1.50%

0.10%

0.00%

1.00%

26.90%

0.20%

0.00%

1.30%

6.20%

0.70%

3.20%

0.30%

0.00%

2.00%

0.00%

0.00%

0.70%

0.10%

0.10%

2.50%

16.30%

0.40%

0.00%

2.70%

4.50%

0.00%

0.80%

1.10%

1.70%

0.10%

1.60%

-----

100.00%

2 98.50%

requency, Cr0) by Primary

adh

Crude Rate ASR Wo

0 0.1

0.3 0.5

0.5 0.9

0.4 0.4

0 0

0 0.1

0.7 0.8

0.1 0.2

0 0

0.4 0.5

1.3 2.1

0.4 0.6

5.7 9

3.6 5

0 0.1

1.9 3.7

1.9 3.5

1.4 2.7

0 0

0.2 0.3

2.2 3.4

0.2 0.4

0.5 0.6

0.5 0.7

1.4 1.9

0.1 0.1

0 0.1

0.9 1.2

25.5 33.8

0.2 0.4

0 0

1.2 1.5

5.8 10.6

0.7 1

3.1 4.2

0.3 0.3

0 0

1.9 2.6

0 0.1

0 0

0.7 1.1

0.1 0.2

0.1 0.1

2.4 2.9

15.4 16.6

0.4 0.4

0 0

2.6 2.5

4.3 6.3

0 0

0.8 1.3

1.1 1.3

1.6 1.7

0.1 0.1

1.5 2.5

----- -----

94.6 130.1

93.2 128.2

rude Incidency Site, Age.

orld All Ages T

1

16

10

7

1

1

14

3

0

16

23

3

100

48

3

24

17

23

2

2

27

1

15

3

36

1

2

17

578

1

1

34

115

3

53

6

0

37

1

0

11

0

1

32

135

2

2

46

97

0

11

26

41

4

20

-----

1 1673 1

2 1637

ce Rate (CIR

Makkah

Total (%) Crude Rat

0.10% 0

1.00% 0.7

0.60% 0.5

0.40% 0.3

0.10% 0

0.10% 0

0.80% 0.6

0.20% 0.1

0.00% 0

1.00% 0.7

1.40% 1

0.20% 0.1

6.00% 4.6

2.90% 2.2

0.20% 0.1

1.40% 1.1

1.00% 0.8

1.40% 1

0.10% 0.1

0.10% 0.1

1.60% 1.2

0.10% 0

0.90% 0.7

0.20% 0.1

2.20% 1.6

0.10% 0

0.10% 0.1

1.00% 0.8

34.50% 26.3

0.10% 0

0.10% 0

2.00% 1.5

6.90% 5.2

0.20% 0.1

3.20% 2.4

0.40% 0.3

0.00% 0

2.20% 1.7

0.10% 0

0.00% 0

0.70% 0.5

0.00% 0

0.10% 0

1.90% 1.5

8.10% 6.2

0.10% 0.1

0.10% 0.1

2.70% 2.1

5.80% 4.4

0.00% 0

0.70% 0.5

1.60% 1.2

2.50% 1.9

0.20% 0.2

1.20% 0.9

----- -----

100.00% 76.2

97.80% 74.6

R) Age-Standa

te ASR World

0

0.9

0.6

0.4

0.1

0

0.6

0.2

0

0.9

1.2

0.2

5.7

2.7

0.2

1.5

1

1.4

0.1

0.1

1.4

0.1

0.6

0.2

2

0

0.1

0.8

29.7

0

0

1.8

6.7

0.2

3

0.4

0

2

0.1

0

0.6

0

0.1

1.6

5.9

0.1

0.1

2.1

5.2

0

0.6

1.3

1.9

0.2

1.2

-----

87.7

85.7

ardised Incid

Easte

All Ages Total (%

0 0.00%

5 0.30%

11 0.80%

3 0.20%

0 0.00%

0 0.00%

3 0.20%

1 0.10%

0 0.00%

6 0.40%

22 1.50%

8 0.60%

77 5.30%

59 4.10%

4 0.30%

19 1.30%

18 1.20%

26 1.80%

1 0.10%

0 0.00%

37 2.60%

1 0.10%

6 0.40%

5 0.30%

32 2.20%

1 0.10%

0 0.00%

12 0.80%

526 36.40%

2 0.10%

2 0.10%

29 2.00%

87 6.00%

9 0.60%

35 2.40%

3 0.20%

0 0.00%

28 1.90%

0 0.00%

0 0.00%

16 1.10%

0 0.00%

2 0.10%

20 1.40%

127 8.80%

2 0.10%

2 0.10%

45 3.10%

65 4.50%

0 0.00%

11 0.80%

23 1.60%

33 2.30%

3 0.20%

18 1.20%

----- -----

1445 100.00%

1413 97.80%

ence Rate

ern Province

%) Crude Rate

0

0.3

0.7

0.2

0

0

0.2

0.1

0

0.4

1.5

0.5

5.2

4

0.3

1.3

1.2

1.8

0.1

0

2.5

0.1

0.4

0.3

2.2

0.1

0

0.8

35.4

0.1

0.1

2

5.9

0.6

2.4

0.2

0

1.9

0

0

1.1

0

0.1

1.3

8.6

0.1

0.1

3

4.4

0

0.7

1.5

2.2

0.2

1.2

-----

% 97.3

95.2

71

ASR World

0

0.4

1

0.3

0

0

0.3

0.2

0

0.6

2.1

0.7

7.9

5.7

0.5

2.1

2.2

2.8

0.1

0

3.7

0.1

0.4

0.5

2.7

0.1

0

0.9

46.7

0.2

0.2

2.7

9.1

0.9

3.1

0.3

0

2.5

0

0

1.8

0

0.1

1.6

9.6

0.1

0.1

3

6.4

0

0.9

2

2.6

0.3

1.7

-----

131.3

128.6

72 72

Tabl

ICD (10t

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C

C88

C90

C91

C92-C94

C95

Other

All

Not C44

le 5.4.1 : Num

th) Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharyn

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchu

Other Thoracic o

Bone

Melanoma of Ski

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft t

Breast

Penis

Prostate

Testis

Other male genit

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary or

Eye

Brain, Nervous sy

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

C96 Non-Hodgkin lym

Immunoprolifera

Multiple Myelom

Lymphoid Leuka

Myeloid Leukaem

Leukaemia unspe

Other & unspecif

All sites Total

All sites but C44

mber Of Case

All Ages

4

33

24

8

2

nx 1

32

0

1

25

73

18

173

126

10

42

11

33

11

28

us,Lung 124

organs 9

31

in 11

135

5

5

tissue 33

20

2

144

29

al 0

89

2

2

92

rgans 2

3

ystem 73

68

5

1

43

mphoma 133

ative dis. 0

ma 15

aemia 39

mia 42

ec. 3

fied 57

-----

1872

1737

es Among Non

Age unk 0-4 5

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 2

0 0

0 0

0 1

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

1 0

0 0

0 2

0 8

0 0

0 0

0 0

0 1

0 3

0 0

0 0

0 4

0 2

0 0

0 0

----- ----- --

1 23 2

1 21 2

n-Saudi Male

5-9 10-14 15-19

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 1 1

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 1 0

0 0 0

0 1 1

0 0 0

2 9 1

0 0 0

0 0 1

0 0 1

0 0 0

2 0 1

0 0 0

0 0 0

0 0 0

0 0 1

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

2 2 2

0 0 0

0 0 0

0 0 0

2 5 5

4 6 5

0 0 0

0 0 0

6 3 3

2 1 0

0 0 1

0 0 0

---- ----- -----

20 29 23

20 29 22

es by Primar

20-24 25-29 3

0 0

1 1

0 1

0 1

0 0

0 0

3 2

0 0

0 0

1 0

0 1

0 0

2 2

0 1

0 0

0 0

0 0

0 0

1 0

0 0

0 1

1 4

5 2

0 1

1 4

0 0

0 0

1 3

1 1

0 0

0 0

4 6

0 0

0 1

0 0

0 0

0 5

0 0

0 0

6 6

1 6

0 0

0 0

2 7

4 7

0 0

0 0

0 3

3 1

0 0

1 1

----- -----

38 68

37 64

y Site And A

30-34 35-39 40-44

1 0 2

1 5 4

2 2 1

3 0 0

0 0 0

0 0 0

4 3 2

0 0 0

0 0 0

1 1 5

3 6 8

1 0 3

5 16 14

7 7 14

1 1 0

1 1 2

0 0 2

0 1 5

1 0 0

0 0 2

4 2 4

1 1 0

0 1 4

1 1 3

7 5 8

0 0 0

0 1 2

5 2 4

0 1 1

0 2 0

0 1 1

6 5 2

0 0 0

3 4 8

0 0 1

0 0 0

2 5 2

0 0 0

1 0 0

7 10 6

12 10 5

1 1 0

1 0 0

8 3 3

10 10 13

0 0 0

0 1 1

1 3 3

2 7 4

0 1 0

6 3 4

----- ----- -----

109 123 143

102 118 135

Age Groups, 2

4 45-49 50-54

0 0

6 6

6 3

2 0

0 1

0 0

3 5

0 0

0 1

2 3

9 10

3 3

19 24

18 21

0 1

3 5

2 1

7 5

5 0

2 3

12 10

1 0

1 1

0 3

10 16

2 1

0 0

3 2

6 3

0 0

1 7

1 2

0 0

14 15

0 0

0 0

3 12

0 0

0 0

3 8

7 9

1 0

0 0

3 1

16 13

0 0

1 2

2 1

3 4

1 0

6 8

- ----- -----

184 210

174 194

2016.

55-59 60-64 65

0 0 0

2 4 0

3 2 0

2 0 0

0 1 0

0 1 0

3 4

0 0 0

0 0 0

3 3 3

14 7 6

3 3 0

21 27 2

19 11 1

1 2 3

6 13 3

1 2 2

8 3 2

2 0

5 6 6

22 22 2

1 0 0

1 4 0

0 2 0

29 15 1

0 0

0 0 2

4 3 2

5 1 0

0 0 0

27 30 3

0 2 0

0 0 0

17 12 5

0 1 0

0 0

13 16 1

0 0 0

0 0 0

6 4

6 5 2

1 1 0

0 0 0

0 2 0

11 12 9

0 0 0

5 2 2

4 0 2

2 8 0

0 0 0

16 6 3

----- ----- --

263 237 17

234 222 16

-69 70-74 75+

0 0 1

0 1 2

0 1 3

0 0 0

0 0 0

0 0 0

1 0 0

0 0 0

0 0 0

3 1 2

6 2 7

0 1 1

21 10 12

17 6 5

3 1 0

3 4 4

2 1 0

2 1 1

1 0 0

6 2 2

21 10 14

0 0 0

0 0 0

0 0 0

11 9 17

1 0 0

2 0 0

2 0 0

0 1 0

0 0 0

33 22 22

0 0 0

0 0 0

5 4 6

0 0 0

1 1 0

13 6 14

0 1 1

0 0 0

1 1 1

2 0 5

0 0 0

0 0 0

0 1 0

9 3 7

0 0 0

2 0 1

2 2 2

0 0 3

0 0 0

3 1 2

--- ----- -----

73 93 135

62 84 118

Total (%)

0.20%

1.80%

1.30%

0.40%

0.10%

0.10%

1.70%

0.00%

0.10%

1.30%

3.90%

1.00%

9.20%

6.70%

0.50%

2.20%

0.60%

1.80%

0.60%

1.50%

6.60%

0.50%

1.70%

0.60%

7.20%

0.30%

0.30%

1.80%

1.10%

0.10%

7.70%

1.50%

0.00%

4.80%

0.10%

0.10%

4.90%

0.10%

0.20%

3.90%

3.60%

0.30%

0.10%

2.30%

7.10%

0.00%

0.80%

2.10%

2.20%

0.20%

3.00%

-----

100.00%

92.80%

Tabl

ICD (10t

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C

C88

C90

C91

C92-C94

C95

Other

All

Not C44

le 5.4.2 : Num

th) Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharyn

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchu

Other Thoracic o

Bone

Melanoma of Ski

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft t

Breast

Vulva

Vagina

Cervix Uteri

Corpus Uteri

Uterus unspec.

Ovary

Other Female Ge

Placenta

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary or

Eye

Brain, Nervous sy

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

C96 Non-Hodgkin lym

Immunoprolifera

Multiple Myelom

Lymphoid Leuka

Myeloid Leukaem

Leukaemia unspe

Other & unspecif

All sites Total

All sites but C44

mber Of Case

All Ages

1

11

12

2

0

nx 0

8

1

0

6

39

8

83

39

7

15

16

22

2

2

us,Lung 33

organs 2

13

in 4

36

0

0

tissue 27

787

3

1

51

78

13

77

enital 3

1

26

1

0

18

rgans 0

4

ystem 31

146

2

0

31

mphoma 65

ative dis. 0

ma 10

aemia 22

mia 22

ec. 5

fied 40

-----

1826

1790

es Among Non

Age unk 0-4 5

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 1

0 0

0 0

0 0

0 0

0 0

0 5

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 3

0 2

0 0

0 1

0 0

1 1

0 1

0 0

0 0

0 5

0 0

0 0

0 4

----- ----- --

1 23 1

1 23 1

n-Saudi Fem

5-9 10-14 15-19

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 1

0 0 0

0 0 0

1 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 1

0 0 0

1 2 1

0 0 0

0 1 0

0 0 0

0 0 0

2 2 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 1 3

0 0 0

0 0 1

2 0 0

0 0 0

0 0 0

0 0 0

0 0 0

1 0 0

4 2 3

0 0 1

0 0 0

0 0 0

0 1 0

0 0 6

0 0 0

0 0 0

5 4 0

1 3 1

0 1 1

0 0 0

---- ----- -----

17 17 19

17 16 19

males by Prim

20-24 25-29 3

0 0

0 2

0 0

0 0

0 0

0 0

1 1

0 0

0 0

0 0

2 2

0 0

1 0

1 0

0 0

0 1

0 0

0 0

0 1

0 0

0 3

0 0

2 1

0 0

0 3

0 0

0 0

1 1

2 31

0 0

0 0

0 3

1 1

0 0

3 4

0 0

0 0

0 0

0 0

0 0

0 0

0 0

0 0

1 4

6 16

0 0

0 0

3 7

3 3

0 0

0 0

0 0

0 3

0 0

0 1

----- -----

27 88

27 85

ary Site And

30-34 35-39 40-44

1 0 0

1 1 1

0 0 1

0 0 0

0 0 0

0 0 0

1 1 0

0 0 0

0 0 0

0 0 0

2 2 7

2 0 2

2 7 9

1 7 4

0 0 1

0 1 1

1 0 0

2 2 2

0 0 0

0 0 0

1 1 2

0 0 0

2 0 0

0 0 0

2 3 0

0 0 0

0 0 0

4 1 1

53 102 123

0 0 0

0 0 0

4 11 5

3 3 6

0 0 2

6 2 9

0 0 0

0 0 0

2 2 3

0 0 0

0 0 0

1 1 0

0 0 0

0 0 0

1 0 5

27 21 22

0 1 0

0 0 0

6 5 1

11 2 3

0 0 0

0 1 0

1 1 0

1 3 1

0 0 1

2 1 1

----- ----- -----

140 182 213

138 179 213

Age Groups

4 45-49 50-54

0 0

0 1

2 0

0 1

0 0

0 0

1 1

0 1

0 0

1 1

3 6

0 1

6 14

2 4

1 1

1 1

3 0

0 3

0 0

1 1

3 7

1 0

0 0

0 1

3 3

0 0

0 0

2 1

130 116

1 1

0 0

6 5

9 14

4 2

9 6

1 2

0 0

4 3

0 0

0 0

0 3

0 0

0 0

1 2

18 11

0 0

0 0

2 0

5 8

0 0

0 2

0 1

4 2

0 0

5 11

- ----- -----

229 237

226 234

s, 2016.

55-59 60-64 65

0 0 0

1 1

0 2 3

0 1 0

0 0 0

0 0 0

0 2 0

0 0 0

0 0 0

1 0 3

3 1 5

0 1

10 7 1

8 4 3

3 0 0

2 1 2

1 3 2

3 5

1 0 0

0 0 0

4 6 0

0 0 0

2 0 0

1 1 0

4 4 6

0 0 0

0 0 0

2 0 3

96 53 3

1 0 0

0 0 0

5 5

14 13 7

2 1

15 7 4

0 0 0

0 0 0

2 4

1 0 0

0 0 0

2 3

0 0 0

0 0 0

3 0

7 4 4

0 0 0

0 0 0

3 1 0

6 4 4

0 0 0

4 0 2

1 0 2

0 0

0 1 0

8 0 4

----- ----- --

216 135 1

212 131 10

-69 70-74 75+

0 0 0

1 0 2

3 2 2

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

3 0 0

5 3 3

1 1 0

12 6 8

3 1 4

0 0 1

2 3 1

2 1 5

1 1 3

0 0 0

0 0 0

0 2 3

0 0 0

0 0 2

0 1 0

6 3 4

0 0 0

0 0 0

3 1 1

37 22 22

0 0 0

0 0 1

1 1 5

7 4 3

1 0 1

4 4 4

0 0 0

0 0 0

1 2 1

0 0 0

0 0 0

1 4 3

0 0 0

0 0 0

1 1 1

4 6 3

0 0 0

0 0 0

0 0 0

4 3 6

0 0 0

2 0 1

2 1 1

1 0 2

0 1 0

4 1 2

--- ----- -----

12 75 95

06 72 91

73

Total (%)

0.10%

0.60%

0.70%

0.10%

0.00%

0.00%

0.40%

0.10%

0.00%

0.30%

2.10%

0.40%

4.50%

2.10%

0.40%

0.80%

0.90%

1.20%

0.10%

0.10%

1.80%

0.10%

0.70%

0.20%

2.00%

0.00%

0.00%

1.50%

43.10%

0.20%

0.10%

2.80%

4.30%

0.70%

4.20%

0.20%

0.10%

1.40%

0.10%

0.00%

1.00%

0.00%

0.20%

1.70%

8.00%

0.10%

0.00%

1.70%

3.60%

0.00%

0.50%

1.20%

1.20%

0.30%

2.20%

-----

100.00%

98.00%

74 74

Table (per 1

ICD (10th)

C00

C01-C02

C03-C06

C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34

C37-C38

C40-C41

C43

C44

C45

C46

C47;C49

C50

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C96

C88

C90

C91

C92-C94

C95

Other

All

Not C44

5.4.3 : Age-S100,000) by P

Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharynx

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchus,Lung Other Thoracic organs

Bone

Melanoma of Skin

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft tissue

Breast

Penis

Prostate

Testis

Other male genital

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary organs

Eye

Brain, Nervous system

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

Non-Hodgkin lymphoma Immunoproliferative dis.

Multiple Myeloma

Lymphoid Leukaemia

Myeloid Leukaemia

Leukaemia unspec.

Other & unspecified

All sites Total

All sites but C44

Spesific IncidePrimary Site a

All Ages Age unk

4 0

33 0

24 0

8 0

2 0

1 0

32 0

0 0

1 0

25 0

73 0

18 0

173 0

126 0

10 0

42 0

11 0

33 0

11 0

28 0

124 0

9 0

31 0

11 0

135 0

5 0

5 0

33 0

20 0

2 0

144 0

29 0

0 0

89 0

2 0

2 0

92 1

2 0

3 0

73 0

68 0

5 0

1 0

43 0

133 0

0 0

15 0

39 0

42 0

3 0

57 0

----- -----

1872 1

1737 1

ence Rate (Aand Age grou

0-4 5-9 10-1

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0.3

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0.3

0 0 0

0 0 0.3

0 0 0

0 0.6 3.1

0 0 0

0.7 0 0

0 0 0

0 0 0

0.4 0.6 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0.7 0 0

2.9 0.6 0.7

0 0 0

0 0 0

0 0 0

0.4 0.6 1.7

1.1 1.1 2.1

0 0 0

0 0 0

1.4 1.7 1

0.7 0.6 0.3

0 0 0

0 0 0

----- ----- ----

8 6 10

8 6 10

IR), Age Stanups, 2016.

14 15-19 20-24

0 0

0 0.4

0 0

0 0

0 0

0 0

3 0.4 1.1

0 0

0 0

0 0.4

0 0

0 0

0 0.7

0 0

0 0

0 0

0 0

0 0

3 0 0.4

0 0

3 0.4 0

0 0.4

1 0.4 1.8

0 0

0.4 0.4

0.4 0

0 0

0.4 0.4

0 0.4

0 0

0 0

0.4 1.4

0 0

0 0

0 0

0 0

0 0

0 0

0 0

7 0.8 2.1

0 0.4

0 0

0 0

7 2.1 0.7

1 2.1 1.4

0 0

0 0

1.3 0

3 0 1.1

0.4 0

0 0.4

-- ----- -----

0 10 14

0 9 13

ndardised In

25-29 30-34 3

0 0.1

0.1 0.1

0.1 0.2

0.1 0.3

0 0

0 0

0.3 0.4

0 0

0 0

0 0.1

0.1 0.3

0 0.1

0.3 0.5

0.1 0.8

0 0.1

0 0.1

0 0

0 0

0 0.1

0 0

0.1 0.4

0.6 0.1

0.3 0

0.1 0.1

0.6 0.8

0 0

0 0

0.4 0.5

0.1 0

0 0

0 0

0.8 0.6

0 0

0.1 0.3

0 0

0 0

0.7 0.2

0 0

0 0.1

0.8 0.8

0.8 1.3

0 0.1

0 0.1

1 0.9

1 1.1

0 0

0 0

0.4 0.1

0.1 0.2

0 0

0.1 0.6

----- ----- -

10 12

9 11

cidence Rate

5-39 40-44 45-49

0 0.2 0

0.4 0.3 0.6

0.1 0.1 0.6

0 0 0.2

0 0 0

0 0 0

0.2 0.2 0.3

0 0 0

0 0 0

0.1 0.4 0.2

0.4 0.6 0.9

0 0.2 0.3

1.2 1.1 2

0.5 1.1 1.9

0.1 0 0

0.1 0.2 0.3

0 0.2 0.2

0.1 0.4 0.7

0 0 0.5

0 0.2 0.2

0.1 0.3 1.3

0.1 0 0.1

0.1 0.3 0.1

0.1 0.2 0

0.4 0.6 1.1

0 0 0.2

0.1 0.2 0

0.1 0.3 0.3

0.1 0.1 0.6

0.1 0 0

0.1 0.1 0.1

0.4 0.2 0.1

0 0 0

0.3 0.6 1.5

0 0.1 0

0 0 0

0.4 0.2 0.3

0 0 0

0 0 0

0.7 0.5 0.3

0.7 0.4 0.7

0.1 0 0.1

0 0 0

0.2 0.2 0.3

0.7 1 1.7

0 0 0

0.1 0.1 0.1

0.2 0.2 0.2

0.5 0.3 0.3

0.1 0 0.1

0.2 0.3 0.6

----- ----- -----

9 11 19

9 10 18

(ASR) Amon

9 50-54 55-59

0 0

0.9 0.5

0.5 0.8

0 0.5

0.2 0

0 0

0.8 0.8

0 0

0.2 0

0.5 0.8

1.5 3.6

0.5 0.8

3.7 5.4

3.3 4.9

0.2 0.3

0.8 1.6

0.2 0.3

0.8 2.1

0 0.5

0.5 1.3

1.5 5.7

0 0.3

0.2 0.3

0.5 0

2.5 7.5

0.2 0

0 0

0.3 1

0.5 1.3

0 0

1.1 7

0.3 0

0 0

2.3 4.4

0 0

0 0

1.9 3.4

0 0

0 0

1.2 1.6

1.4 1.6

0 0.3

0 0

0.2 0

2 2.8

0 0

0.3 1.3

0.2 1

0.6 0.5

0 0

1.2 4.1

----- -----

33 68

30 61

ng Non-Saud

60-64 65-69 70-

0 0 0

1.9 0 3

1 0 3

0 0 0

0.5 0 0

0.5 0 0

1.9 1.4 0

0 0 0

0 0 0

1.4 4.2 3

3.4 8.4 6.

1.4 0 3

13 29.2 30

5.3 23.7 18

1 4.2 3

6.3 4.2 12

1 2.8 3

1.4 2.8 3

0 1.4 0

2.9 8.4 6.

10.6 29.2 30

0 0 0

1.9 0 0

1 0 0

7.2 15.3 27

0 1.4 0

0 2.8 0

1.4 2.8 0

0.5 0 3

0 0 0

14.5 46 66

1 0 0

0 0 0

5.8 7 12

0.5 0 0

0 1.4 3

7.7 18.1 18

0 0 3

0 0 0

1.9 1.4 3

2.4 2.8 0

0.5 0 0

0 0 0

1 0 3

5.8 12.5 9.

0 0 0

1 2.8 0

0 2.8 6.

3.9 0 0

0 0 0

2.9 4.2 3

----- ----- ---

115 241 28

107 226 25

di Males

-74 75+ CrudeRate

0 3.6 0

3 7.3 0.4

3 10.9 0.3

0 0 0.1

0 0 0

0 0 0

0 0 0.4

0 0 0

0 0 0

3 7.3 0.3

.1 25.5 0.9

3 3.6 0.2

0.4 43.6 2.2

8.3 18.2 1.6

3 0 0.1

2.2 14.5 0.5

3 0 0.1

3 3.6 0.4

0 0 0.1

.1 7.3 0.3

0.4 50.9 1.5

0 0 0.1

0 0 0.4

0 0 0.1

7.4 61.8 1.7

0 0 0.1

0 0 0.1

0 0 0.4

3 0 0.2

0 0 0

6.9 80 1.8

0 0 0.4

0 0 0

2.2 21.8 1.1

0 0 0

3 0 0

8.3 50.9 1.1

3 3.6 0

0 0 0

3 3.6 0.9

0 18.2 0.8

0 0 0.1

0 0 0

3 0 0.5

.1 25.5 1.7

0 0 0

0 3.6 0.2

.1 7.3 0.5

0 10.9 0.5

0 0 0

3 7.3 0.7

--- ----- -----

83 491 23.3

56 429 21.6

e ASR World

0.1

0.5

0.4

0.1

0

0

0.4

0

0

0.5

1.4

0.3

3.7

2.3

0.3

1.1

0.2

0.5

0.2

0.7

3.4

0.1

0.7

0.1

3.3

0.1

0.1

0.5

0.2

0

5.2

0.4

0

1.6

0

0.1

2.6

0.1

0.1

1.3

1

0

0

0.8

2.6

0

0.3

1

0.8

0

0.8

-----

39.9

36.6

Table (per 1

ICD (10th)

C00

C01-C02 C03-C06 C07-C08

C09

C10

C11

C12-C13

C14

C15

C16

C17

C18

C19-C20

C21

C22

C23-C24

C25

C30-C31

C32

C33-C34 C37-C38 C40-C41

C43

C44

C45

C46

C47;C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C64

C65

C66

C67

C68

C69

C70-C72

C73

C74

C75

C81

C82-C85;C9

C88

C90

C91

C92-C94

C95

Other

All

Not C44

5.4.4 : Age-S00,000) by Pr

Site

Lip

Tongue

Mouth

Salivary glands

Tonsil

Other Oropharynx

Nasopharynx

Hypopharynx

Pharynx unspec.

Oesophagus

Stomach

Small intestine

Colon

Rectum

Anus

Liver

Gallbladder etc.

Pancreas

Nose, sinuses etc.

Larynx

Trachea,Bronchus,Lung

Other Thoracic organs

Bone

Melanoma of Skin

Other Skin

Mesothelioma

Kaposi sarcoma

Connective,Soft tissue

Breast

Vulva

Vagina

Cervix Uteri

Corpus Uteri

Uterus unspec.

Ovary

Other Female Genital

Placenta

Kidney

Renal Pelvis

Ureter

Bladder

Other Urinary organs

Eye

Brain, Nervous system

Thyroid

Adrenal gland

Other Endocrine

Hodgkin disease

Non-Hodgkin lymphoma

Immunoproliferative dis

Multiple Myeloma

Lymphoid Leukaemia

Myeloid Leukaemia

Leukaemia unspec.

Other & unspecified

All sites Total

All sites but C44

Spesific Inciderimary Site a

All Ages

Age unk

1 0

11 0

12 0

2 0

0 0

0 0

8 0

1 0

0 0

6 0

39 0

8 0

83 0

39 0

7 0

15 0

16 0

22 0

2 0

2 0

g 33 0

2 0

13 0

4 0

36 0

0 0

0 0

27 0

787 0

3 0

1 0

51 0

78 0

13 0

77 0

3 0

1 0

26 0

1 0

0 0

18 0

0 0

4 0

31 0

146 0

2 0

0 0

31 1

a 65 0

s. 0 0

10 0

22 0

22 0

5 0

40 0

----- -----

1826 1

1790 1

ence Rate (Aand Age grou

0-4 5-9 10-1

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0.3 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0.4 0 0

0 0.3 0.7

0 0 0

0 0 0.4

0 0 0

0 0 0

1.9 0.6 0.7

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0

0 0 0.4

0 0 0

0 0 0

0 0.6 0

0 0 0

0 0 0

0 0 0

0 0 0

1.1 0.3 0

0.8 1.2 0.7

0 0 0

0.4 0 0

0 0 0

0.4 0 0.4

0.4 0 0

0 0 0

0 0 0

1.9 1.5 1.5

0 0.3 1.1

0 0 0.4

1.5 0 0

----- ----- ----

9 5 6

9 5 6

IR), Age Stanps, 2016.

14 15-19 20-24

0 0

0 0

0 0

0 0

0 0

0 0

0 0.5

0 0

0 0

0 0

0 1

0 0

0.5 0.5

0 0.5

0 0

0 0

0 0

0 0

0 0

0 0

0.5 0

0 0

7 0.5 1

0 0

4 0 0

0 0

0 0

7 0 0.5

0 1

0 0

0 0

0 0

0 0.5

0 0

4 1.4 1.4

0 0

0.5 0

0 0

0 0

0 0

0 0

0 0

0 0

7 1.4 0.5

0.5 2.9

0 0

0 0

4 0 1.4

2.7 1.4

0 0

0 0

5 0 0

1 0.5 0

4 0.5 0

0 0

-- ----- -----

9 13

9 13

ndardised In

25-29 30-34 35

0 0.2

0.5 0.2 0

0 0

0 0

0 0

0 0

0.2 0.2 0

0 0

0 0

0 0

0.5 0.5 0

0 0.5

0 0.5

0 0.2

0 0

0.2 0 0

0 0.2

0 0.5 0

0.2 0

0 0

0.7 0.2 0

0 0

0.2 0.5

0 0

0.7 0.5 0

0 0

0 0

0.2 1 0

7.4 12.7

0 0

0 0

0.7 1 2

0.2 0.7 0

0 0

1 1.4 0

0 0

0 0

0 0.5 0

0 0

0 0

0 0.2 0

0 0

0 0

1 0.2

3.8 6.5 3

0 0 0

0 0

1.7 1.4 0

0.7 2.6 0

0 0

0 0 0

0 0.2 0

0.7 0.2 0

0 0

0.2 0.5 0

----- ----- -

21 34

20 33

cidence Rate

5-39 40-44 45-49

0 0 0

0.2 0.2 0

0 0.2 0.8

0 0 0

0 0 0

0 0 0

0.2 0 0.4

0 0 0

0 0 0

0 0 0.4

0.4 1.4 1.1

0 0.4 0

1.3 1.8 2.3

1.3 0.8 0.8

0 0.2 0.4

0.2 0.2 0.4

0 0 1.1

0.4 0.4 0

0 0 0

0 0 0.4

0.2 0.4 1.1

0 0 0.4

0 0 0

0 0 0

0.6 0 1.1

0 0 0

0 0 0

0.2 0.2 0.8

19 25.2 49.5

0 0 0.4

0 0 0

2.1 1 2.3

0.6 1.2 3.4

0 0.4 1.5

0.4 1.8 3.4

0 0 0.4

0 0 0

0.4 0.6 1.5

0 0 0

0 0 0

0.2 0 0

0 0 0

0 0 0

0 1 0.4

3.9 4.5 6.9

0.2 0 0

0 0 0

0.9 0.2 0.8

0.4 0.6 1.9

0 0 0

0.2 0 0

0.2 0 0

0.6 0.2 1.5

0 0.2 0

0.2 0.2 1.9

----- ----- -----

34 44 87

33 44 86

(ASR) Amon

50-54 55-59

0 0

1 1.6

0 0

1 0

0 0

0 0

1 0

1 0

0 0

1 1.6

6.1 4.7

1 0

14.2 15.5

4.1 12.4

1 4.7

1 3.1

0 1.6

3 4.7

0 1.6

1 0

7.1 6.2

0 0

0 3.1

1 1.6

3 6.2

0 0

0 0

1 3.1

117.5 148.8

1 1.6

0 0

5.1 7.8

14.2 21.7

2 3.1

6.1 23.3

2 0

0 0

3 3.1

0 1.6

0 0

3 3.1

0 0

0 0

2 4.7

11.1 10.9

0 0

0 0

0 4.7

8.1 9.3

0 0

2 6.2

1 1.6

2 0

0 0

11.1 12.4

----- -----

240 335

237 329

ng Non-Saud

60-64 65-69 70-

0 0 0

2.2 3.5 0

4.3 10.5 10.

2.2 0 0

0 0 0

0 0 0

4.3 0 0

0 0 0

0 0 0

0 10.5 0

2.2 17.6 16.

2.2 3.5 5.4

15.2 42.2 32.

8.7 10.5 5.4

0 0 0

2.2 7 16.

6.5 7 5.4

10.8 3.5 5.4

0 0 0

0 0 0

13 0 10.

0 0 0

0 0 0

2.2 0 5.4

8.7 21.1 16.

0 0 0

0 0 0

0 10.5 5.4

114.8 130 119

0 0 0

0 0 0

10.8 3.5 5.4

28.2 24.6 21.

2.2 3.5 0

15.2 14.1 21.

0 0 0

0 0 0

8.7 3.5 10.

0 0 0

0 0 0

6.5 3.5 21.

0 0 0

0 0 0

0 3.5 5.4

8.7 14.1 32.

0 0 0

0 0 0

2.2 0 0

8.7 14.1 16.

0 0 0

0 7 0

0 7 5.4

0 3.5 0

2.2 0 5.4

0 14.1 5.4

----- ----- ---

293 393 40

284 372 39

di Females

74 75+ CrudeRate

0 0 0

0 18.4 0.3

.9 18.4 0.3

0 0 0.1

0 0 0

0 0 0

0 0 0.2

0 0 0

0 0 0

0 0 0.2

.3 27.5 1.1

4 0 0.2

.6 73.4 2.3

4 36.7 1.1

0 9.2 0.2

.3 9.2 0.4

4 45.9 0.4

4 27.5 0.6

0 0 0.1

0 0 0.1

.9 27.5 0.9

0 0 0.1

0 18.4 0.4

4 0 0.1

.3 36.7 1

0 0 0

0 0 0

4 9.2 0.7

9.7 201.

9 21.4

0 0 0.1

0 9.2 0

4 45.9 1.4

.8 27.5 2.1

0 9.2 0.4

.8 36.7 2.1

0 0 0.1

0 0 0

.9 9.2 0.7

0 0 0

0 0 0

.8 27.5 0.5

0 0 0

0 0 0.1

4 9.2 0.8

.6 27.5 4

0 0 0.1

0 0 0

0 0 0.8

.3 55.1 1.8

0 0 0

0 9.2 0.3

4 9.2 0.6

0 18.4 0.6

4 0 0.1

4 18.4 1.1

-- ----- -----

08 872 49.5

92 835 48.6

75

e ASR World

0

0.7

1.1

0.1

0

0

0.3

0.1

0

0.5

2.3

0.4

5.8

2.4

0.5

1.1

1.6

1.6

0.1

0.1

2.1

0.1

0.8

0.3

2.7

0

0

1.3

33.8

0.1

0.2

2.6

4.8

0.7

4.2

0.1

0

1.4

0.1

0

1.7

0

0.2

1.3

4.8

0.1

0

0.8

3.8

0

0.8

1.2

1

0.3

2.3

-----

92.1

89.4

76 76

Acknowle

We wo

Report’ R

Dr. Al

for Can

Hospita

Dr. Ha

Center,

Fahad S

Main Office

Mr. M

Assista

Informa

Ms. M

Cancer

Ms. W

Mr. Ah

Ms. G

Central R

Dr. Mu

Mr. M

Mr. M

Mr. Im

Western R

Dr. Ha

Mr. Sa

Mr. Ah

Mr. W

Southern

Dr. Ab

Mr. Sy

Mr. Sa

edgment

ould like to e

Reviewers

i Al-Zahrani -

ncer Control and

al & Research)

ani Al-Hashm

Hematology an

Specialist Hosp

e

ohammed A

nt of Health Dat

ation Center

Malak Al-Jam

r Registry

Wafa Al-Zahra

hmed Al-Raw

Ghadi Al-Gosa

Region

ushabab As

ohammed H

ohamed Kam

man Daggal

Region

assnah Al-G

ameer Kaifah

hmed Al-Nem

Waleed Al-Qa

Region

bdurahman A

yed Zafar Iqb

aleh Al-Olyan

express our d

for their invaluable contribution and support.

:

- (Executive dir

d Prevention, K

mi - (Director, O

nd Stem Cell Tra

pital

Al-Shehri - Ge

ta Management

aan - Acting M

ani

waji

abi

siri - Director

ayder (CTR)

mal Abdulqad

Ghamdi- Direc

h

mari

htani

Al-Shehri- Di

bal

ni

deepest grat

ector, Gulf Cen

King Faisal Spec

Oncology

ansplant Center

neral Manager

t, National Heal

Manager, Saudi

r

)

der (CTR)

ctor

rector

titude to the members of SCR committee and staff of the registry

ter

cialist

r, King

th

East

D

M

Mad

D

M

M

Dr. Shouk

Medical Onc

Research)

Dr. Suliem

Health & Pe

Cancer Cen

Dr. Hind

Registries

Ms. Ama

Registry

Mr. Zeya

Mr. Fawa

tern Region

Dr. Ali Al.Am

Mr. Abdulma

inah & Nort

Dr. Amal Al-B

Mr. Yousef A

Mr. Akram Z

ki Bazarbsh

cology, King Fa

man Al-Sheh

ediatrics Genera

nter

Al-Mutlaq -

Department

al Al- Madouj

ad Al-Shahra

az Al-Omran

mri- Director

ajeed Alam

thern Region

Behani- Dire

Abdulhadi (C

amzami

i - (Head, Sect

aisal Specialist H

hri - Consultant

al Director of Sa

Manger, Nation

j - Adviser, Sau

ani

n

n

ctor

TR)

ion of

Hospital &

t Public

audi National

al Health

udi Cancer

Ca

ancer InSa

ncidencudi Ara2016

ce Repabia

ort

77

78 78

تقيم ن والمس اللاهودجكن وي هودجكن

بنسبة) حالة

لجهاز العصبي ن اللمفاوي طا) حالة ٢٩( ين

سرطان الكلى

%١٦,٥٨,١ ٧,٠ ٥,٨ ٥,١ ٥,٠ ٤,٦ ٣,٩ ٣,٨ ٣,٧

%٢٩,١ ١٥,٥ ١٣,٤ ١١,٠ ٧,١ ٥,٠ ٣,٧ ٣,١ ٢,٤ ٢,١

ان القولونرططان اللمفاوي سرطان اللمفاو

ح٤٤٦(الرئة .% ٣,١نسبة

الدماغ وا نثم السرطا %

العين سرطانل منهما، ثم س

٥٨٠٣٩٥٥ ٤٦٩ ٤٠٥ ٣٣٤ ٢٩٨ ٢٩٠ ٢٦٥ ٢٢٩ ٢٢٢ ٢١٢

٣٨١١١١ ٥٩ ٥١ ٤٢ ٢٧ ١٩ ١٤ ١٢ ٩ ٨

تلاه سر %١ثم السرط % ٨يليه الس % ٤

يليه سرطان بن) حالة ٤٠٥

سين

تلاه سرطا % %١١,٦ بنسبة

، يليه % ٧,٣ لكل % ٤,١بة ٢ %.

جكن

ن

صبي

سين

صبين

جكن

جنسين

٧,٣بنسبة ٨,٢بنسبة ) لة٦,بنسبة ) ة

ي % ٣,٤سبة ٥( البروستات

ن لכא אلجنس

٣٠,٤بنسبة ب) حالة ٧٦(

بنسبة ) حالةبنسبة) حالة٢٣,بنسبة ) لة

جنسين

الذكورستقيموالم لون

اللاهودج مفاويوستاتالدم ضاض

ةد

دجكنهو مفاويةالدرقية ةوالجهازالعص اغ

ن لכא אلجنس

الذكور الدم ضاض

والجهازالعص اغهودجكن مفاوياللاهودج مفاويظامينالكظرية ة

الضامة سجةلخصية ى

ديين لכא אلج

)حالة ٢٢٨حال١٠٧٦(ية حالة ٦١٠(دم نسب) حالة ٤٥

خيرا سرطان

ل אلسعوديين

) حالة ٢٠٠( (ي هودجكن

ح ٤٨( لعظام٢٧(ة الضامة

حال ١٥( رقية

ديين لכא אلج

%٣٠ القول١١ الليم٩ البرو٦ ابيض٥ الرئة٣ الكبد٣ الليم٣ المثانة٢ الغدة٢ الدما

ل אلسعوديين

%ابيض ٣٢الدما ١٣الليم ٩,الليم ٧,العظ ٦,العين ٦,الغد ٥,الأنس ٤,الخص ٤,الكلى ٣,

بين אلسعود

٨٢(ة الأولى ن الغدة الدرقي ابيضاض الد

٥٤( ن الرحم وأ % ٣,٢سبة

بين אאطفאل

لمرتبة الأولى رطان اللمفاوي

ال ثم سرطان رية والأنسجةان الغدة الدرق

بين אلسعود

% ٧٢ ٠,٤١,٦ ,٦ ,٢ ,١ ,٨ ,١ ,٠ ,١ ,٠

بين אאطفאل

% ٢٢,٢ ٣,٤ ,١ ,٦ ,٥ ,٥ ,٤ ,٧ ,٣ ,٦

כثر شيوعא ب

لثدي المرتبةسرطان ثم %ثم سرطان %ثم سرطان %

بنس) حالة ٤١

כثر شيوعא ب

ضاض الدم المرلسرطثم ا %

% ٩,١نسبة ة الكظر الغدا سرطا وأخير

כثر شيوعא ب

٧٣٥٨٢٢٤٠ ٨٥٤ ٧٠٤ ٤٥٤ ٣٧٢ ٢٧٦ ٢٣٠ ٢١٩ ١٥٥ ١٤٨

כثر شيوعא ب

٢٧٦٨٩ ٣٧ ٢٥ ٢١ ١٨ ١٨ ١٥ ١٣ ١٢ ١٠

אلعشرة אאכ

السرطان ل ١٢,٦بنسبة ) % ٦,٤بنسبة

٣,٨بنسبة ) ٧(طان الكبد

אلعشرة אאכ

ل سرطان ابيض١٤,٦بنسبة

بن) حالة ٦٠(ثم سرطان ،

، % ٤,٠نسبة

אلعشرة אאכ

لاناث

ةتقيم

لاهودجكنم

ودجكن

از العصبي لج

אلعشرة אאכ

لأناثم

ازالعصبي لجودجكن

دجكنلاهوضامةيةة

אلسرطאنאت

احتل)حالة ١٦٥٩() حالة ٨٤١(

)حالة ٤٩٥( ثم سرط% ٣,٤

אلسرطאنאت

احتلب) حالة ٩٦(

(اللاهودجكن % ٤,٤بنسبة

بن) حالة ٢٦(

אلسرطאنאت

الا الثدي

الغدة الدرقية القولون والمست

الرحم الليمفاوي اللا ابيضاض الدم الليمفاوي هو

المبيض الدماغ والجها

الرئة

אلسرطאنאت

االدم ابيضاض

والجها الدماغ

هو الليمفاوي

العظام الكلى

اللا الليمفاوي

الض الأنسجة

الكظري الغدة

الدرقية الغدة

العين

א

)))

א

)اب)

א

א

ركز الأبحاث المملكة ناطق

يناير في عام تحلل البيانات على صفحة

ية الحكومية وغير % ,٧٨

سبة أجمالية %.

اموع

٣٦٩٨

٩١,٣النساء بمعدل عمري منطقة مكة ة ، و منطقة لسرطان لدى

١٠٠٠٠٠كل ١٠٠٠٠٠لكل

2016عאم

لتخصصي ومرسة فروع في مني ومات من شهرة العالمية وتحنموذج خاص

لمرافق الصحي١يين بنسبة

حالة بنس ٥% ٥٥,٩قدرها

سعوديين نثى

١٨٢

سمة ، وبين ابم بين الذكور

نسمة، ثم ١٠نسمة ١٠٠٠٠

بالس للإصابة حالة لك ,١٣٠

حالة ٨٧,٧ل

عودية لع

الملك فيصل ال السجل خمسةفي جمع المعلومنظمة الصحةصائية وفق نم

https://nhic

من مختلف المسعودي ١٣١٦١

٥٨٠٣ الذكور ق إجماليةسبة

غير سأن

٢٦

نس ١٠٠٠٠٠ لات السرطان

٠٠٠٠لة لكل ٠حالة لكل ٧

رية المعيارية١اض بمعدل

المكرمة بمعدل

ربية אلسع

بمستشفى ا) ميضم . لحكومية

سجل نشاطه المعتمد من منبمعلومات إحص

c.gov.sa/eSer

و المسجلة ٢١ ذه الحالات

ى السعوديين حالة بنس ٧٣

ذكر

١٨٧٢

حالة لكل ٧٤ لحدوث حالا

حال ٩٦,٤ عدل٧١,٤ ف بمعدل

لمعدلات العمرا منطقة الريا منطقة مكة ا

ملכة אلعر

م١٩٩٢(هـ ١ الصحية الحك

بدأ الس .صحيةحسب النظام

ة والباحثين بم

rvices/Pages

٠١٦ في عام ، من بين هذ السرطان لدى

٥٨سعوديات

اموع

١٣١٦١

٤,٧ين الرجال ة أعلى معدل ة الرياض بمعمنطقة الجوف

كما بلغت ا. نسمة تليها ١

نسمة ثم ١٠٠ .نسمة ١

ن في אلمم

٤١٢ في عام من القطاعات القطاعات الصات وتدخل حلجهات المختصة :حي السعودي

/TumorRegis

طان المكتشفةحالة ١٦٨٥٩

عدد حالات لدى الإناث الس

سعوديين أنثى

٧٣٥٨

لسرطان بينطقة الشرقيةة تلتها منطقة

نسمة ثم م ١.نسمة ١٠٠٠

٠٠٠٠٠ة لكل ٠٠٠حالة لكل٠٠٠٠٠لة لكل

אلسرطאن

رאم

ورام عودي للأة وبمشاركة من

عدد من ب في البيانا وترميز

ل بتزويد الجلمجلس الصحstration.aspx

٢٠١٦ م

حالات السرط٩ة السعودية

وكان . % ٢١عدد الحالات ل

ذكر

٥٨٠٣

ي للإصابة باسجلت المنط.

نسمة ١٠٠٠٠٠٠٠٠٠ لكل ٠٠٠لكل ٦٩,٠

حالة ١٣١,٣ ح٩٥,٥بمعدل

حالة ٨٠,٨عدل

אحصאئيאت

عودي لאو

ئ السجل السع وزارة الصحةلى وجود مكاتبث يتم جمع و

يقوم السجل وقع الرسمي للx

لسرطאن لعא

إجمالي عدد ملكة العربية

٩, بنسبة ٣٦بينما بلغ ع %

لكلي

ذ ١

٣

المعدل المعيارينسمة ١٠٠٠٠

٠حالة لكل ١حالة ٧٣,٢ل

٠ الية بمعدلالشرقية طقةالجوف بم طقة

ة القصيم بمعد

א

אلسجل אلسع

أنشئتحت إشراف بالإضافة إلى

م، حيث ١٩٩٤. بشكل دوريالسجل في المو

אحصאئيאت אل

بلغ إوالخاصة بالمم

٦٩٨سعوديين % ٤٤,١قدرها

اموع ال

١٦٨٥٩

بلغ ا٠٠ة لكل حال

١٠٤,٣معياري بمعدل المكرمة

الحدود الشمافبالمنطالنساء

نسمة ، ثم منطنسمة ومنطقة

79

א

تحب

با

א

وسق

حمااانن

آله وصحبه

يكم التقريرجل وأنشطته فق الصحية

، بنسبة )يين

، بينما % ٤٤

يف الصحي، ضع الحقيقي

طويلة المدى طان وتبادل

عم حكومتنا ذلك بجهود داد البرامج

א"

محمد وعلى آ

ضع بين أيدينجازات السج

المرافمختلف من السعودي(

٤,١ها ية قدر.

برامج التثقي تعكس الوض

.لجغرافيوطنية ط جية

لمرضى السرط

عالى ثم بدع، وكذ- االله

وقاموا بإعد

אא" في

، نبينا مح لين

صحية أن يضى أحدث إنجن كافة من مخ

حالة "١٣١٦

نسبة إجمالي% ٥٥,٩درها

التوعوية وب دقيقة التيمر والموقع ا

إستراتيجيذ ة المقدمة لمر

ل من االله تعأيدهما -ين

عناية كبيرة

ه الزملاء في .كة

:))نبياء والمرسل

للمعلومات الصي يحتوي علىلات السرطان

٦١"من بينها .% ٢١,٩غت حالات، بن" ٥

ة إجمالية قدعم الجهود بالبيانات الدب النوع والعمف على تنفي

صحيةعاية ال.

ا جاء بفضلعهده الأمينض السرطان ع

ر الذي قام بهكافة في المملك

:;<ى أشرف الأن

كز الوطني لالذي م،٢٠١٦

تسجيل حالاحالة، م)١٦٨

، بنسبة بلغ)٥٨٠٣"لذكور

حالة بنسبة على د" سجل

في المملكة، شيوعاً حسب قام بالإشراستويات الرع.مية المختلفةحي في بلادنا وسمو ولي ي أولوا مرض

لجهد المستمرت السرطان ك

אאא

<والسلام على ة

ممثلاً في المرك٦لأورام لعام

ت في رصد وت٨٥٩( تي بلغت

)ير السعوديين السعوديين ال

" ٧٣٥٨"يات الس"درة عن

ل السرطان واع السرطان حي السعودي ر وتحسين مسعات الحكوميفي اال الصحين الشريفين لمؤسسات الذي

ل الدؤوب واحالات تسجيل

K

والصلاة ، ين

ي السعودي مم السعودي للأ

وتمثلت ، خراً، التي المملكة

من غير( حالة سرطان لدى لإناث السعوديصائيات الصادصين في مجاديد أكثر أنولس الصحي

وتطوير ، نبية في القطار ملموس في خادم الحرمينوالهيئات والمؤ

.قاية منه

نتيجة العمله وأهدافه لت

الله رب العالمين ،،د

لس الصحيمال السجل تي تمت مؤخلخاصة في ا

ح"٣٦٩٨"، و%دد حالات السلحالات لدى الإعدت الإحصحثين والمختصفي المملكة، وتحد أنوه بأن ا

حة السرطانين المراكز الطبراه من تطورعلى رأسها خاطاع الصحي لتوعوية للوق

..لختامقرير تحقق نحقيق رسالته

الحمد اللهأجمعين، وبعد

سر ايالسنوي لأعموبرامجه التيالحكومية وا

% ٧٨,١بلغت وكان عدبلغ عدد الحاوقد ساعوتزويد الباحللسرطان في وأود أن لعلاج ومكافحالخبرات بينإنّ ما نرالرشيدة وعمنسوبي القطالعلاجية والوفي الختهذا التقمشكورين، لتح

أ

اواب

ب

ول

لا

اما

م

ة

ي

صحية

م

سرطאن

لسعودية

لسعودي

ومאت אلص

ي لאورאم

مرض אلسر

لعربية אل

لصحي אل

ي للمعلو

سعودي

אصאبة بم

٢٠١٦

لمملכة א

مجلس א

ز אلوطني

لسجل אلس

معدل אא

אل

אلم

אلمرכز

א

رتقري

2019 يو يوليحرر في ح